Nuclear receptor binding SET domain protein2 / 3 inhibitor and pharmaceutical composition and application thereof
By developing a new small molecule compound that has inhibitory activity on NSD2 and NSD3, the problem of poor effectiveness of NSD2/NSD3 inhibitors in the prior art has been solved, and the goal of improving pharmacokinetics and safety is achieved. Potential for the treatment of NSD2/NSD3-mediated disease.
Patent Information
- Application Number
- CN202410710193.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-31
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art has not yet developed effective NSD2/NSD3 small molecule inhibitors for the treatment of NSD2/NSD3-mediated diseases, and there are problems of poor pharmacokinetics, high toxicity and many side effects.
Provided a novel small molecule compound with inhibitory activity against NSD2 and/or NSD3 and with improved pharmacokinetic properties such as improved bioavailability, metabolic stability, appropriate half-life and duration of action, and Lower toxicity and fewer side effects.
The compound showed higher NSD2 inhibitory activity, with dual-targeting characteristics, inhibitory activity against both NSD2 and NSD3, with a potential for the treatment of diseases mediated by NSD2 and/or NSD3, with better pharmacokinetics and Safety features reduce the risk of drug resistance.
Smart Images

Figure CN119060053A_ABST
Abstract
Description
[0001] Citation of Related Applications
[0002] This application claims the priority of Chinese patent application 202310644957.9 filed on May 31, 2023, the priority of Chinese patent application 202310684793.2 filed on June 9, 2023, and the priority of Chinese patent application 202311131654.3 filed on August 31, 2023, the contents of which are incorporated by reference into this application in their entirety and for all purposes. Technical Field
[0003] The present application relates to a novel nuclear receptor binding SET domain protein 2 / 3 inhibitor and a pharmaceutical composition and application thereof. Background Art
[0004] NSDs are multi-domain proteins, including PWWP, PHD-finger, SET-CD and the unique C5HCH motif of NSDs; pre-SET, SET and post-SET constitute SET-CD. NSDs have three subtypes, NSD1, NSD2 and NSD3. NSD2 and NSD3 are histone H3 lysine 36 (H3K36) methyltransferases that catalyze H3K36 dimethylation, thereby affecting gene transcription, DNA replication and cell differentiation, and play an important role in maintaining chromatin stability and regulating gene expression.
[0005] The highly conserved SET catalytic domain has methyltransferase activity, PWWP is the key to the binding of NSDs to methylated histone H3 and DNA, and PHD is the key to the binding of NSDs to other methylated histones.
[0006] Overexpression or mutation of NSD family proteins is closely related to the occurrence of various cancers. For example, in multiple myeloma patients, 15-20% are caused by abnormal overexpression of NSD2. Acute lymphoblastic leukemia (ALL) is the most common blood disease diagnosed in pediatrics, and about 10% of pediatric acute lymphoblastic leukemia patients carry the NSD2 protein E1099K mutation. In addition, NSD2 (E1099K) mutations have also been found in 5-10% of mantle cell lymphoma patients and patients with lung cancer, colon cancer, and thyroid cancer.
[0007] NSD3 is located on chromosome 8p11-12, which is amplified in many malignant tumors, leading to increased expression of NSD3, which is crucial for tumor maintenance. TCGA data show that NSD3 gene abnormalities (overexpression and SET domain mutation activation) account for about 60% of all lung squamous cell carcinoma patients. TCGA pan-cancer sample data show that in addition to lung squamous cell carcinoma (LUSC), breast cancer, esophageal cancer, head and neck cancer, bile duct cancer, hepatocellular carcinoma, gastric adenocarcinoma, etc. also have high expression of NSD3.
[0008] Transcriptome and proteomic analysis results from biological samples of primary LUSC patients support NSD3 as a new LUSC therapeutic target.
[0009] Gang Yuan et al. reported that NSD3 is a driver gene for squamous cell lung cancer rather than FGFR1 as previously believed (Wanqiu Li et al., Elevated NSD3 histone methylation activity drives squamous cell lung cancer, Nature, Vol. 590, February 18, 2021). The NSD3 activity-enhanced mutant T1232A was shown to promote tumor growth in animal experiments. NSD3-mediated H3K36me2 promotes the occurrence and development of LUSC, and the MYC signaling pathway is activated. The LUSCPDX model validates the combination of NSD3 inhibitors and BETi, that is, NSD3 as a driver of squamous cell lung cancer and a potential drug combination.
[0010] It can be seen that NSD family proteins are considered to be potential targets for cancer targeted drug therapy.
[0011] International patent application WO2021026803A1 filed by Novartis discloses piperidinyl-methyl-purine amine compounds as NSD2 inhibitors and anticancer agents, and discloses the NSD2 inhibitory activity IC 50 The range is 0.01 to 1 μM, but no data on the inhibitory activity against NSD3 are published.
[0012] There remains a need in the art to develop new NSD2 / NSD3 small molecule inhibitors for treating diseases, disorders or conditions mediated by NSD2 / NSD3. Summary of the invention
[0013] The present invention provides new small molecule compounds. In some embodiments, the compounds of the present invention have NSD2 inhibitory activity. In some embodiments, the compounds of the present invention show higher NSD2 inhibitory activity than the prior art (e.g., compounds disclosed in WO2021026803A1, particularly compounds of Example 1 thereof). In some embodiments, the compounds of the present invention show dual-targeting characteristics, i.e., both NSD2 and NSD3 have inhibitory activity. In some embodiments, the compounds of the present invention show selective NSD3 inhibitory activity. Therefore, the compounds of the present invention have the potential to treat diseases, disorders or conditions mediated by NSD2 and / or NSD3. The compounds of the present invention also have improved pharmacokinetic properties (e.g., improved bioavailability, improved metabolic stability, suitable half-life and duration of action), improved safety (lower toxicity (e.g., reduced cardiotoxicity) and / or fewer side effects), less prone to drug resistance and other more excellent properties.
[0014] In one aspect, the present invention provides a compound of formula (I) as defined below:
[0015]
[0016] or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably a deuterated compound), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof,
[0017] in:
[0018] Ring A is a benzene ring or a 5-6 membered heteroaryl group;
[0019] L is a direct key, C 1-6 Alkylene, -C 1-6 Alkylene-O-, or -OC 1-6 Alkylene-;
[0020] L 1 For direct keys, O, S, C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -SC 1-6 Alkylene-, -C 1-6 Alkylene-S-, -NH-CO- or -CO-NH-;
[0021] R 1 H or C 1-6 alkyl;
[0022] R2 H or C 1-6 alkyl;
[0023] R 3 H, halogen, OH, NH 2 、CN、NO 2 or part;
[0024] Ring B is C 3-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl or 3-10 membered heterocyclyl;
[0025] R b OH, NH 2 、Halogen、CN、NO 2 , C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -NR 4 C(=O)CR 6 =C(R 6 ) 2 or -(CR 4 R 5 ) l -NR 4 -C(=O)-R 7 , wherein the C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted by 1, 2, 3 or more independently selected from OH, NH 2 、Halogen、CN、NO 2 , C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Substitution of haloalkyl groups;
[0026] Ring C is a 9-10 membered heteroaryl group having 2, 3, 4 or 5 nitrogen heteroatoms;
[0027] R c C 1-6 Alkyl or -OC 1-6 alkyl;
[0028] R is:
[0029] (1) optionally 1, 2 or more independently selected from halogen, OH, NH 2 、CN、NO 2 -OC substituted with COOH 1-6 alkyl;
[0030] (2)-NR e R f , where R e and R f are each independently H, or optionally substituted by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 and COOH substituted C 1-6 alkyl;
[0031] (3)–(CH 2 ) w -O-(CH 2 ) v -C 6-10 Aryl or
[0032] (4) part,
[0033] in:
[0034] Ring D is a 5-6 membered heterocycloalkyl group containing 1 nitrogen heteroatom and 0 or 1 O or S heteroatoms;
[0035] R a1 For: COOH, -NR g R h 、COOR g ,CONR g R h , or -C 1-6 Alkylene-NR g R h ;
[0036] Each R a2 Independently for:
[0037] (1) Halogen, OH, NH 2 、CN、NO 2 , COOH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C1-6 Alkylene-SR g , -C 1-6 Halogenated alkylene -OR g , -C 1-6 Halogenated alkylene-SR g , -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C 1-4 Alkylene-S(O)-C 1-6 Alkyl, -C 1-6 Alkylene-S(O) 2 -C 1-6 Alkyl, -C(C 1-6 alkyl)=NO(C 1-6 alkyl), -C(O)-C 1-6 Alkyl, or -C(O)-NR g R h ;or
[0038] (2)-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 , where R 14 For-OC 1-6 Alkyl, C 3-7 Cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, the C 3-7 The cycloalkyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl are each independently unsubstituted or substituted with C 1-6 Alkyl or -OC 1-6 Alkyl substitution; or
[0039] (3)-(CR 11 R 12 ) t -C(O)-NR 15 R 16 , where R 15 is hydrogen or C 1-6 Alkyl, R 16 For hydrogen, C 1-6 Alkyl, or 5-6 membered heterocyclic group; or R 15 and R 16 Together with the nitrogen atom to which they are attached, they form an unsubstituted or C 1-6 an alkyl-substituted 5-6 membered heterocyclic group; or
[0040] (4) 5-10 membered heterocyclic group, or -C 1-6 Alkylene-(5-10 membered heterocyclyl), wherein each of the 5-10 membered heterocyclyl is unsubstituted or replaced by C 1-6 Alkyl substitution; or
[0041] (5) 5-10 membered heteroaryl, or -C 1-6 Alkylene-(5-10 membered heteroaryl), wherein each of the 5-10 membered heteroaryl is unsubstituted or substituted with: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, halogen, OH, CN, -C(O)NH 2 , -C 1-6 Alkylene-C(O)NH 2 、-C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C 1-6 Alkyl, -C(O)N(C 1-6 alkyl) 2 , -C 1-6 Alkylene-C(O)N(C 1-6 alkyl) 2 , or -C 3-7 Cycloalkyl;
[0042] R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 、-OC 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The substituents of aryl and 5-10 membered heteroaryl are substituted with C 1-6 alkyl;
[0043] R 4 , R 5 , R 6 , R 11 , R 12 and R 13 Each time it appears, it is independently H, C 1-6 Alkyl or C 3-7 Cycloalkyl;
[0044] R 7 C 1-6 Alkyl or C 1-6 Haloalkyl;
[0045] l, m, n, p, q, w, v and s are each independently 0, 1, 2, 3 or 4;
[0046] t is independently 1, 2, 3 or 4; and
[0047] in:
[0048] When the R 1 and R 2 are all H, the ring C is The ring A is a pyridyl ring, the L and L 1 are all direct bonds, and the R is the part, the ring D is a piperidinyl ring, and the R a1 and R a2 At least one of them is NH 2 , then the following conditions are met:
[0049] (1) If p is not 0, then R a1 With at least one R a2 Connect to the same location;
[0050] (2) If n is 1, then R b Not halogen;
[0051] (3) If n is greater than 1, then R b Not all halogens; and
[0052] (4) The compound of formula (I) is not any of the compounds disclosed in Examples 1-325 of international patent application WO2021026803, in particular not the following compounds, or their stereoisomers, tautomers, diastereomers, racemates, cis-trans isomers, isotope-labeled compounds, N-oxides, metabolites, esters, prodrugs, crystalline forms, hydrates, solvates or pharmaceutically acceptable salts:
[0053]
[0054]
[0055]
[0056]
[0057] In another aspect, the present invention provides a compound of formula (I) as defined below:
[0058]
[0059] or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably a deuterated compound), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof.
[0060] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of formula (I) according to the present invention, or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The pharmaceutical composition is preferably a solid preparation, a liquid preparation or a transdermal preparation. In some embodiments, the pharmaceutical composition of the present invention may also include one or more additional therapeutic agents.
[0061] In another aspect, the present invention provides a pharmaceutical combination comprising a compound of formula (I) according to the present invention, or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotopically labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystalline form, hydrate, solvate or pharmaceutically acceptable salt thereof, and one or more additional therapeutically active agents.
[0062] In some embodiments, the one or more additional therapeutically active agents are anti-cancer agents, analgesics, or anti-inflammatory agents.
[0063] In another aspect, the present invention provides a compound of formula (I) according to the present invention, or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to the present invention, or a pharmaceutical combination according to the present invention, for use as a drug.
[0064] In another aspect, the present invention provides a method for treating a disease, disorder or condition mediated by nuclear receptor binding SET domain protein 2 (NSD2) in an individual, wherein the method comprises: administering to the individual a therapeutically effective amount of a compound of formula (I) according to the present invention, or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotopically labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystalline form, hydrate, solvate or pharmaceutically acceptable salt thereof; or administering to the individual a therapeutically effective amount of the pharmaceutical composition according to the present invention; or administering to the individual a therapeutically effective amount of the pharmaceutical combination according to the present invention.
[0065] In another aspect, the present invention provides a compound of formula (I) according to the present invention, or its stereoisomers, tautomers, diastereomers, racemates, cis-trans isomers, isotopically labeled compounds (preferably deuterated), N-oxides, metabolites, esters, prodrugs, crystalline forms, hydrates, solvates or pharmaceutically acceptable salts, or the pharmaceutical composition according to the present invention, or the pharmaceutical combination according to the present invention for the preparation of a medicament for treating a disease, disorder or condition mediated by NSD2 in an individual.
[0066] In some embodiments, the disease, disorder or condition mediated by NSD2 is selected from solid tumors, leukemia, myeloma, lymphoma and hypertension. Preferably, the disease, disorder or condition mediated by NSD2 is selected from breast cancer, cervical cancer, skin cancer, ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, colon cancer, head and neck cancer, thyroid cancer, peripheral nerve sheath tumors, osteosarcoma, multiple myeloma, neuroblastoma, leukemia, non-Hodgkin's lymphoma and pulmonary hypertension. More preferably, the disease, disorder or condition mediated by NSD2 is selected from acute lymphocytic leukemia, cutaneous squamous cell carcinoma or mantle cell lymphoma.
[0067] In another aspect, the present invention provides a method for treating a disease, disorder or condition mediated by nuclear receptor binding SET domain protein 3 (NSD3) in an individual, wherein the method comprises: administering to the individual a therapeutically effective amount of a compound of formula (I) according to the present invention, or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotopically labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystalline form, hydrate, solvate or pharmaceutically acceptable salt thereof; or administering to the individual a therapeutically effective amount of the pharmaceutical composition according to the present invention; or administering to the individual a therapeutically effective amount of the pharmaceutical combination according to the present invention.
[0068] In another aspect, the present invention provides a compound of formula (I) according to the present invention, or its stereoisomers, tautomers, diastereomers, racemates, cis-trans isomers, isotopically labeled compounds (preferably deuterated), N-oxides, metabolites, esters, prodrugs, crystalline forms, hydrates, solvates or pharmaceutically acceptable salts, or the pharmaceutical composition according to the present invention, or the pharmaceutical combination according to the present invention for the preparation of a medicament for treating a disease, disorder or condition mediated by NSD3 in an individual.
[0069] In some embodiments, the disease, disorder or condition mediated by NSD3 is selected from squamous cell lung carcinoma, breast cancer, esophageal cancer, head and neck cancer, bile duct cancer, hepatocellular carcinoma, gastric adenocarcinoma, pancreatic cancer and osteosarcoma. DETAILED DESCRIPTION
[0070] definition
[0071] Unless otherwise defined below, the meanings of all technical terms and scientific terms used herein are intended to be the same as those generally understood by those skilled in the art. Reference to the technology used herein is intended to refer to the technology generally understood in the art, including those changes in technology or replacement of equivalent technology that are obvious to those skilled in the art. Although it is believed that the following terms are well understood by those skilled in the art, the following definitions are still set forth to better explain the present invention.
[0072] The terms "comprising," "including," "having," "containing," or "involving," and other variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps (i.e., these terms also encompass the terms "consisting essentially of" and "consisting of").
[0073] As used herein, the term "alkane" means a straight-chain or branched saturated aliphatic hydrocarbon.
[0074] As used herein, the term "alkyl" means a linear or branched monovalent saturated aliphatic hydrocarbon, which can be viewed as a group derived from an alkane by losing one hydrogen atom. In some embodiments, the alkyl group has 1 to 12, such as 1 to 6 (e.g., 1, 2, 3, 4, 5, or 6) carbon atoms. For example, as used herein, the term "C 1-6 "Alkyl" refers to a straight or branched chain group of 1 to 6 carbon atoms, including "C 2-6 Alkyl", "C 2-5 Alkyl", "C 1-4 Alkyl", "C 1-3 Alkyl" and "C 1-2 Alkyl". "C 1-6 Examples of "alkyl" include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl. The alkyl is optionally substituted with 1 or more (such as 1 to 3) suitable substituents such as halogen (in this case, the group is referred to as "haloalkyl", for example CF 3 , C 2 F 5 , CHF 2 , CH 2 F, CH 2 CF 3 , CH 2 Cl or -CH 2 CH 2 CF 3 The term “C 1-4The term "alkyl" refers to an alkyl group having 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
[0075] As used herein, the term "alkylene" refers to a linear or branched divalent saturated aliphatic hydrocarbon obtained by further losing 1 H from the above-mentioned "alkyl". In some embodiments, the alkylene group has 1 to 12 carbon atoms, preferably 1, 2, 3, 4, 5 or 6 carbon atoms, such as methylene, ethylene, propylene or butylene.
[0076] As used herein, the term "alkenyl" means a linear or branched monovalent aliphatic hydrocarbon group containing one or more double bonds. In some embodiments, the alkenyl group has 2-6 carbon atoms ("C 2-6 alkenyl), for example 2 to 4 carbon atoms ("C 2-4 alkenyl"), or 2 to 3 carbon atoms ("C 2-3 Examples of the alkenyl group include, for example, -CH=CH 2 、-CH 2 CH=CH 2 、-C(CH 3 )=CH 2 、-CH 2 -CH=CH-CH 3 , 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl and 4-methyl-3-pentenyl. When the compounds of the present invention contain alkenyl, the compounds may be present in pure E (entgegen) form, pure Z (zusammen) form or any mixture thereof. The term "alkenylene" is the corresponding divalent radical, including, for example, "C 2-6 Alkenylene", "C 2-4 "Alkenylene" and "C 2-3 "Alkenylene", etc., specific examples of which include but are not limited to: -CH=CH-, -CH 2 CH=CH-, -C(CH 3 )=CH-, butenylene, pentenylene, hexenylene, cyclopentenylene, cyclohexenylene and the like.
[0077] As used herein, the term "alkynyl" means a linear or branched monovalent aliphatic hydrocarbon group containing one or more triple bonds. In some embodiments, the alkynyl group has 2, 3, 4, 5, or 6 carbon atoms ("C 2-6 alkynyl”), for example 2 to 4 carbon atoms (“C 2-4 alkynyl”), or 2 to 3 carbon atoms (“C 2-3The alkynyl group is optionally substituted with one or more (such as 1 to 3) identical or different substituents. The term "alkynylene" is a corresponding divalent group, including, for example, "C 2-6 Alkynylidene", "C 2-4 Alkynylidene" and "C 2-3 Examples include, but are not limited to, The alkynylene group is optionally substituted with one or more (such as 1 to 3) identical or different substituents.
[0078] As used herein, the terms "cycloalkyl", "hydrocarbon ring" and "cycloalkylene" refer to saturated (i.e., "cycloalkyl" and "cycloalkylene") or partially unsaturated (i.e., having one or more double bonds (i.e., "cycloalkenyl" and "cycloalkenylene") and / or triple bonds in the ring) monocyclic or polycyclic fused hydrocarbon rings having, for example, 3-10 (suitably 3-8, more suitably 3-7, 3-6, 4-6 or 5-6) ring carbon atoms. Rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, etc. In some embodiments, cycloalkyl includes aryl-fused cycloalkyl, as long as the entire ring system is non-aromatic.
[0079] As used herein, the term "fused" means that two or more ring structures share two adjacent atoms with each other.
[0080] As used herein, the terms "cycloalkyl" and "cycloalkylene" refer to a saturated monocyclic or polycyclic (such as bicyclic) fused hydrocarbon ring (e.g., a monocyclic ring such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or a bicyclic ring such as ). The cycloalkyl and cycloalkylene groups have 3 to 10 carbon atoms, suitably 3-8, such as 3-7, 3-6, 4-6 or 5-6 carbon atoms. For example, the term "C 3-6 "Cycloalkyl" refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring of 3 to 6 ring carbon atoms (for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl). The cycloalkyl and "cycloalkylene" are optionally substituted by 1 or more (such as 1 to 3) suitable substituents (for example, methyl or halogen), for example, methyl-substituted cyclopropyl.
[0081] As used herein, the terms "cycloalkenyl" and "cycloalkenylene" refer to monocyclic or polycyclic (such as bicyclic) fused hydrocarbon rings (e.g., monocyclic, such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadiene, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cyclooctenyl, cyclononenyl, or bicyclic) having one or more double bonds in the ring. The cycloalkenyl and "cycloalkenylene" have 3 to 10 carbon atoms, suitably 3-8, such as 3-7, 3-6, 4-6 or 5-6. The cycloalkenyl and cycloalkenylene are optionally substituted with 1 or more (such as 1 to 3) suitable substituents, such as methyl-substituted cyclopentenyl.
[0082] As used herein, the terms "heterocyclyl", "heterocycle" and "heterocyclylene" refer to a saturated (i.e., "heterocycloalkyl" and "heterocycloalkylene") or partially unsaturated (e.g., having one or more double bonds within the ring (i.e., "heterocycloalkenyl" and "heterocycloalkenylene")) monovalent monocyclic or bicyclic fused ring structure having 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms in the ring and 1 or more (e.g., 1, 2, 3 or 4) selected from O, S, S(O), S(O) 2 and NR' containing heteroatoms, wherein R' is a hydrogen atom, C 1-6 Alkyl or C 1-6 Haloalkyl. One or more ring carbon atoms in the heterocyclic group may be replaced by C(O). The heterocyclic group may be connected to the rest of the molecule via any of the carbon atoms or the nitrogen atom (if present). In particular, a 3-10 membered heterocyclic group is a group having 3-10 (e.g., 3-8, 3-7, 3-6, 4-6 or 5-6) carbon atoms and heteroatoms in the ring. Heterocyclic groups include nitrogen-containing heterocyclic groups, oxygen-containing heterocyclic groups and sulfur-containing heterocyclic groups. Examples that can be listed include, but are not limited to, oxirane, aziridine, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, dioxolyl, pyrrolidinyl, pyrrolidonyl, oxazolidine, thiazolidinyl, pyrazolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, hexahydropyrimidinyl, triazinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, azocyclooctanyl, dihydropyrrolyl, dihydroimidazolyl, azocyclooctenyl. The heterocyclic radical is optionally substituted by one or more (such as 1 to 3) suitable substituents (e.g., halogen, OH, NH 2 , C 1-6 Alkyl, C 1-6 haloalkyl) substituted.
[0083] As used herein, the term "nitrogen-containing heterocyclic group" refers to a saturated or unsaturated monocyclic or bicyclic group having 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms and at least one nitrogen atom in the ring, which may also optionally contain one or more (e.g., 1, 2, 3 or 4) selected from N, O, C(O), S, S(O) and S(═O). 2 Ring members. One or more ring carbon atoms in the nitrogen-containing heterocyclic group can be replaced by C (O). The nitrogen-containing heterocyclic group can be connected to the rest of the molecule by any one of the carbon atoms or a nitrogen atom. The nitrogen-containing heterocyclic group can be a saturated nitrogen-containing monocyclic ring. In particular, 3 to 10 yuan of nitrogen-containing heterocyclic rings are groups having 3-10 carbon atoms and heteroatoms (at least one of which is a nitrogen atom) in the ring, including but not limited to three-membered nitrogen-containing heterocyclic rings (such as aziridine), four-membered nitrogen-containing heterocyclic rings (such as azetidinyl), five-membered nitrogen-containing heterocyclic rings (such as pyrrolyl, pyrrolidinyl (pyrrolidine ring), pyrrolinyl, pyrrolidonyl, imidazolyl, imidazolidinyl, imidazolinyl, pyrazolyl, pyrazolinyl), six-membered nitrogen-containing heterocyclic rings (such as piperidinyl (piperidine ring), morpholinyl, thiomorpholinyl, piperazinyl), seven-membered nitrogen-containing heterocyclic rings, etc.
[0084] As used herein, the term "heterocyclic group" includes nitrogen-containing heterocyclic groups, oxygen-containing heterocyclic groups and sulfur-containing heterocyclic groups, and covers fused ring structures, and the connection point of the fused ring structure with other groups can be on any ring in the fused ring structure. Therefore, the heterocyclic group of the present invention also includes but is not limited to heterocyclic groups and heterocyclic groups, heterocyclic groups and cycloalkyl groups, monoheterocyclic groups and monoheterocyclic groups, and monoheterocyclic groups and monocycloalkyl groups, such as 3-7 membered (mono) heterocyclic groups and 3-7 membered (mono) heterocyclic groups, 3-7 membered (mono) heterocyclic groups and (mono) cycloalkyl groups, 3-7 membered (mono) heterocyclic groups and C 4-6 (Mono)cycloalkyl, examples of which are not limited to pyrrolidinyl-cyclopropyl, cyclopentyl-aziridine, pyrrolidinyl-cyclobutyl, pyrrolidinyl-pyrrolidinyl, pyrrolidinyl-piperidinyl, pyrrolidinyl-piperazinyl, piperidinyl-morpholinyl, In some embodiments, heterocyclyl also includes heteroaryl-fused heterocyclyl or cycloalkyl, and aryl-fused heterocyclyl, as long as the entire ring system is non-aromatic. In some embodiments, heterocyclyl includes 5-6 membered monocyclic heteroaryl-fused C 5-6 Monocyclic cycloalkyl, 5-6 membered monocyclic heteroaryl fused 5-6 membered monocyclic heterocyclyl, and benzo fused 5-6 membered monocyclic heterocyclyl, such as pyrrolotetrahydropyridinyl, pyrazolotetrahydropyridinyl, imidazotetrahydropyridinyl, indolyl or indolonyl.
[0085] As used herein, the term "aryl" refers to an all-carbon monocyclic or fused-ring polycyclic aromatic group having a conjugated π electron system. 6-14"Aryl" means an aromatic group containing 6 to 14 (e.g. 6 to 12) carbon atoms, such as phenyl or naphthyl. The aryl group is optionally substituted by 1 or more (e.g. 1 to 3) suitable substituents (e.g. halogen, OH, CN, NO 2 , C 1-6 The term "aryl" refers to a monocyclic aromatic ring and at least one of the bicyclic aromatic rings is an aromatic ring. Representative examples include, but are not limited to, phenyl, naphthyl, indenyl, indanyl, wait.
[0086] As used herein, the term "heteroaryl" refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) aromatic ring system having 5 to 14 ring atoms, such as 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, specifically having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 carbon atoms and independently selected from N, O, S and S(O). 2 1, 2, 3, 4 or 5 identical or different heteroatoms. One or more ring carbon atoms in the heteroaryl group may be replaced by C(O). The heteroaryl group may be benzo-fused. Examples of heteroaryl groups include, but are not limited to, pyridyl, pyridone, pyrimidinyl, pyrimidone, pyrazinyl, pyridazinyl, thiazolyl, thienyl, oxazolyl, furanyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, triazinyl, oxadiazolyl, thiadiazolyl, benzothiazolyl, benzisothiazolyl, imidazopyridinyl, quinolyl, indolyl, pyrrolopyridazinyl, benzo furanyl, benzothienyl, indazolyl, benzoxazolyl, benzisoxazolyl, quinazolinyl, pyrrolopyridinyl, pyrazolopyrimidinyl, imidazopyridazinyl, pyrazolopyridinyl, triazolopyridinyl, isoquinolyl, tetrahydroisoquinolyl, benzimidazolyl, cinnolinyl, indolizinyl, phthalazinyl, isoindolyl, pteridinyl, purinyl, furazanyl, benzofurazanyl, quinoxalinyl, naphthyridinyl or furopyridinyl. Heteroaryl may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) suitable substituents. Wherein, the ring of the "heteroaryl" includes a monocyclic group is an aromatic ring and at least one of the fused rings of the bicyclic or tricyclic group is an aromatic ring, for example
[0087] As used herein, the term "halo" or "halogen" group is defined to include F, Cl, Br, or I.
[0088] As used herein, the term "haloalkyl" refers to an alkyl group substituted by one or more (such as 1 to 3) the same or different halogen atoms, said alkyl group being as defined herein. 1-6 Haloalkyl", "C 1-4 "Haloalkyl" and "C1-3 "Haloalkyl" refers to haloalkyl groups having 1 to 6 carbon atoms, 1 to 4 carbon atoms, and 1 to 3 carbon atoms, respectively, such as -CF 3 , -C 2 F 5 , -CHF 2 、-CH 2 F, -CH 2 CF 3 、-CH 2 Cl or -CH 2 CH 2 CF 3 wait.
[0089] The term "substituted" means that one or more (e.g., one, two, three, or four) hydrogens on the designated atom are replaced by a selection from the indicated group, provided that the normal valence of the designated atom in the present context is not exceeded and the substitution forms a stable compound. Combinations of substituents and / or variables are permitted only if such combinations form stable compounds.
[0090] If a group is described as "optionally substituted by" or "optionally substituted", the group can be: (1) unsubstituted or (2) substituted. If a carbon of a group is described as optionally substituted by one or more of the listed substituents, one or more hydrogens on that carbon (to the extent of any hydrogens present) can be replaced, individually and / or together, with independently selected optional substituents. If a nitrogen of a group is described as optionally substituted by one or more of the listed substituents, one or more hydrogens on the nitrogen (to the extent of any hydrogens present) can each be replaced with an independently selected optional substituent. The optional substituents can be selected from: halogen, OH, SH, CN, NO 2 , C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -O-halogenated C 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -SC 1-6 Alkyl, NH 2 、-NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2 , -C 1-6 Alkylene -OH, -C 1-6 Alkylene -SH, -C 1-6 Alkylene -CN, -C 1-6 Alkylene-NH 2 , -C 1-6Alkylene-NH(C 1-6 Alkyl), -C 1-6 Alkylene-N(C 1-6 alkyl) 2 , -C 1-6 Alkyl-OC 1-6 Alkyl, -C 0-6 Alkylene -C(O)OH, -C 0-6 Alkylene-C(O)OC 1-6 Alkyl, -C 0-6 Alkylene-C(O)NH 2 , -C 0-6 Alkylene-C(O)NH(C 1-6 Alkyl), -C 0-6 Alkylene-C(O)N(C 1-6 alkyl) 2 , -C 0-6 Alkylene-S(O) 2 C 1-6 Alkyl, -C 0-6 Alkylene-S(O) 2 NH 2 , -C 0-6 Alkylene-S(O) 2 NH(C 1-6 Alkyl), -C 0-6 Alkylene-S(O) 2 N(C 1-6 alkyl) 2 、-NH-C(O)C 1-6 Alkyl, -N(C 1-6 Alkyl)-C(O)C 1-6 Alkyl, -NH-C(O)OH, -NH-C(O)OC 1-6 Alkyl, -N(C 1-6 Alkyl)-C(O)OC 1-6 Alkyl, -NH-C(O)NH 2 、-NH-C(O)NH(C 1-6 alkyl), -NH-C(O)N(C 1-6 alkyl) 2 、-NH-S(O) 2 -C 1-6 Alkyl, -N(C 1-6 Alkyl)-S(O) 2 -C 1-6 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-(3-10 membered heterocyclic group), -C 0-6 Alkylene-phenyl and -C 0-6Alkylene-(5-10 membered heteroaryl).
[0091] If substituents are described as being "independently selected" from a group, each substituent is selected independently of the other. Thus, each substituent may be the same as or different from another (other) substituent.
[0092] As used herein, the term "one or more" means 1 or more than 1, such as 2, 3, 4, 5 or 10, where reasonable.
[0093] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.
[0094] When a bond to a substituent is shown as passing through a bond connecting two atoms in a ring (a "floating bond"), such a substituent may be bonded to any ring-forming atom in the substitutable ring, unless otherwise indicated. Where an available ring member is shown to carry a substitutable hydrogen atom, the substitutable hydrogen atom is substantially substituted (i.e., not present) when the floating bond is bonded to the available ring member.
[0095] The present invention also includes all pharmaceutically acceptable isotope-labeled compounds, which are identical to the compounds of the present invention, except that one or more atoms are replaced by atoms having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominant in nature. Examples of isotopes suitable for inclusion in the compounds of the present invention include, but are not limited to, isotopes of hydrogen (e.g., deuterium (D, 2 H), tritium (T, 3 H)); isotopes of carbon (e.g. 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 36 Cl); isotopes of fluorine (e.g. 18 F); isotopes of iodine (e.g. 123 I and 125 I); isotopes of nitrogen (e.g. 13 N and 15 N); isotopes of oxygen (e.g. 15 O. 17 O and 18 O); isotopes of phosphorus (e.g. 32 P); and sulfur isotopes (e.g. 35 S). Certain isotopically-labeled compounds of the invention (e.g., those incorporating a radioactive isotope) are useful in drug and / or substrate tissue distribution studies (e.g., assays). 3 H) and carbon-14 (i.e. 14 C) are particularly useful for this purpose because of their ease of incorporation and ease of detection.11 C. 18 F. 15 O and 13 N) substitution can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies. Isotope-labeled compounds of the present invention can be prepared by methods similar to those described in the accompanying routes and / or examples and preparations by using appropriate isotope-labeled reagents instead of the non-labeled reagents previously used. Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent can be isotopically substituted, for example, D 2 O, acetone-d 6 or DMSO-d 6 In some embodiments, the isotopically labeled compounds of the present invention are deuterated.
[0096] The term "stereoisomer" means an isomer formed due to at least one asymmetric center, which has the same chemical composition but different spatial arrangements of atoms or groups. In compounds with one or more (e.g., 1, 2, 3, or 4) asymmetric centers, it can produce a racemic mixture, a single enantiomer, a diastereomeric mixture, and a single diastereomer. Specific individual molecules can also exist as geometric isomers (cis / trans). Similarly, the compounds of the present invention can exist as mixtures (commonly referred to as tautomers) of two or more structures in rapid equilibrium in different forms. Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. It is to be understood that the scope of the present application encompasses all such isomers or mixtures thereof in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%).
[0097] "Diastereomers" refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Mixtures of diastereomers can be separated by high-resolution analytical methods such as electrophoresis and chromatography.
[0098] "Enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another.
[0099] The term "chiral" refers to molecules that have the property of non-superimposability of mirror image pairs, whereas the term "achiral" refers to molecules that are superimposable on their mirror image pairs.
[0100] The compounds of the invention may be prepared in racemic form, or individual enantiomers may be prepared by enantioselective synthesis or by resolution.
[0101] As used herein, the term "cis-trans isomers" or "geometric isomers" is caused by the inability to rotate freely around double bonds or single bonds of ring-forming carbon atoms. The compounds provided herein include all cis, trans, cis (syn), anti (anti), entgegen (E) and zusammen (Z) isomers and their corresponding mixtures.
[0102] In this article, solid lines can be used Solid wedge Virtual wedge Depicting chemical bonds of the compounds of the invention. The use of solid lines to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers at that carbon atom are included (e.g., specific enantiomers, racemic mixtures, etc.). The use of solid or dashed wedges to depict bonds to asymmetric carbon atoms is intended to indicate that the stereoisomers shown are present. When present in a racemic mixture, the solid and dashed wedges are used to define relative stereochemistry, not absolute stereochemistry. Unless otherwise indicated, the compounds of the invention are intended to exist in the form of stereoisomers, which include cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof. The compounds of the invention may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereoisomer pairs).
[0103] It should also be understood that certain compounds of the present invention may exist in free form for treatment, or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, metabolites or prodrugs, which, after being administered to a patient in need thereof, can directly or indirectly provide a compound of the present invention or a metabolite or residue thereof. Therefore, when referring to "compounds of the present invention" herein, the above-mentioned various derivative forms of the compounds are also intended to be covered.
[0104] The term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients making up the formulation and / or the mammal to be treated therewith.
[0105] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof.
[0106] Suitable acid addition salts are formed from acids that form pharmaceutically acceptable salts. Examples include aspartate, benzoate, bicarbonate / carbonate, bisulfate / sulfate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hydrobromide / bromide, hydroiodide / iodide, maleate, malonate, methylsulfate, naphthoate (naphthylate), nicotinate, nitrate, orotate, oxalate, palmitate and other similar salts.
[0107] Suitable base addition salts are formed from bases which form pharmaceutically acceptable salts. Examples include aluminum, arginine, choline, diethylamine, lysine, magnesium, meglumine, potassium and other similar salts.
[0108] For a review of suitable salts see Stahl and Wermuth, "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds of the invention are known to those skilled in the art.
[0109] As used herein, the term "ester" means an ester derived from the compounds of the general formulae herein, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release the compounds of the present invention in free acid or alcohol form). The compounds of the present invention themselves may also be esters.
[0110] The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be a single polymorph or a mixture of more than one polymorph in any ratio.
[0111] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain polar solvents as structural elements of the crystal lattice of the compounds, in particular water, methanol or ethanol. The amount of polar solvents, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.
[0112] Those skilled in the art will appreciate that not all nitrogen-containing heterocycles are capable of forming N-oxides, as nitrogen requires an available lone pair of electrons to oxidize to an oxide; those skilled in the art will recognize nitrogen-containing heterocycles that are capable of forming N-oxides. Those skilled in the art will also recognize that tertiary amines are capable of forming N-oxides. Synthetic methods for preparing N-oxides of heterocycles and tertiary amines are well known to those skilled in the art, including oxidation of heterocycles and tertiary amines with peroxyacids such as peracetic acid and meta-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxirane such as dimethyldioxirane. These methods for preparing N-oxides have been extensively described and reviewed in the literature, see for example: TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; AR Katritzky and AJ Boulton, Eds., Academic Press; and GWH Cheeseman and ES G Werstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, AR Katritzky and AJ Boulton, Eds., Academic Press.
[0113] Also included within the scope of the present invention are metabolites of the compounds of the present invention, i.e., substances formed in vivo upon administration of the compounds of the present invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic hydrolysis, etc. of the administered compound. Thus, the present invention includes metabolites of the compounds of the present invention, including compounds prepared by contacting the compounds of the present invention with a mammal for a period of time sufficient to produce a metabolic product thereof.
[0114] The present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may have less pharmacological activity or no pharmacological activity themselves, and can be converted into compounds of the present invention having the desired activity by, for example, hydrolytic cleavage when administered to the body or thereon. Usually such prodrugs will be functional group derivatives of the compounds, which are easily converted into the desired therapeutically active compounds in vivo. For additional information on the use of prodrugs, see "Pro-drugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series (T. Higuchi and V. Stella) and "Bioreversible Carriers in Drug Design," Pergamon Press, 1987 (EB Roche ed., American Pharmaceutical Association). The prodrugs of the present invention can be prepared, for example, by replacing appropriate functional groups present in the compounds of the present invention with certain parts known to those skilled in the art as "pro-moiety" (e.g., "Design of Prodrugs", H. Bundgaard (Elsevier, 1985)).
[0115] The present invention also encompasses compounds of the present invention containing protecting groups. In any process of preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive groups or reactive groups on any related molecules, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved by conventional protecting groups, for example, those described in Protective Groups in Organic Chemistry, ed. JFW McOmie, Plenum Press, 1973; and TW Greene & P. GMWuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Using methods known in the art, the protecting groups can be removed at an appropriate subsequent stage.
[0116] As used herein, the term "about" means within ±10% of the stated numerical value, preferably within ±5%, and more preferably within ±2%.
[0117] Compound
[0118] In one aspect, the present invention provides compounds of formula (I):
[0119]
[0120] or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably a deuterated compound), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof,
[0121] in:
[0122] Ring A is a benzene ring or a 5-6 membered heteroaryl group;
[0123] L is a direct key, C 1-6 Alkylene, -C 1-6 Alkylene-O-, or -OC 1-6 Alkylene-;
[0124] L 1 For direct keys, O, S, C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -SC 1-6 Alkylene-, -C 1-6 Alkylene-S-, -NH-CO- or -CO-NH-;
[0125] R 1 H or C 1-6 alkyl;
[0126] R 2 H or C 1-6 alkyl;
[0127] R 3 H, halogen, OH, NH 2 、CN、NO 2 or part;
[0128] Ring B is C 3-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl or 3-10 membered heterocyclyl;
[0129] R b OH, NH 2 、Halogen、CN、NO 2 , C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), C3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -NR 4 C(=O)CR 6 =C(R 6 ) 2 or -(CR 4 R 5 ) l -NR 4 -C(=O)-R 7 , wherein the C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted by 1, 2, 3 or more independently selected from OH, NH 2 、Halogen、CN、NO 2 , C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Substitution of haloalkyl groups;
[0130] Ring C is a 9-10 membered heteroaryl group having 2, 3, 4 or 5 nitrogen heteroatoms;
[0131] R c C 1-6 Alkyl or -OC 1-6 alkyl;
[0132] R is:
[0133] (1) optionally 1, 2 or more independently selected from halogen, OH, NH 2 、CN、NO 2 -OC substituted with COOH 1-6 alkyl;
[0134] (2)-NR e R f , where R e and R f are each independently H, or optionally substituted by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 and COOH substituted C 1-6 alkyl;
[0135] (3)–(CH 2 ) w -O-(CH 2 ) v -C 6-10 Aryl or
[0136] (4) part,
[0137] in:
[0138] Ring D is a 5-6 membered heterocycloalkyl group containing 1 nitrogen heteroatom and 0 or 1 O or S heteroatoms;
[0139] R a1 For: COOH, -NR g R h 、COOR g ,CONR g R h , or -C 1-6 Alkylene-NR g R h ;
[0140] Each R a2 Independently for:
[0141] (1) Halogen, OH, NH 2 、CN、NO 2 , COOH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C 1-6 Alkylene-SR g , -C 1-6 Halogenated alkylene -OR g , -C 1-6 Halogenated alkylene-SR g , -C 1-6 Alkylene-
[0142] NR g R h , -C 1-6 Alkylene -CN, -C 1-4 Alkylene-S(O)-C 1-6 Alkyl, -C 1-6 Alkylene-S(O) 2 -C 1-6 Alkyl, -C(C 1-6 alkyl)=NO(C 1-6 alkyl), -C(O)-C 1-6 Alkyl, or -C(O)-NR g R h ;or
[0143] (2)-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 , where R 14 For-OC 1-6 Alkyl, C 3-7 Cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, the C 3-7 The cycloalkyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl are each independently unsubstituted or substituted with C 1-6 Alkyl or -OC 1-6 Alkyl substitution; or
[0144] (3)-(CR 11 R 12 ) t -C(O)-NR 15 R 16 , where R 15 is hydrogen or C 1-6 Alkyl, R 16 For hydrogen, C 1-6 Alkyl, or 5-6 membered heterocyclic group; or R 15 and R 16 Together with the nitrogen atom to which they are attached, they form an unsubstituted or C 1-6 an alkyl-substituted 5-6 membered heterocyclic group; or
[0145] (4) 5-10 membered heterocyclic group, or -C 1-6 Alkylene-(5-10 membered heterocyclyl), wherein each of the 5-10 membered heterocyclyl is unsubstituted or replaced by C 1-6 Alkyl substitution; or
[0146] (5) 5-10 membered heteroaryl, or -C 1-6 Alkylene-(5-10 membered heteroaryl), wherein each of the 5-10 membered heteroaryl is unsubstituted or substituted with: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene-OH,
[0147] -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, halogen, OH, CN, -C(O)NH 2 , -C 1-6 Alkylene-C(O)NH 2 ,
[0148] -C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C 1-6 Alkyl, -C(O)N(C 1-6 alkyl) 2 , -C 1-6 Alkylene-C(O)N(C 1-6 alkyl) 2 , or -C 3-7 Cycloalkyl;
[0149] R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 、-OC 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The substituents of aryl and 5-10 membered heteroaryl are substituted with C 1-6 alkyl;
[0150] R 4 , R 5 , R 6 , R 11 , R 12 and R 13 Each time it appears, it is independently H, C 1-6 Alkyl or -C 3-7 Cycloalkyl;
[0151] R 7 C 1-6 Alkyl or C 1-6 Haloalkyl;
[0152] l, m, n, p, q, w, v and s are each independently 0, 1, 2, 3 or 4;
[0153] t is independently 1, 2, 3 or 4; and
[0154] in:
[0155] When the R 1 and R 2 are all H, the ring C is The ring A is a pyridyl ring, the L and L 1 are all direct bonds, and the R is the part, the ring D is a piperidinyl ring, and the R a1 and R a2 At least one of them is NH 2 , then the following conditions are met:
[0156] (1) If p is not 0, then R a1 With at least one R a2 Connect to the same location;
[0157] (2) If n is 1, then R b Not halogen;
[0158] (3) If n is greater than 1, then R b Not all halogens; and
[0159] (4) The compound of formula (I) is not any of the compounds disclosed in Examples 1-325 of international patent application WO2021026803, in particular not the following compounds, or their stereoisomers, tautomers, diastereomers, racemates, cis-trans isomers, isotope-labeled compounds, N-oxides, metabolites, esters, prodrugs, crystalline forms, hydrates, solvates or pharmaceutically acceptable salts:
[0160]
[0161]
[0162]
[0163]
[0164]
[0165] In some embodiments, the present invention provides compounds of formula (I):
[0166]
[0167] or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably a deuterated compound), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof,
[0168] in:
[0169] Ring A is a benzene ring or a 5-6 membered heteroaryl group;
[0170] L is a direct key, C 1-6 Alkylene, -C 1-6 Alkylene-O-, or -OC 1-6 Alkylene-;
[0171] L 1 For direct keys, O, S, C 1-6 Alkylene, C 2-6 Alkenylene, C2-6 Alkynylidene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -SC 1-6 Alkylene-, -C 1-6 Alkylene-S-, -NH-CO- or -CO-NH-;
[0172] R 1 H or C 1-6 alkyl;
[0173] R 2 H or C 1-6 alkyl;
[0174] R 3 H, halogen, OH, NH 2 、CN、NO 2 or part;
[0175] Ring B is C 3-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl or 3-10 membered heterocyclyl;
[0176] R b OH, NH 2 、Halogen、CN、NO 2 , C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -NR 4 C(=O)CR 6 =C(R 6 ) 2 or -(CR 4 R 5 ) l -NR 4 -C(=O)-R 7 , wherein the C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted by 1, 2, 3 or more independently selected from OH, NH 2 、Halogen、CN、NO 2 , C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Substitution of haloalkyl groups;
[0177] Ring C is a 9-10 membered heteroaryl group having 2, 3, 4 or 5 nitrogen heteroatoms;
[0178] R c C 1-6 Alkyl or -OC 1-6 alkyl;
[0179] R is:
[0180] (1) optionally 1, 2 or more independently selected from halogen, OH, NH 2 、CN、NO 2 -OC substituted with COOH 1-6 alkyl;
[0181] (2)-NR e R f , where R e and R f are each independently H, or optionally substituted by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 and COOH substituted C 1-6 Alkyl; or
[0182] (3) part,
[0183] in:
[0184] Ring D is a 5-6 membered heterocycloalkyl group containing 1 nitrogen heteroatom and 0 or 1 O or S heteroatoms;
[0185] R a1 For: COOH, -NR g R h , or -C 1-6 Alkylene-NR g R h ;
[0186] Each R a2 Independently for:
[0187] (1) Halogen, OH, NH 2 、CN、NO 2 , COOH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C1-6 Alkylene-SR g , -C 1-6 Halogenated alkylene -OR g , -C 1-6 Halogenated alkylene-SR g , -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C 1-4 Alkylene-S(O)-C 1-6 Alkyl, -C 1-6 Alkylene-S(O) 2 -C 1-6 Alkyl, -C(C 1-6 alkyl)=NO(C 1-6 alkyl), -C(O)-C 1-6 Alkyl, or -C(O)-NR g R h ;or
[0188] (2)-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 , where R 14 C 3-7 Cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, the C 3-7 The cycloalkyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl are each independently unsubstituted or substituted with C 1-6 Alkyl or -OC 1-6 Alkyl substitution; or
[0189] (3)-(CR 11 R 12 ) t -C(O)-NR 15 R 16 , where R 15 is hydrogen or C 1-6 Alkyl, R 16 For hydrogen, C 1-6 Alkyl or 5-6 membered heterocyclic group; or R 15 and R 16 Together with the nitrogen atom to which they are attached, they form an unsubstituted or C 1-6 an alkyl-substituted 5-6 membered heterocyclic group; or
[0190] (4) 5-10 membered heterocyclic group, or -C 1-6Alkylene-(5-10 membered heterocyclyl), wherein each of the 5-10 membered heterocyclyl is unsubstituted or replaced by C 1-6 Alkyl substitution; or
[0191] (5) 5-10 membered heteroaryl, or -C 1-6 Alkylene-(5-10 membered heteroaryl), wherein each of the 5-10 membered heteroaryl is unsubstituted or substituted with: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, halogen, OH, CN, -C(O)NH 2 , -C 1-6 Alkylene-C(O)NH 2 、-C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C 1-6 Alkyl, -C(O)N(C 1-6 alkyl) 2 , -C 1-6 Alkylene-C(O)N(C 1-6 alkyl) 2 , or -C 3-7 Cycloalkyl;
[0192] R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 、-OC 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The substituents of aryl and 5-10 membered heteroaryl are substituted with C 1-6 alkyl;
[0193] R 4 , R 5 , R 6 , R 11 , R 12 and R 13 Each occurrence is independently H or C 1-6 alkyl;
[0194] R 7 C 1-6 Alkyl or C 1-6 Haloalkyl;
[0195] l, m, n, p, q and s are each independently 0, 1, 2, 3 or 4;
[0196] t is independently 1, 2, 3 or 4; and
[0197] in:
[0198] When the R 1 and R 2 are all H, the ring C is The ring A is a pyridyl ring, the L and L 1 are all direct bonds, and the R is the part, the ring D is a piperidinyl ring, and the R a1 and R a2 At least one of them is NH 2 , then the following conditions are met:
[0199] (1) If p is not 0, then R a1 With at least one R a2 Connect to the same location;
[0200] (2) If n is 1, then R b Not halogen;
[0201] (3) If n is greater than 1, then R b Not all halogens; and
[0202] (4) The compound of formula (I) is not any of the compounds disclosed in Examples 1-325 of international patent application WO2021026803, in particular not the following compounds, or their stereoisomers, tautomers, diastereomers, racemates, cis-trans isomers, isotope-labeled compounds, N-oxides, metabolites, esters, prodrugs, crystalline forms, hydrates, solvates or pharmaceutically acceptable salts:
[0203]
[0204]
[0205]
[0206]
[0207]
[0208] In some embodiments, the present invention provides compounds of formula (I):
[0209]
[0210] or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably a deuterated compound), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof,
[0211] in:
[0212] Ring A is a benzene ring or a 6-membered heteroaryl group;
[0213] L is a direct key, C 1-6 Alkylene, -C 1-6 Alkylene-O-, or -OC 1-6 Alkylene-;
[0214] L 1 For direct keys, O, S, C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -SC 1-6 Alkylene-, -C 1-6 Alkylene-S-, -NH-CO- or -CO-NH-;
[0215] R 1 H or C 1-6 alkyl;
[0216] R 2 H or C 1-6 alkyl;
[0217] R 3 H, Br, OH, NH 2 、CN、NO 2 or part;
[0218] Ring B is C 3-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl or 3-10 membered heterocyclyl;
[0219] R b OH, NH 2 、Halogen、CN、NO 2 , oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C6-10 Aryl, 5-10 membered heteroaryl, -NR 4 C(=O)CR 6 =C(R 6 ) 2 or -(CR 4 R 5 ) l -NR 4 -C(=O)-R 7 , wherein the C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted by 1, 2, 3 or more independently selected from OH, NH 2 、Halogen、CN、NO 2 , C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Substitution of haloalkyl groups;
[0220] Preferably, R b OH, NH 2 , halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, wherein the C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted by 1, 2, 3 or more independently selected from OH, NH 2 , halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Substitution of haloalkyl groups;
[0221] Ring C is a 9-10 membered heteroaryl group having 2, 3, 4 or 5 nitrogen heteroatoms;
[0222] R c C 1-6 Alkyl or -OC 1-6 alkyl;
[0223] R is:
[0224] (1) optionally 1, 2 or more independently selected from halogen, OH, NH 2 、CN、NO 2 -OC substituted with COOH 1-6 Alkyl; or
[0225] (2)-NR e R f , where R e and R f are each independently H, or optionally substituted by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 and COOH substituted C 1-6 Alkyl; or
[0226] (3)–(CH 2 ) w -O-(CH 2 ) v -C 6-10 aryl; or
[0227] (4) part;
[0228] Preferably, R is:
[0229] (1) optionally 1, 2 or more independently selected from halogen, OH, NH 2 、CN、NO 2 -OC substituted with COOH 1-6 Alkyl; or
[0230] (2)-NR e R f , where R e and R f are each independently H, or optionally substituted by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 and COOH substituted C 1-6 Alkyl; or
[0231] (3) part;
[0232] in:
[0233] Ring D is a 5-6 membered heterocycloalkyl group containing 1 nitrogen heteroatom and 0 or 1 O or S heteroatoms;
[0234] R a1 For: COOH, -NR g R h 、COOR g,CONR g R h , or -C 1-6 Alkylene-NR g R h ;
[0235] Each R a2 Independently for:
[0236] (1) Halogen, NH 2 、CN、NO 2 , COOH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C 1-6 Alkylene-SR g , -C 1-6 Halogenated alkylene-SR g , -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C 1-4 Alkylene-S(=O)-C 1-6 Alkyl, -C 1-6 Alkylene-S(=O) 2 -C 1-6 Alkyl, -C(=O)-C 1-6 Alkyl, or -C(=O)-NR g R h ;or
[0237] (2)-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 , where R 14 For-OC 1-6 Alkyl, C 3-7 Cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, the C 3-7 The cycloalkyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl are each independently unsubstituted or substituted with C 1-6 Alkyl or -OC 1-6 Alkyl substitution; or
[0238] (3)-(CR 11 R 12 ) t -C(=O)-NR 15 R 16 , where R 15 is hydrogen or C 1-6 Alkyl, R 16 For hydrogen, C 1-6 Alkyl, or 5-6 membered heterocyclic group; or R 15 and R 16 Together with the nitrogen atom to which they are attached, they form an unsubstituted or C 1-6 an alkyl-substituted 5-6 membered heterocyclic group; or
[0239] (4) 5-10 membered heterocyclic group, or -C 1-6 Alkylene-(5-10 membered heterocyclyl), wherein each of the 5-10 membered heterocyclyl is unsubstituted or replaced by C 1-6 The heteroatoms of the 5-10 membered heterocyclic group are selected from 0, 1, 2 or 3 N atoms and 0 or 1 O or S atoms; or
[0240] (5) 5-10 membered heteroaryl, wherein each of the 5-10 membered heteroaryl is unsubstituted or substituted by the following groups: 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, OH, CN, -C(=O)NH 2 , -C 1-6 Alkylene-C(=O)NH 2 、-C(=O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(=O)NH-C 1-6 Alkyl, -C(=O)N(C 1-6 alkyl) 2 , -C 1-6 Alkylene-C(=O)N(C 1-6 alkyl) 2 , or -C 3-7 Cycloalkyl;
[0241] R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from halogen, OH, NH 2 、CN、NO 2 , C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-10Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The substituents of aryl and 5-10 membered heteroaryl are substituted with C 1-6 alkyl;
[0242] R 4 , R 5 , R 6 , R 11 , R 12 and R 13 Each time it appears, it is independently H, C 1-6 Alkyl or C 3-7 Cycloalkyl;
[0243] Preferably, R 4 , R 5 , R 6 , R 11 , R 12 and R 13 Each occurrence is independently H or C 1-6 alkyl;
[0244] R 7 C 1-6 Alkyl or C 1-6 Haloalkyl;
[0245] l, m, n, p, q, w, v and s are each independently 0, 1, 2, 3 or 4;
[0246] t is independently 1, 2, 3 or 4; and
[0247] in:
[0248] When the R 1 and R 2 are H, L and L 1 are all direct bonds, and the R is the part, the ring D is a piperidinyl ring, and the R a1 and R a2 At least one of them is NH 2 , then the following conditions are met:
[0249] (1) If p is not 0, then R a1 With at least one R a2 Connect to the same location;
[0250] (2) If n is 1, then R b Not halogen;
[0251] (3) If n is greater than 1, then R b Not all halogens; and
[0252] (4) Ring C is not
[0253] (5) The compound of formula (I) is not the following compound, or its stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound, N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt:
[0254]
[0255] In some embodiments, R is optionally substituted by 1 or 2 independently selected from F, Cl, OH, NH 2 、CN、NO 2 -OC substituted with COOH 1-6 alkyl.
[0256] Preferably, R is optionally substituted by 1 or 2 independently selected from NH 2 -OC substituted with COOH 1-4 alkyl.
[0257] More preferably, R is -O-(CH 2 ) 2 -NH 2 、-O-(CH 2 ) 3 -NH 2 or -O-(CH 2 ) 2 -CH(COOH)-NH 2 .
[0258] In other embodiments, R is -NR e R f .
[0259] In some embodiments, R e and R f Each is independently H, or is optionally substituted by 1, 2, 3 or more independently selected from F, Cl, OH, NH 2 、CN、NO 2 and COOH substituted C 1-6 alkyl.
[0260] In some preferred embodiments, R e and R f Each is independently H, or is optionally substituted by 1, 2 or 3 independently selected from F, Cl, OH, NH 2 and CN substituted C 1-4 alkyl.
[0261] In some more preferred embodiments, R e and Rf Each independently is CH 3 , or -(CH 2 ) 2 -NH 2 .
[0262] In some more preferred embodiments, R is -N(CH 3 )-(CH 2 ) 2 -NH 2 .
[0263] In other embodiments, R is -(CH 2 ) w -O-(CH 2 ) v -C 6-10 Aryl, wherein w and v are preferably each independently 0, 1 or 2.
[0264] Preferably, w and v are both 1.
[0265] Preferably, the -(CH 2 ) w -O-(CH 2 ) v -C 6-10 C in aromatic groups 6-10 Aryl is phenyl.
[0266] In other embodiments, R is -(CH 2 )-O-(CH 2 )-phenyl.
[0267] In other embodiments, R is part.
[0268] In some embodiments, R 3 H, F, Cl, Br, OH, NH 2 、NO 2 or part.
[0269] In some embodiments, R 3 H, Br, OH, NH 2 、CN、NO 2 or part.
[0270] In some embodiments, R 3 H, F, Cl, Br or part.
[0271] In some embodiments, R 3 is H, Br or part;
[0272] In some preferred embodiments, R 3 For the part.
[0273] In some embodiments, the present invention provides a compound of formula (I) as described above, wherein the compound has a structure shown in formula (I-0):
[0274]
[0275] In some embodiments as described above, R 1 H or C 1-3 Alkyl, preferably H.
[0276] In some embodiments as described above, R 2 H or C 1-3 Alkyl, preferably H.
[0277] In some embodiments, the ring C is a 9-membered heteroaryl group containing 2, 3 or 4 nitrogen heteroatoms. Preferably, the ring C is a structure shown in the following formula:
[0278]
[0279] wherein X is N or CH, and Y is N or CH.
[0280] More preferably, the ring C is Even more preferred
[0281] In some embodiments, R c C 1-4 Alkyl or -OC 1-4 alkyl.
[0282] In some embodiments, m is 0 or 1.
[0283] In some embodiments, m is 0.
[0284] In some embodiments, the present invention provides a compound of formula (I) as described above, wherein the compound has a structure shown in formula (I-1), formula (I-2), formula (I-3) or formula (I-4):
[0285]
[0286] In some embodiments as described above, the ring A is a benzene ring or a 5-6 membered nitrogen-containing heteroaryl group.
[0287] In some embodiments, the ring A is a benzene ring or a 6-membered nitrogen-containing heteroaryl group.
[0288] In some embodiments, the ring A is a benzene ring or a 5-6 membered heteroaryl ring containing 1, 2 or 3 nitrogen heteroatoms.
[0289] In some embodiments, the ring A is a benzene ring or a 6-membered heteroaryl containing 1, 2, or 3 nitrogen heteroatoms.
[0290] In some embodiments, the ring A is a benzene ring or a 6-membered heteroaryl ring containing 1 or 2 nitrogen heteroatoms.
[0291] In some embodiments, the ring A is a benzene ring, a pyridyl ring, or a pyridazinyl ring.
[0292] In some embodiments, Ring A is: Where the bond identified by "a" is connected to L, the bond identified by "b" is connected to R, and the bond identified by "c" is connected to L 1 .
[0293] In some embodiments, Ring A is
[0294] In some embodiments, L is a direct bond, C 1-3 Alkylene, -C 1-3 Alkylene-O-, or -OC 1-3 Preferably, L is C 1-2 More preferably, L is -CH 2 -or-CH(CH) 3 -. Even more preferably, L is -CH 2 -.
[0295] In some embodiments, the present invention provides a compound of formula (I) as described above, wherein the compound has a structure shown in formula (I-5), formula (I-6) or formula (I-7):
[0296]
[0297] In some embodiments as described above, the ring D is pyrrolidinyl, piperidinyl, morpholinyl, or thiomorpholinyl.
[0298] In some preferred embodiments, the ring D is pyrrolidinyl or piperidinyl, more preferably Further more preferably
[0299] In some embodiments, R a1 COOH, -NR g R h 、COOR g ,CONRg R h , or -C 1-3 Alkylene-NR g R h .
[0300] Preferably, R a1 COOH, -NR g R h 、COOR g ,CONR g R h , or -C 1-2 Alkylene-NR g R h .
[0301] In some embodiments, R a1 COOH, -NR g R h , or -C 1-3 Alkylene-NR g R h .
[0302] Preferably, R a1 COOH, -NR g R h , or -C 1-2 Alkylene-NR g R h .
[0303] Preferably, R a1 For-NR g R h .
[0304] In some such embodiments, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2 or 3 independently selected from F, Cl, OH, NH 2 、CN、NO 2 and-OC 1-3 Alkyl substituents substituted C 1-3 alkyl.
[0305] Preferably, R g and R h Each occurrence is independently H.
[0306] In some embodiments, R a1 COOH, NH 2 、-NH-CH 2 CH 2 -OH, COOCH(CH 3 ) 2、CONHCH 3 , or -CH 2 -NH 2 .
[0307] Preferably, R a1 COOH, NH 2 、-NH-CH 2 CH 2 -OH or -CH 2 -NH 2 .
[0308] Preferably, R a1 COOCH(CH 3 ) 2 、CONHCH 3 or NH 2 .
[0309] Preferably, R a1 CONHCH 3 or NH 2 .
[0310] Preferably, R a1 For NH 2 .
[0311] In some embodiments as described above, Parts are:
[0312] in particular or
[0313] in particular or
[0314] in particular in particular Best
[0315] where p is independently 0 or 1 at each occurrence.
[0316] In some embodiments, the present invention provides a compound of formula (I) as described above, wherein the compound has a structure shown in formula (I-8):
[0317]
[0318] Where: X 1 N or CH, Y 1 is N or CH, r is 0 or 1, and p is 0 or 1.
[0319] In some preferred embodiments, the compound has a structure shown by formula (I-9), formula (I-10), formula (I-11), formula (I-12) or formula (I-13):
[0320]
[0321] where p is independently 0 or 1 at each occurrence.
[0322] In other embodiments, the present invention provides a compound of formula (I) as described above, wherein the compound has a structure shown in formula (I-14):
[0323]
[0324] Where: X 1 N or CH, Y 1 is N or CH, r is 0 or 1, and p is 0 or 1.
[0325] In some preferred embodiments, the compound has a structure shown in formula (I-15) or formula (I-16):
[0326]
[0327] where p is independently 0 or 1 at each occurrence.
[0328] In other embodiments, the present invention provides a compound of formula (I) as described above, wherein the compound has a structure shown in formula (I-17):
[0329]
[0330] Where: X 1 N or CH, Y 1 is N or CH, r is 0 or 1, and p is 0 or 1.
[0331] In some preferred embodiments, the compound has a structure shown in formula (I-18):
[0332]
[0333] In other embodiments, the present invention provides a compound of formula (I) as described above, wherein the compound has a structure shown in formula (I-19):
[0334]
[0335] Where: X 1 N or CH, Y 1 is N or CH, r is 0 or 1, and p is 0 or 1.
[0336] In some preferred embodiments, the compound has a structure shown in formula (I-20:
[0337]
[0338] In some embodiments as described above, each R a2 Independently: halogen, OH, NH 2 、CN、NO 2 , COOH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C(O)-NR g R h 、-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 or a 5-10 membered heteroaryl group, wherein each of the 5-10 membered heteroaryl groups is unsubstituted or substituted by: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, halogen, OH, CN, -C(O)NH 2 , -C 1-6 Alkylene-C(O)NH 2 、-C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C 1-6 Alkyl, -C(O)N(C 1-6 alkyl) 2 , -C 1-6 Alkylene-C(O)N(C 1-6 alkyl) 2 , or -C 3-7 Cycloalkyl;
[0339] In some preferred embodiments, each Ra2 independently: halogen, NH 2 、CN、NO 2 , COOH, C 1-6 Alkyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C(O)-NR g R h 、-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 or a 5-10 membered heteroaryl group, wherein each of the 5-10 membered heteroaryl groups is unsubstituted or substituted by: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, OH, CN, -C(O)NH 2 , -C 1-6 Alkylene-C(O)NH 2 、-C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C 1-6 Alkyl, -C(O)N(C 1-6 alkyl) 2 , -C 1-6 Alkylene-C(O)N(C 1-6 alkyl) 2 , or -C 3-7 Cycloalkyl.
[0340] In some preferred embodiments, each R a2 Independently: F, Cl, OH, NH 2 、CN、NO 2 , COOH, C 1-3 Alkyl, C 1-3 Haloalkyl, C 2-4 Alkynyl, -C 1-3 Alkylene-OR g , -C1-3 Alkylene-NR g R h , -C 1-3 Alkylene -CN, -C(O)-NR g R h 、-C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 or a 5-10 membered heteroaryl group, wherein each of the 5-10 membered heteroaryl groups is unsubstituted or substituted by: C 1-3 Alkyl, halogenated C 1-3 Alkyl, -C 1-3 Alkylene -OH, -OC 1-3 Alkyl, -OC 1-3 Alkyl halide, F, Cl, OH, CN, -C(O)NH 2 , -C 1-3 Alkylene-C(O)NH 2 、-C(O)NH-C 1-3 Alkyl, -C 1-3 Alkylene-C(O)NH-C 1-3 Alkyl, -C(O)N(C 1-3 alkyl) 2 , -C 1-3 Alkylene-C(O)N(C 1-3 alkyl) 2 , or -C 3-7 Cycloalkyl.
[0341] In some preferred embodiments, each R a2 Independently: F, Cl, NH 2 、CN、NO 2 , COOH, C 1-3 Alkyl, C 2-4 Alkynyl, -C 1-3 Alkylene-OR g , -C 1-3 Alkylene-NR g R h , -C 1-3 Alkylene -CN, -C(O)-NR g R h 、-C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 or a 5-10 membered heteroaryl group, wherein each of the 5-10 membered heteroaryl groups is unsubstituted or substituted by: C1-3 Alkyl, halogenated C 1-3 Alkyl, -C 1-3 Alkylene -OH, -OC 1-3 Alkyl, -OC 1-3 Haloalkyl, OH, CN, -C(O)NH 2 , -C 1-3 Alkylene-C(O)NH 2 、-C(O)NH-C 1-3 Alkyl, -C 1-3 Alkylene-C(O)NH-C 1-3 Alkyl, -C(O)N(C 1-3 alkyl) 2 , -C 1-3 Alkylene-C(O)N(C 1-3 alkyl) 2 , or -C 3-7 Cycloalkyl.
[0342] In some preferred embodiments, each R a2 Independently: halogen, OH, NH 2 、CN、NO 2 , COOH, C 1-6 Alkyl, C 1-6 Haloalkyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C(O)-NR g R h , or -(CR 11 R 12 ) q -C(=O)-OR 13 or a 5-10 membered heteroaryl group, wherein each of the 5-10 membered heteroaryl groups is unsubstituted or substituted by: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, halogen, OH, CN, -C(O)NH 2 , -C 1-6 Alkylene-C(O)NH 2 、-C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C1-6 Alkyl, -C(O)N(C 1-6 alkyl) 2 , -C 1-6 Alkylene-C(O)N(C 1-6 alkyl) 2 , or -C 3-7 Cycloalkyl.
[0343] In some preferred embodiments, each R a2 Independently: F, Cl, OH, NH 2 、CN、NO 2 , COOH, C 1-3 Alkyl, C 1-3 Haloalkyl, -C 1-3 Alkylene-OR g , -C 1-3 Alkylene-NR g R h , -C 1-3 Alkylene -CN, -C(O)-NR g R h , or -C(=O)-OR 13 or a 5-10 membered heteroaryl group, wherein each of the 5-10 membered heteroaryl groups is unsubstituted or substituted by: C 1-3 Alkyl, halogenated C 1-3 Alkyl, -C 1-3 Alkylene -OH, -OC 1-3 Alkyl, -OC 1-3 Alkyl halide, F, Cl, OH, CN, -C(O)NH 2 , -C 1-3 Alkylene-C(O)NH 2 、-C(O)NH-C 1-3 Alkyl, -C 1-3 Alkylene-C(O)NH-C 1-3 Alkyl, -C(O)N(C 1-3 alkyl) 2 , -C 1-3 Alkylene-C(O)N(C 1-3 alkyl) 2 , or -C 3-7 Cycloalkyl.
[0344] In some preferred embodiments, each R a2 Independently: CN, COOH, -C(O)-NR g R h , -C 1-6 Alkylene-OR g 、-(CR 11 R 12 )q -C(=O)-OR 13 or an unsubstituted 5-10 membered heteroaryl.
[0345] In some preferred embodiments, each R a2 Independently: CN, COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 , 5-6 membered heteroaryl.
[0346] In some preferred embodiments, each R a2 Independently: CN, COOH, -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 or -C(O)-NR g R h or unsubstituted 5-membered heteroaryl, preferably oxazolyl, isoxazolyl, thiazolyl or isothiazolyl.
[0347] In some preferred embodiments, each R a2 independently: COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 .
[0348] In some embodiments, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from F, Cl, OH, NH 2 、CN、NO 2 , C 1-3 Alkyl, -OC 1-3 Alkyl, C 3-6 Cycloalkyl, C 6-10 The C substituted with aryl, 5-10 membered heteroaryl or 3-6 membered heterocyclic group 1-4 alkyl.
[0349] In some embodiments, R g and R h is independently H at each occurrence, or is optionally substituted by 1, 2 or 3 independently selected from halogen, -OH, C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-10 Cycloalkyl, C 6-10The C substituted by the substituent of the aryl group or the 3-10 membered heterocyclic group 1-6 alkyl.
[0350] In some such embodiments, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from F, Cl, OH, NH 2 、CN、NO 2 , C 1-3 Alkyl, -OC 1-3 Alkyl, C 3-6 Cycloalkyl, C 6-10 The C substituted with aryl, 5-10 membered heteroaryl or 3-6 membered heterocyclic group 1-3 alkyl.
[0351] In some preferred embodiments, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2 or 3 independently selected from F, Cl, OH, NH 2 、CN、NO 2 , C 1-3 Alkyl, -OC 1-3 Alkyl, C 3-6 C substituted by a cycloalkyl group, a phenyl group, or a 3-6-membered heterocyclic group 1-3 alkyl.
[0352] In some preferred embodiments, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2 or 3 independently selected from F, Cl, -OH, C 1-3 Alkyl, -OC 1-3 Alkyl, C 3-6 C substituted by a cycloalkyl group, a phenyl group, or a 3-6-membered heterocyclic group 1-3 alkyl.
[0353] In some more preferred embodiments, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2 or 3 independently selected from F, Cl, OH, methyl, -O-CH 3 , cyclopropyl, phenyl substituted C 1-2 alkyl.
[0354] In some further more preferred embodiments, R g and R h Each occurrence is independently H, CH 3 、-CH 2 CH 3、-C(CH 3 ) 3 、-CH 2 CH 2 -OH, -CH 2 -OCH 3 、-CH 2 CH 2 -OCH 3 、-CH 2 F, -CHF 2 , -CF 3 、-CH 2 CF 3 , -CH 2 -cyclopropyl, -CH 2 CH 2 -cyclopropyl, -CH 2 -phenyl,
[0355] In some further more preferred embodiments, R g and R h Each occurrence is independently H, CH 3 、-CH 2 CH 3 、-CH 2 CH 2 -OH, -CH 2 CH 2 -OCH 3 、-CH 2 F, -CHF 2 , -CF 3 、-CH 2 CF 3 、-CH 2 CH 2 -cyclopropyl.
[0356] In some further more preferred embodiments, R g and R h Each occurrence is independently H, CH 3 、-CH 2 CH 3 、-CH 2 CF 3 、-CH 2 CH 2 -OH, -CH 2 -cyclopropyl, -CH 2 -phenyl.
[0357] In some preferred embodiments, R 13 Independently for C 1-3The alkyl group is preferably methyl, ethyl, isopropyl, n-propyl or tert-butyl; preferably methyl, ethyl, isopropyl, n-propyl; preferably methyl, isopropyl or tert-butyl; more preferably isopropyl or tert-butyl.
[0358] In some preferred embodiments, R 13 Independently for C 3-6 Cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; preferably cyclopentyl.
[0359] In some preferred embodiments, each R a2 Independently for:
[0360] F, Cl, OH, NH 2 、CN、NO 2 , COOH, -CH 2 -OH, -CH 2 -O-CH 3 、-C(O)NH 2 、-C(O)NHCH 3 、-C(O)NH-CH 2 CH 3 、-C(O)N(CH 3 ) 2 、-C(O)NH-CH 2 CH 2 -OH, -C(O)NH-CH 2 CH 2 -OCH 3 、-C(O)NH-CH 2 CF 3 、-C(O)NH-CH 2 -cyclopropyl, -C(O)OCH(CH 3 ) 2 、-C(O)OC(CH 3 ) 3 , ethynyl, -C(O)O-cyclopentyl, -C(O)CH 2 OCH 3 、-C(O)NH-C(CH 3 ) 3 , -CH 2 -OCH 2 -phenyl; or
[0361] unsubstituted 5- or 6-membered heteroaryl, preferably unsubstituted 5-membered heteroaryl, more preferably oxazolyl, isoxazolyl, thiazolyl (preferably ) or isothiazolyl.
[0362] In some preferred embodiments, each R a2Independently: F, Cl, OH, NH 2 、CN、NO 2 , COOH, -CH 2 -OH, -CH 2 -O-CH 3 、-C(O)NH 2 、-C(O)NHCH 3 、-C(O)NH-CH 2 CH 3 、-C(O)N(CH 3 ) 2 、-C(O)NH-CH 2 CH 2 -OH, -C(O)NH-CH 2 CH 2 -OCH 3 、-C(O)NH-CH 2 CF 3 、-C(O)NH-CH 2 -cyclopropyl, -C(O)OCH(CH 3 ) 2 ; or an unsubstituted 5- or 6-membered heteroaryl, preferably an unsubstituted 5-membered heteroaryl. Preferably, the unsubstituted 5-membered heteroaryl is oxazolyl, isoxazolyl, thiazolyl (preferably ) or isothiazolyl.
[0363] In some preferred embodiments, each R a2 Independently: COOH, -CH 2 -OH, -C(O)NH 2 、-C(O)NHCH 3 、-C(O)N(CH 3 ) 2 、-C(O)NH-CH 2 CH 3 、-C(O)NH-CH 2 CF 3 、-C(O)NH-CH 2 -Cyclopropyl, -C(O)NH-CH 2 CH 2 -OH, -C(O)OCH(CH 3 ) 2 、-C(O)OC(CH 3 ) 3 、-CH 2 -O-CH 3 、-CH 2 -OCH 2 -phenyl.
[0364] In some embodiments as described above, p is independently 0 or 1 at each occurrence.
[0365] In some embodiments according to the compounds of formula (I-9), formula (I-10), formula (I-11), formula (I-12) or formula (I-13), Parts are:
[0366] Best
[0367] Best
[0368] Best
[0369] In some embodiments according to the compound of formula (I-15) or formula (I-16), Part of
[0370] In some embodiments as described above, L 1 For direct keys, O, S, C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 Alkynylidene, -OC 1-3 Alkylene-, -C 1-3 Alkylene-O-, -SC 1-3 Alkylene-, -C 1-3 Alkylene-S-, -NH-CO- or -CO-NH-; preferably, L 1 For direct keys, C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 Alkyne, -NH-CO- or -CO-NH-; preferably, L 1 For direct key or C 2-3 Alkenylene.
[0371] Preferably, L 1 For direct keys, O, C 1-2 Alkylene, -CH=CH-, -C≡C-, -O-CH 2 -、-CH 2 -O-, -NH-CO- or -CO-NH-.
[0372] More preferably, L 1 For direct keys, C 1-2Alkylene, -CH=CH-, -C≡C-, -NH-CO- or -CO-NH-.
[0373] More preferably, L 1 For direct bond, -CH 2 CH 2 -, -CH=CH-, -C≡C-, -NH-CO- or -CO-NH-.
[0374] More preferably, L 1 It is a direct bond or -CH=CH-.
[0375] In some embodiments as described above, the ring B is C 5-10 Cycloalkyl (preferably C 5-10 Cycloalkyl), C 6-10 aryl, 5-10 membered heteroaryl or 5-10 membered heterocyclyl.
[0376] Preferably, the ring B is a benzo-fused C 5-6 Monocyclic cycloalkyl (preferably benzo-fused C 5-6 monocyclic cycloalkyl), pyrido-fused C 5-6 Monocyclic cycloalkyl (preferably pyrido-fused C 5-6 Monocyclic cycloalkyl), C 6-10 aryl, a 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, a 9-10 membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a benzo-fused 5- or 6-membered monocyclic heterocyclyl.
[0377] Preferably, the ring B is a benzo-fused C 5-6 Monocyclic cycloalkyl, C 6-10 aryl, a 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, a 9-10 membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a benzo-fused 5- or 6-membered monocyclic heterocyclyl.
[0378] Preferably, the ring B is C 6-10 aryl, 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, 9-10 membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, benzo-fused 5 or 6 membered monocyclic heterocyclyl.
[0379] More preferably, the ring B is tetrahydronaphthyl, phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl (e.g. 1,2,3-triazole, 1,2,4-triazole), pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzofuranyl, benzothiophenyl, naphthyridinyl, indolyl, isoindolyl, indolyl, benzimidazolyl, benzopyrazolyl, benzopyridinyl (e.g. quinoline, isoquinoline), benzopyrrolyl, pyridocyclohexyl or indolonyl.
[0380] More preferably, the ring B is tetrahydronaphthyl, phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzofuranyl, benzothiophenyl, naphthyridinyl, indolyl, isoindolyl, indolyl or indolonyl.
[0381] More preferably, the ring B is tetrahydronaphthyl, phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, benzofuranyl, naphthyridinyl, benzimidazolyl, benzopyrazolyl, benzopyridinyl, benzopyrrolyl, pyridocyclohexyl or indolonyl.
[0382] More preferably, the ring B is phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, benzofuranyl, indolyl, benzopyrazolyl, benzopyridinyl, benzopyrrolyl, or pyridocyclohexyl.
[0383] More preferably, the ring B is tetrahydronaphthyl, phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, benzofuranyl, naphthyridinyl or indolinone.
[0384] In some embodiments as described above, n is 0, 1 or 2.
[0385] In some embodiments as described above, Parts are:
[0386]
[0387] In some embodiments as described above, Parts are:
[0388]
[0389]
[0390] In some embodiments as described above, Parts are:
[0391]
[0392] In some embodiments as described above, Parts are:
[0393]
[0394]
[0395] In some embodiments as described above, R b OH, NH 2 、Halogen、CN、NO 2 , C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), C 6-10 Aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the C 6-10 Aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group is optionally substituted by 1, 2, 3 or more independently selected from OH, NH 2 、F、Cl、CN、NO 2 , C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl and -OC 1-4 Substitution of haloalkyl groups;
[0396] Preferably, R b OH, NH 2 、Halogen、CN、NO 2 , C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, -OC 1-4 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-6 Cycloalkyl), C 6-10 Aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the C 6-10 Aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl or 3-6 membered heterocyclyl is optionally substituted by 1, 2, 3 or more independently selected from OH, NH 2 、F、Cl、CN、NO 2 , C 1-4Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl and -OC 1-4 The substituents of the haloalkyl group are substituted.
[0397] Preferably, R b Halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), C 3-10 Cycloalkyl and C 6-10 Aryl, wherein the C 6-10 Aryl is optionally substituted by 1, 2, 3 or more independently selected from halogen and -OC 1-6 The alkyl group is substituted with a substituent.
[0398] Preferably, R b Halogen, CN, C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, -OC 1-4 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-6 wherein the phenyl group is optionally substituted by 1, 2 or 3 groups independently selected from halogen and -OC 1-4 The alkyl group is substituted with a substituent.
[0399] Preferably, R b For halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, -OC 1-4 haloalkyl, -O-cyclopentyl or phenyl, wherein the phenyl is optionally substituted by 1 or 2 independently selected from halogen and -OC 1-4 The alkyl group is substituted with a substituent.
[0400] Preferably, R b OH, NH 2 、F、Cl、CN、NO 2 , methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, CF 3 、-O-CF 3 、-O-CH 3 、-O-CH 2 CH 3, -O-phenyl, -O-cyclopentyl, phenyl, cyclopentyl or cyclohexyl, wherein the phenyl, cyclopentyl or cyclohexyl is optionally substituted by 1 or 2 independently selected from OH, NH 2 、F、Cl、CN、NO 2 、-O-CH 3 and-O-CH 2 CH 3 substituted by a substituent.
[0401] Preferably, R b F, Cl, CN, -CF 3 、-OCF 3 , methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 , -O-phenyl, -O-cyclopentyl or phenyl, wherein the phenyl group is optionally substituted by 1 or 2 independently selected from F, Cl, -O-CH 3 and-O-CH 2 CH 3 substituted by a substituent.
[0402] More preferably, R b F, Cl, CN, CF 3 、-O-CF 3 , methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 , -O-phenyl, -O-cyclopentyl,
[0403] In some embodiments as described above, wherein Parts are:
[0404]
[0405]
[0406] In some embodiments as described above, wherein Parts are:
[0407]
[0408] In some embodiments as described above,
[0409] R b OH, NH 2 、Halogen、CN、NO 2 , C1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the C 6-10 Aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group is optionally substituted by 1, 2, 3 or more independently selected from OH, NH 2 、F、Cl、CN、NO 2 , C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl and -OC 1-4 The substituents of the haloalkyl group are substituted.
[0410] Preferably, R b OH, NH 2 、F、Cl、CN、NO 2 , methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 , phenyl, cyclopentyl or cyclohexyl, wherein the phenyl, cyclopentyl or cyclohexyl is optionally substituted by 1 or 2 independently selected from OH, NH 2 、F、Cl、CN、NO 2 、-O-CH 3 and-O-CH 2 CH 3 substituted by a substituent.
[0411] More preferably, R b F, Cl, CN, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 ,
[0412] In some preferred embodiments, the Parts are:
[0413]
[0414] The first aspect, the I-2 aspect, and the I-3 aspect of the present invention relate to compounds of formula (I-9), formula (I-10), formula (I-11), formula (I-12) and / or formula (I-13), wherein:
[0415] Ra2 For: CN, COOH, -C 1-6 Alkylene-OR g 、-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(O)-NR g R h ; or unsubstituted 5-10 membered heteroaryl;
[0416] R g and R h is independently H at each occurrence, or is optionally substituted by 1, 2 or 3 independently selected from halogen, -OH, C 3-10 Substituents of the cycloalkyl group substituted with C 1-6 alkyl;
[0417] The ring B is C 6-10 aryl, 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, 9-10 membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, benzo-fused 5 or 6 membered monocyclic heterocyclyl;
[0418] R b Halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Haloalkyl, -OC 1-6 Alkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), and C 6-10 Aryl, wherein the C 6-10 Aryl is optionally substituted by 1, 2, 3 or more independently selected from halogen and -OC 1-6 Substitution of alkyl groups;
[0419] R 13 C 3-6 Cycloalkyl or C 1-6 alkyl;
[0420] n is 0, 1 or 2; and
[0421] p is 0 or 1.
[0422] In some preferred embodiments, R a2 For: CN, COOH, -C 1-6 Alkylene-OR g 、-C(=O)-OR 13 or -C(O)-NR g R h; or unsubstituted 5- or 6-membered heteroaryl.
[0423] Preferably, R a2 For: CN, COOH, -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 or -C(O)-NR g R h or unsubstituted 5-membered heteroaryl, preferably oxazolyl, isoxazolyl, thiazolyl or isothiazolyl.
[0424] In some preferred embodiments, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2 or 3 independently selected from F, Cl, -OH and C 3-6 Substituents of the cycloalkyl group substituted with C 1-3 alkyl.
[0425] Preferably, R g and R h Each occurrence is independently H, CH 3 、-CH 2 CH 3 、-CH 2 CH 2 OH, -CH 2 -cyclopropyl, -CH 2 F, -CHF 2 , -CF 3 or -CH 2 CF 3 .
[0426] In some preferred embodiments, wherein R a2 CN, COOH, -CH 2 -OH, -CH 2 -O-CH 3 、-C(O)NH 2 、-C(O)NHCH 3 、-C(O)NH-CH 2 CH 3 、-C(O)NH-CH 2 CH 2 OH, -C(O)NH-CH 2 -cyclopropyl, -C(O)N(CH 3 ) 2 、-C(O)NH-CH 2 CF 3 , -O-phenyl, -O-cyclopentyl, -CH 2 O-CH 2-phenyl, -C(=O)-O-cyclopentyl, -C(=O)-OC(CH 3 ) 3 or
[0427] In some preferred embodiments, wherein Parts are:
[0428] Best
[0429] In some preferred embodiments, the ring B is phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, benzofuranyl, phenylpyrazolyl, phenylpyridinyl, pyridocyclohexyl, benzopyrrolyl, naphthyridinyl or indolinone.
[0430] In some preferred embodiments, Parts are:
[0431]
[0432] In some preferred embodiments, R b Halogen, CN, C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, -OC 1-4 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 wherein the phenyl group is optionally substituted by 1, 2 or 3 groups independently selected from halogen and -OC 1-4 Substitution of alkyl groups;
[0433] Preferably, R b F, Cl, CN, -CF 3 、-OCF 3 , methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 , -O-phenyl, -O-cyclopentyl or phenyl, wherein the phenyl group is optionally substituted by 1 or 2 independently selected from F, Cl, -O-CH 3 and-O-CH 2 CH 3 Substituents are substituted;
[0434] More preferably, R b F, Cl, CN, -CF 3 、-OCF 3, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 ,,-O-phenyl,-O-cyclopentyl,
[0435] In some preferred embodiments, Parts are:
[0436]
[0437]
[0438] The first sub-aspect and the I-2 sub-aspect of the present invention relate to compounds of formula (I-9), formula (I-10), formula (I-11), formula (I-12) and / or formula (I-13), wherein:
[0439] R a2 For: CN, COOH, -C 1-6 Alkylene-OR g 、-C(O)-NR g R h or -(CR 11 R 12 ) q -C(O)-OR 13 ; or unsubstituted 5-10 membered heteroaryl;
[0440] R g and R h is independently H at each occurrence, or C optionally substituted by 1, 2 or 3 substituents independently selected from halogen 1-6 alkyl;
[0441] R 13 Independently for C 1-6 alkyl;
[0442] The ring B is C 6-10 aryl, 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, 9-10 membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, benzo-fused 5 or 6 membered monocyclic heterocyclyl;
[0443] R b Halogen, CN, C 1-6 Alkyl, -OC 1-6 Alkyl and C 6-10 Aryl, wherein the C 6-10Aryl is optionally substituted by 1, 2, 3 or more independently selected from halogen and -OC 1-6 Substitution of alkyl groups;
[0444] n is 0, 1 or 2; and p is 0 or 1.
[0445] In some embodiments according to the first sub-aspect, the I-2 sub-aspect, R a2 For: CN, COOH, -C 1-6 Alkylene-OR g 、-C(O)-OR 13 or -C(O)-NR g R h ; or unsubstituted 5- or 6-membered heteroaryl.
[0446] Preferably, R a2 For: CN, COOH, -C 1-3 Alkylene-OR g 、-C(O)-OR 13 or -C(O)-NR g R h or unsubstituted 5-membered heteroaryl, preferably oxazolyl, isoxazolyl, thiazolyl or isothiazolyl.
[0447] In some embodiments according to the first sub-aspect, the I-2 sub-aspect, R g and R h is independently H at each occurrence, or C optionally substituted with 1, 2 or 3 substituents independently selected from F and Cl 1-3 alkyl.
[0448] Preferably, R g and R h Each occurrence is independently H, CH 3 、-CH 2 CH 3 、-CH 2 F, -CHF 2 , -CF 3 or -CH 2 CF 3 .
[0449] In some preferred embodiments, R a2 CN, COOH, -CH 2 -OH, -CH 2 -O-CH 3 、-C(O)NH 2 、-C(O)NHCH 3 、-C(O)NH-CH 2 CH 3、-C(O)N(CH 3 ) 2 、-C(O)NH-CH 2 CF 3 、-C(O)OCH(CH 3 ) 2 or
[0450] In some embodiments according to the first sub-aspect and the I-2 sub-aspect, Parts are:
[0451] Best
[0452] According to some embodiments of the first sub-aspect and the I-2 sub-aspect, the ring B is phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, benzofuranyl, naphthyridinyl or indolinone.
[0453] According to some embodiments of the first sub-aspect and the I-2 sub-aspect, Parts are:
[0454]
[0455]
[0456] In some embodiments according to the first sub-aspect, the I-2 sub-aspect, R b Halogen, CN, C 1-4 Alkyl, -OC 1-4 Alkyl and phenyl, wherein the phenyl is optionally substituted by 1, 2 or 3 independently selected from halogen and -OC 1-4 The alkyl group is substituted with a substituent.
[0457] Preferably, R b F, Cl, CN, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 or phenyl, wherein the phenyl is optionally substituted by 1 or 2 independently selected from F, Cl, -O-CH 3 and-O-CH 2 CH 3 substituted by a substituent.
[0458] More preferably, R b F, Cl, CN, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3、-O-CH 2 CH 3 ,
[0459] In some preferred embodiments, the Parts are:
[0460]
[0461]
[0462] The first sub-aspect of the present invention relates to compounds of formula (I-9), formula (I-10), formula (I-11), formula (I-12) and / or formula (I-13), wherein:
[0463] R a2 For: CN, COOH, -C 1-6 Alkylene-OR g or -C(O)-NR g R h ; or unsubstituted 5-10 membered heteroaryl;
[0464] R g and R h is independently H at each occurrence, or C optionally substituted by 1, 2 or 3 substituents independently selected from halogen 1-6 alkyl;
[0465] The ring B is C 6-10 aryl, 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, 9-10 membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, benzo-fused 5 or 6 membered monocyclic heterocyclyl;
[0466] R b Halogen, CN, C 1-6 Alkyl, -OC 1-6 Alkyl and C 6-10 Aryl, wherein the C 6-10 Aryl is optionally substituted by 1, 2, 3 or more independently selected from halogen and -OC 1-6 Substitution of alkyl groups;
[0467] n is 0, 1 or 2; and
[0468] p is 0 or 1.
[0469] In some embodiments according to the first sub-aspect, R a2 For: CN, COOH, -C 1-6 Alkylene-OR g or -C(O)-NRg R h ; or unsubstituted 5- or 6-membered heteroaryl.
[0470] Preferably, R a2 For: CN, COOH, -C 1-3 Alkylene-OR g or -C(O)-NR g R h or unsubstituted 5-membered heteroaryl, preferably oxazolyl, isoxazolyl, thiazolyl or isothiazolyl.
[0471] In some embodiments according to the first sub-aspect, R g and R h is independently H at each occurrence, or C optionally substituted with 1, 2 or 3 substituents independently selected from F and Cl 1-3 alkyl.
[0472] Preferably, R g and R h Each occurrence is independently H, CH 3 、-CH 2 CH 3 、-CH 2 F, -CHF 2 , -CF 3 or -CH 2 CF 3 .
[0473] In some preferred embodiments, R a2 CN, COOH, -CH 2 -OH, -CH 2 -O-CH 3 、-C(O)NH 2 、-C(O)NHCH 3 、-C(O)NH-CH 2 CH 3 、-C(O)N(CH 3 ) 2 、-C(O)NH-CH 2 CF 3 or
[0474] In some embodiments according to the first sub-aspect, Parts are:
[0475] Best
[0476] According to some embodiments of the first sub-aspect, the ring B is phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, benzofuranyl, naphthyridinyl or indolinone.
[0477] According to some embodiments of the first sub-aspect, the Parts are:
[0478]
[0479] In some embodiments according to the first sub-aspect, R b Halogen, CN, C 1-4 Alkyl, -OC 1-4 Alkyl and phenyl, wherein the phenyl is optionally substituted by 1, 2 or 3 independently selected from halogen and -OC 1-4 The alkyl group is substituted with a substituent.
[0480] Preferably, R b F, Cl, CN, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 or phenyl, wherein the phenyl is optionally substituted by 1 or 2 independently selected from F, Cl, -O-CH 3 and-O-CH 2 CH 3 substituted by a substituent.
[0481] More preferably, R b F, Cl, CN, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 ,
[0482] In some preferred embodiments, the Parts are:
[0483]
[0484]
[0485] The II-3 sub-aspect of the present invention relates to compounds of formula (I-9), formula (I-10), formula (I-11), formula (I-12) and / or formula (I-13) as described above in the first sub-aspect, the I-2 sub-aspect, and the I-3 sub-aspect, wherein:
[0486] in:
[0487] p is 1;
[0488] R a2 COOH, -C 1-6 Alkylene-OR g or -C(O)-NR g R h ;
[0489] R g and R h Each occurrence is independently H, unsubstituted C 1-6 Alkyl or C substituted by -OH 1-6 alkyl;
[0490] L 1 For direct key or C 2-3 alkenylene;
[0491] The ring B is phenyl, naphthyl, pyrazolyl, benzofuranyl, pyridinyl, phenylpyrazolyl, phenylpyridinyl or naphthyridinyl; and
[0492] R b For halogen, C 1-6 Alkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 wherein the phenyl group is optionally substituted by 1, 2 or 3 groups independently selected from halogen and -OC 1-6 The alkyl group is substituted with a substituent.
[0493] In some preferred embodiments, wherein R g and R h Each occurrence is independently H or unsubstituted C 1-3 Alkyl, preferably H, -CH 3 、-CH 2 CH 3 or -CH 2 CH 2 OH.
[0494] In some preferred embodiments, wherein R a2 COOH, -CH 2 -OH, -C(O)NH 2 、-C(O)NHCH 3 、-C(O)N(CH 3 ) 2 、C(O)NHCH 2 CH 3 or -C(O)NHCH 2 CH 2 OH.
[0495] In some preferred embodiments, wherein Parts are:
[0496]
[0497] In some preferred embodiments, wherein L 1 It is a direct bond or -CH=CH-.
[0498] In some preferred embodiments, Parts are:
[0499]
[0500] In some preferred embodiments, wherein:
[0501] R b For halogen, C 1-4 Alkyl, -OC 1-4 Alkyl, -O-phenyl, -O-cyclopentyl or unsubstituted phenyl;
[0502] Preferably, R b F, Cl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 , -O-phenyl, -O-cyclopentyl or unsubstituted phenyl;
[0503] More preferably, R b F, Cl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 、-O-CF 3 , -O-phenyl, -O-cyclopentyl or
[0504] In some preferred embodiments, Parts are:
[0505]
[0506]
[0507] The second sub-aspect of the present invention relates to compounds of formula (I-9), formula (I-10), formula (I-11), formula (I-12) and / or formula (I-13) as described above in the first sub-aspect, wherein:
[0508] p is 1;
[0509] R a2 COOH, -C 1-6 Alkylene-OR g or -C(O)-NR g R h ;
[0510] R g and R h Each occurrence is independently H or unsubstituted C 1-6 alkyl;
[0511] L 1 For direct key or C 2-3 alkenylene;
[0512] The ring B is phenyl, naphthyl, pyrazolyl, benzofuranyl or naphthyridinyl; and
[0513] R b For halogen, C 1-6 Alkyl, -OC 1-6 Alkyl or phenyl, wherein the phenyl is optionally substituted by 1, 2 or 3 independently selected from halogen and -OC 1-6 The alkyl group is substituted with a substituent.
[0514] In some embodiments according to the first sub-aspect and / or the second sub-aspect above, R g and R h Each occurrence is independently H or unsubstituted C 1-3 Alkyl, preferably H or CH 3 .
[0515] In some preferred embodiments, R a2 COOH, -CH 2 -OH, -C(O)NH 2 、-C(O)NHCH 3 or -C(O)N(CH 3 ) 2 .
[0516] In some embodiments according to the first sub-aspect and / or the second sub-aspect above, Parts are:
[0517]
[0518] In some embodiments according to the first sub-aspect and / or the second sub-aspect above, L 1 It is a direct bond or -CH=CH-.
[0519] In some embodiments according to the first sub-aspect and / or the second sub-aspect above, Parts are:
[0520]
[0521] In some embodiments according to the first sub-aspect and / or the second sub-aspect above, R b For halogen, C 1-4 Alkyl, -OC 1-4 Preferably, R b F, Cl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 or unsubstituted phenyl. More preferably, R b F, Cl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 ,or
[0522] In some preferred embodiments, the Parts are:
[0523]
[0524] Without wishing to be bound by any theory, the inventors surprisingly found that the compounds of the present invention according to this second sub-aspect show higher NSD2 inhibitory activity than the prior art (e.g., compounds disclosed in WO2021026803A1, in particular the compounds of Example 1 thereof).
[0525] The III-3 aspect of the present invention relates to a compound of formula (I-9) or formula (I-10) as described above in the first aspect, the I-2 aspect, the I-3 aspect, wherein:
[0526] Where: L 1 For direct keys, C 1-3 Alkylene, C 2-3 alkenylene, -NH-CO- or -CO-NH-;
[0527] The ring B is phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, benzofuranyl, naphthyridinyl, phenylpropyridinyl, phenylpropyrazolyl, pyridocyclohexyl, benzopyrrolyl or indolonyl; and
[0528] R b For halogen, C 1-4 Alkyl, -OC 1-4 Alkyl, -OC1-4 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 wherein the phenyl group is optionally substituted by 1, 2 or 3 groups independently selected from halogen and -OC 1-4 The alkyl group is substituted with a substituent.
[0529] In some preferred embodiments, wherein: L 1 For direct keys, C 1-2 Alkylene, C 2-3 alkenylene, -NH-CO- or -CO-NH-;
[0530] Preferably, L 1 For direct bond, -CH 2 CH 2 -, -CH=CH-, -NH-CO- or -CO-NH-.
[0531] In some preferred embodiments, Parts are:
[0532]
[0533]
[0534] In some preferred embodiments, wherein:
[0535] R b F, Cl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 、-O-CF 3 、-O-(C 6-10 Aryl), -O-(C 3-10 wherein the phenyl group is optionally substituted by 1 or 2 independently selected from F, Cl, -O-CH 3 and-O-CH 2 CH 3 Substituents are substituted;
[0536] Preferably, R b F, Cl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 、-O-CF 3 , -O-phenyl, -O-cyclohexyl-,
[0537] In some preferred embodiments, Parts are:
[0538]
[0539]
[0540] The third sub-aspect of the present invention relates to a compound of formula (I-9) or formula (I-10) as described above in the first sub-aspect, wherein:
[0541] L 1 For direct keys, C 1-3 Alkylene, C 2-3 alkenylene, -NH-CO- or -CO-NH-;
[0542] The ring B is phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, benzofuranyl, naphthyridinyl or indolinone; and
[0543] R b For halogen, C 1-4 Alkyl, -OC 1-4 Alkyl and phenyl, wherein the phenyl is optionally substituted by 1, 2 or 3 independently selected from halogen and -OC 1-4 The alkyl group is substituted with a substituent.
[0544] In some embodiments according to the first sub-aspect and / or the third sub-aspect above, L 1 For direct keys, C 1-2 Alkylene, C 2-3 Preferably, L 1 For direct bond, -CH 2 CH 2 -, -CH=CH-, -NH-CO- or -CO-NH-.
[0545] In some embodiments according to the first sub-aspect and / or the third sub-aspect above, Parts are:
[0546]
[0547] In some embodiments according to the first sub-aspect and / or the third sub-aspect above, R b F, Cl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3or phenyl, wherein the phenyl is optionally substituted by 1 or 2 independently selected from F, Cl, -O-CH 3 and-O-CH 2 CH 3 Preferably, R b F, Cl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH 3 、-O-CH 2 CH 3 ,
[0548] In some preferred embodiments, the Parts are:
[0549]
[0550] Without wishing to be bound by any theory, the inventors surprisingly found that the compounds of the invention according to this third sub-aspect show a dual targeting profile, ie have inhibitory activity against both NSD2 and NSD3.
[0551] The VI-3 aspect of the present invention relates to a compound of formula (I-9) as described above in the first aspect, the I-2 aspect, and the I-3 aspect, wherein:
[0552] R a2 For -C 1-6 Alkylene-OR g or -C(O)-NR g R h ;
[0553] R g and R h Each occurrence is independently H, unsubstituted C 1-6 alkyl or optionally substituted by 1, 2, 3 or more independently selected from halogen, C 3-6 Cycloalkyl substituted C 1-6 alkyl;
[0554] L 1 is a direct key;
[0555] The ring B is pyrrolyl, pyrazolyl, imidazolyl, pyridyl, benzopyridyl, phenylpropyrrolyl or triazolyl;
[0556] R b is optionally substituted by 1, 2 or 3 independently selected from halogen, -OC 1-6 Haloalkyl and -OC 1-6 a phenyl group substituted with an alkyl substituent;
[0557] n is 0 or 1; and p is 0 or 1.
[0558] In some preferred embodiments, wherein R g and R h Each occurrence is independently H or unsubstituted C 1-3 Alkyl, preferably H, CH 3 、-CH 2 -CF 3 or -CH 2 -cyclopropyl.
[0559] In some preferred embodiments, wherein R a2 -CH 2 -CH 3 、-CH 2 -O-CH 3 、-C(O)NHCH 3 or -C(O)N(CH 3 ) 2 、-C(O)NH-CH 2 -CF 3 、-C(O)NH-CH 2 -cyclopropyl.
[0560] In some preferred embodiments, wherein Parts are:
[0561] Best
[0562] In some preferred embodiments, Parts are:
[0563]
[0564] In some preferred embodiments, wherein:
[0565] R b For halogen, C 1-6 haloalkyl, 1, 2 or 3 independently selected from halogen and -OC 1-6 a phenyl group substituted with an alkyl substituent;
[0566] Preferably, R b For halogen, C 1-3 haloalkyl, 1 or 2 independently selected from halogen and -OC 1-4 The substituent of the alkyl group is substituted with phenyl.
[0567] More preferably, R b F, CF 3 , 1 or 2 independently selected from F, Cl, -O-CH 3and-O-CH 2 CH 3 Substituted phenyl.
[0568] More preferably, R b F, CF 3 , 1 or 2 independently selected from F and -O-CH 3 Substituted phenyl.
[0569] More preferably, R b F, CF 3 ,
[0570] In some preferred embodiments, Parts are:
[0571]
[0572] The VI-2 aspect of the present invention relates to a compound of formula (I-9) as described above in the first aspect and the I-2 aspect, wherein:
[0573] R a2 For -C 1-6 Alkylene-OR g 、-C(O)-NR g R h or -(CR 11 R 12 ) q -C(O)-OR 13 ;
[0574] R g and R h Each occurrence is independently H or unsubstituted C 1-6 alkyl;
[0575] R 13 Independently for C 1-6 alkyl;
[0576] L 1 is a direct key;
[0577] The ring B is pyrrolyl, pyrazolyl, imidazolyl or triazolyl;
[0578] R b is optionally substituted by 1, 2 or 3 independently selected from halogen and -OC 1-6 a phenyl group substituted with an alkyl substituent;
[0579] n is 0 or 1; and
[0580] p is 0 or 1.
[0581] In some embodiments according to the first sub-aspect and / or the fourth sub-aspect above, R g and R h Each occurrence is independently H or unsubstituted C 1-3 Alkyl, preferably H or CH 3 .
[0582] In some preferred embodiments, R 13 It is a C1-3 alkyl group, preferably a methyl group, an ethyl group, a n-propyl group or an isopropyl group, and more preferably an isopropyl group.
[0583] In some preferred embodiments, R a2 -CH 2 -CH 3 、-C(O)NHCH 3 or -C(O)N(CH 3 ) 2 .
[0584] In some embodiments according to the first sub-aspect and / or the I-2 sub-aspect and / or the IV sub-aspect above, Parts are: Best
[0585] In some embodiments according to the first sub-aspect and / or the I-2 sub-aspect and / or the IV sub-aspect above, Parts are:
[0586] In some embodiments according to the first sub-aspect and / or the I-2 sub-aspect and / or the IV sub-aspect above, R b is substituted by 1, 2 or 3 independently selected from halogen and -OC 1-6 Preferably, R b is 1 or 2 independently selected from halogen and -OC 1-4 More preferably, R b is 1 or 2 independently selected from F, Cl, -O-CH 3 and-O-CH 2 CH 3 More preferably, R b is 1 or 2 independently selected from F and -O-CH 3 More preferably, R b for
[0587] In some preferred embodiments, the Parts are:
[0588]
[0589] A fourth aspect of the present invention relates to a compound of formula (I-9) as described above in the first aspect, wherein:
[0590] R a2 For -C 1-6 Alkylene-OR g or -C(O)-NR g R h ;
[0591] R g and R h Each occurrence is independently H or unsubstituted C 1-6 alkyl;
[0592] L 1 is a direct key;
[0593] The ring B is pyrrolyl, pyrazolyl, imidazolyl or triazolyl;
[0594] R b is optionally substituted by 1, 2 or 3 independently selected from halogen and -OC 1-6 a phenyl group substituted with an alkyl substituent;
[0595] n is 0 or 1; and
[0596] p is 0 or 1.
[0597] In some embodiments according to the first sub-aspect and / or the fourth sub-aspect above, R g and R h Each occurrence is independently H or unsubstituted C 1-3 Alkyl, preferably H or CH 3 .
[0598] In some preferred embodiments, R a2 -CH 2 -CH 3 、-C(O)NHCH 3 or -C(O)N(CH 3 ) 2 .
[0599] In some embodiments according to the first sub-aspect and / or the fourth sub-aspect above, Parts are:
[0600] Best
[0601] In some embodiments according to the first sub-aspect and / or the fourth sub-aspect above, Parts are:
[0602] In some embodiments according to the first sub-aspect and / or the fourth sub-aspect above, R b is substituted by 1, 2 or 3 independently selected from halogen and -OC 1-6 Preferably, R b is 1 or 2 independently selected from halogen and -OC 1-4 More preferably, R b is 1 or 2 independently selected from F, Cl, -O-CH 3 and-O-CH 2 CH 3 More preferably, R b is 1 or 2 independently selected from F and -O-CH 3 More preferably, R b for
[0603] In some preferred embodiments, the Parts are:
[0604]
[0605]
[0606] In some embodiments, the present invention provides a compound of formula (I) as described above, wherein the compound has a structure shown in formula (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (II-I), (II-J), (II-K), (II-L), (II-M), (II-N):
[0607]
[0608]
[0609] wherein x is selected from 0, 1, 2 or 3; ring Q is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl; R Q Selected from OH, NH 2 、Halogen、CN、NO 2 , C 1-6 Alkyl, C1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Haloalkyl; X 1 , Y 1 , B, R b ,n,r,R a2 , p is defined as above.
[0610] In some embodiments, in Formula (II-A) and (II-B), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 Selected from CH, Y 1 is selected from N; r is selected from 0 or 1, preferably, r is selected from 1; Ring B is selected from C 6-10 Aryl, 5-10 membered heteroaryl; preferably, ring B is selected from C 6-10 aryl, 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, 9-10-membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; p is selected from 0 or 1, preferably, in formula (II-B), p is selected from 0; n is selected from 0, 1 or 2; R a2 Selected from CN, -COOH, -C(O)-NR g R h 、-C(=O)-OR 13 , 5-6 membered heteroaryl; preferably, in formula (II-A), R a2 Selected from CN, -COOH, -C(O)-NR g R h 、-C(=O)-OR 13 , 5-6 membered heteroaryl; More preferably, in formula (II-A), R a2 is selected from CN, -COOH, 5-6 membered heteroaryl; R b Selected from halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl.
[0611] In some embodiments, in Formula (II-C), (II-D), (II-E), (II-F), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 Selected from CH, Y 1 is selected from N; r is selected from 0 or 1, preferably, r is selected from 1; p is selected from 0 or 1, preferably, p is selected from 0; Ring B is selected from C 6-10Aryl, 5-10 membered heteroaryl; preferably, ring B is selected from C 6-10 Aryl; R a2 Selected from CN, -COOH, -C(O)-NR g R h 、-C(=O)-OR 13 , preferably, R a2 Selected from -COOH, -C(O)-NR g R h 、-C(=O)-OR 13 ; n is selected from 0, 1 or 2; R b Selected from halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl.
[0612] In some embodiments, in Formula (II-G), (II-H), (II-I), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 Selected from CH, Y 1 Select from N, or X 1 and Y 1 are CH; r is selected from 0 or 1, preferably, r is selected from 1; W 1 and W 2 are each independently selected from CH or N; preferably, W 1 and W 2 Also selected from N, or W 1 and W 2 One of them is selected from CH, and the other is selected from N; p is selected from 0 or 1; preferably, in formula (II-H) and (II-I), p is selected from 0; R a2 Selected from COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 Preferably, R a2 Selected from COOH, -C(O)-NR g R h ; n is selected from 0, 1 or 2, preferably, n is selected from 0 or 1; R b Halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl.
[0613] In some embodiments, in Formula (II-J) and (II-K), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 and Y 1 All are CH; W 1 , W 2 , W 3 and W 4 are each independently selected from CH or N; preferably, W 1 and W 2 One of them is selected from CH, and the other is selected from N, or W 1 and W 2 Also selected from CH; W 3 and W 4 One of them is selected from CH, the other is selected from N; r is selected from 0 or 1, preferably, r is selected from 1; p is selected from 0 or 1, preferably, p is selected from 1; R a2 Selected from COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 Preferably, R a2 Selected from -C(O)-NR g R h , -C 1-3 Alkylene-OR g ; n is selected from 0, 1 or 2, preferably, n is selected from 0 or 1; R b Halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl.
[0614] In some embodiments, in Formula (II-L), (II-M), (II-N), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 and Y 1 and CH; r is selected from 0 or 1, preferably, r is selected from 1; Ring B is selected from a 5-membered heteroaryl group, preferably, Ring B is selected from a 5-membered heteroaryl group having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, more preferably, Ring B is selected from a 5-membered heteroaryl group having 1, 2 or 3 nitrogen heteroatoms, such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl; preferably, Selected from Wherein the bond marked by "*" is connected to the Q ring; the ring Q is selected from C 6-10 Aryl, C3-6 Cycloalkyl, 3-6 membered heterocyclyl, 5-10 membered heteroaryl; preferably, ring Q is selected from C 6-10 Aryl; x is selected from 0, 1 or 2; R Q Selected from OH, halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 haloalkyl; p is selected from 0 or 1, preferably, in formula (II-M) and (II-N), p is preferably 0; R a2 Selected from CN, COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 Preferably, R a2 Selected from COOH, -C(O)-NR g R h .
[0615] Without wishing to be bound by any theory, the inventors surprisingly found that the compounds of the invention according to this fourth sub-aspect show selective NSD3 inhibitory activity.
[0616] The present invention encompasses compounds resulting from any combination of the various embodiments.
[0617] In some embodiments, the present invention provides a compound of formula (I), or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof, wherein the compound is selected from:
[0618]
[0619]
[0620]
[0621]
[0622]
[0623]
[0624]
[0625]
[0626] Pharmaceutical compositions and uses
[0627] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of the formula (I) according to the present invention, including a compound of the formula (I-0) to the formula (I-16), or a stereoisomer, a tautomer, a diastereomer, a racemate, a cis-trans isomer, an isotope-labeled compound (preferably a deuterated compound), an N-oxide, a metabolite, an ester, a prodrug, a crystal form, a hydrate, a solvate or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier. The pharmaceutical composition is preferably a solid preparation, a liquid preparation or a transdermal preparation. In some embodiments, the pharmaceutical composition of the present invention may also include one or more additional therapeutic agents.
[0628] In another aspect, the present invention provides a pharmaceutical combination comprising a compound of formula (I) according to the present invention, including compounds of formula (I-0) to formula (I-16), or stereoisomers, tautomers, diastereomers, racemates, cis-trans isomers, isotope-labeled compounds (preferably deuterated), N-oxides, metabolites, esters, prodrugs, crystal forms, hydrates, solvates or pharmaceutically acceptable salts thereof, and one or more additional therapeutically active agents.
[0629] In some embodiments, the one or more additional therapeutically active agents are anti-cancer agents, analgesics, or anti-inflammatory agents.
[0630] In another aspect, the present invention provides compounds of formula (I) according to the present invention, including compounds of formula (I-0) to formula (I-16), or stereoisomers, tautomers, diastereomers, racemates, cis-trans isomers, isotope-labeled compounds (preferably deuterated compounds), N-oxides, metabolites, esters, prodrugs, crystal forms, hydrates, solvates or pharmaceutically acceptable salts thereof, or the pharmaceutical composition according to the present invention, or the pharmaceutical combination according to the present invention, which are used as drugs.
[0631] In another aspect, the present invention provides a method for treating a disease, disorder or condition mediated by nuclear receptor binding SET domain protein 2 (NSD2) in an individual, wherein the method comprises: administering to the individual a therapeutically effective amount of a compound of formula (I) according to the present invention, including compounds of formula (I-0) to formula (I-16), or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotopically labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystalline form, hydrate, solvate or pharmaceutically acceptable salt thereof; or administering to the individual a therapeutically effective amount of the pharmaceutical composition according to the present invention; or administering to the individual a therapeutically effective amount of the pharmaceutical combination according to the present invention.
[0632] In another aspect, the present invention provides a compound of formula (I) according to the present invention, including compounds of formula (I-0) to formula (I-16), or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to the present invention, or a pharmaceutical combination according to the present invention for the preparation of a medicament for treating a disease, disorder or condition mediated by NSD2 in an individual.
[0633] In some embodiments, the disease, disorder or condition mediated by NSD2 is selected from solid tumors, leukemia, myeloma, lymphoma and hypertension. Preferably, the disease, disorder or condition mediated by NSD2 is selected from breast cancer, cervical cancer, skin cancer, ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, colon cancer, head and neck cancer, thyroid cancer, peripheral nerve sheath tumors, osteosarcoma, multiple myeloma, neuroblastoma, leukemia, non-Hodgkin's lymphoma and pulmonary hypertension. More preferably, the disease, disorder or condition mediated by NSD2 is selected from acute lymphocytic leukemia, cutaneous squamous cell carcinoma or mantle cell lymphoma.
[0634] In another aspect, the present invention provides a method for treating a disease, disorder or condition mediated by nuclear receptor binding SET domain protein 3 (NSD3) in an individual, wherein the method comprises: administering to the individual a therapeutically effective amount of a compound of formula (I) according to the present invention, including compounds of formula (I-0) to (I-16), preferably a compound of formula (I-9) or (I-10), more preferably a compound of formula (I-9), or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotopically labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystalline form, hydrate, solvate or pharmaceutically acceptable salt thereof; or administering to the individual a therapeutically effective amount of the pharmaceutical composition according to the present invention; or administering to the individual a therapeutically effective amount of the pharmaceutical combination according to the present invention.
[0635] In another aspect, the present invention provides a compound of formula (I) according to the present invention, including compounds of formula (I-0) to (I-16), preferably a compound of formula (I-9) or (I-10), more preferably a compound of formula (I-9), or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to the present invention, or a pharmaceutical combination according to the present invention for the preparation of a medicament for treating a disease, disorder or condition mediated by NSD3 in an individual.
[0636] In some embodiments, the disease, disorder or condition mediated by NSD3 is selected from squamous cell lung carcinoma, breast cancer, esophageal cancer, head and neck cancer, bile duct cancer, hepatocellular carcinoma, gastric adenocarcinoma, pancreatic cancer and osteosarcoma.
[0637] In the present invention, "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle that is administered together with a therapeutic agent and is suitable for contact with the tissues of humans and / or other animals without excessive toxicity, irritation, allergic reaction or other problems or complications corresponding to a reasonable benefit / risk ratio within the scope of reasonable medical judgment.
[0638] As used herein, unless otherwise indicated, the terms "treat," ...
[0639] As used herein, "individual" includes humans or non-human animals. Exemplary human individuals include human individuals (referred to as patients) suffering from diseases (e.g., diseases described herein) or normal individuals. "Non-human animals" in the present invention include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0640] Example
[0641] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0642] NMR was measured using a Bruker Avance III 400 NMR spectrometer, and the chemical shift (δ) was measured at 10 -6 The solvent was deuterated methanol (CD 3 OD), deuterated chloroform (CDCl 3 ) or hexadeuterated dimethyl sulfoxide (DMSO-d6), etc., and the internal standard is tetramethylsilane (TMS).
[0643] MS was measured using an Agilent (ESI) mass spectrometer (Agilent 1260, Agilent 6125B).
[0644] High performance liquid chromatography (HPLC) assay conditions: Gilson high pressure liquid chromatograph (Gilson GX-281), C18 column (10 μM, 19 mm x 250 mm), UV detection band at 220 and 254 nm, elution conditions: 5-95% acetonitrile (containing 0.05% v / v formic acid or ammonium bicarbonate) gradient elution for 15 minutes.
[0645] Reverse phase purification was performed using the Biotage Isolera Rapid Purification System.
[0646] Thin layer chromatography separation and purification was performed using thin layer chromatography silica gel plates (aluminum plates (20 cm x 20 cm x 1 mm) produced by Meck, or GF 254 produced in Yantai).
[0647] The microwave reaction was carried out using a Biotage Initiator+ (400 W, RT-300° C.) microwave reactor.
[0648] TLC or LCMS is commonly used for reaction monitoring. Common developing solvent systems include: dichloromethane / methanol, n-hexane / ethyl acetate, petroleum ether / ethyl acetate. The volume ratio of the solvent is adjusted according to the polarity of the compound or by adding triethylamine.
[0649] The silica gel used in column chromatography is generally 100-200 mesh silica gel. Commonly used eluent systems: dichloromethane / methanol, petroleum ether / ethyl acetate, the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine can also be added for adjustment.
[0650] The reagents and solvents of the present invention were purchased from Aldrich Chemical Company, Anage, J&K Technology, Shanghai Bid Pharmaceutical Technology Co., Ltd., Yaoshi Technology, and Shanghai Titan Technology Co., Ltd.
[0651] In conventional synthesis methods and synthesis examples of compounds and intermediates of the present invention, the meanings of the abbreviations are as shown below.
[0652]
[0653]
[0654] Synthesis Example
[0655] Preparation of intermediates
[0656] Synthesis of intermediate 1 (compound int.1)
[0657]
[0658] Step 1: Add compound int.1_1 (5 g, 37.0 mmol), BOC anhydride (32.3 g, 148 mmol) and 4-dimethylaminopyridine (0.45 g, 3.70 mmol) to tetrahydrofuran (180 mL) at room temperature and react for 16 hours at room temperature. LC-MS monitoring showed that the reaction was complete. The reaction solution was adjusted to pH 6 with dilute hydrochloric acid (0.5 mol / L), extracted with ethyl acetate (15 mL*3), and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound int.1_2. LC-MS (ESI): m / z=436[M+H] + .
[0659] Step 2: At room temperature, compound int.1_2 (10 g, 23.0 mmol) and saturated sodium bicarbonate solution (50 mL) were added to methanol (100 mL), and the mixture was heated to 60°C for 1 hour. TLC (petroleum ether: tetrahydrofuran = 3:1) showed that the raw material point disappeared and new points were generated. After the reaction solution was cooled naturally, the pH was adjusted to 6 with dilute hydrochloric acid (0.5 mol / L), and then extracted with ethyl acetate (50 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-50% tetrahydrofuran / petroleum ether) to obtain compound int.1. 1 H NMR (400MHz, DMSO-d6) δ: 13.69 (br d, J = 1.6Hz, 1H), 8.81 (s, 1H), 8.64 (br s, 1H), 1.37 (s, 18H).
[0660] Synthesis of intermediate 2 (compound int.2)
[0661]
[0662] Step 1: At room temperature, add compound int.2_1 (40 g, 171 mmol), trimethylsilyl cyanide (85.1 g, 857 mmol), ammonium carbonate (165 g, 1715 mmol), potassium carbonate (118 g, 857 mmol) and ammonia water (400 mL) to ethanol (400 mL), heat to 80 ° C, and react for 16 hours. LC-MS monitoring reaction is complete, the reaction solution is filtered and concentrated, the residue is slurried with water (300 mL) and then slurried with petroleum ether (300 mL) to obtain compound int.2_2. LC-MS (ESI): m / z = 304 [M + H] + .
[0663] Step 2: Add compound int.2_2 (50 g, 165 mmol), BOC anhydride (144 g, 659 mmol), triethylamine (33.4 g, 330 mmol) and 4-dimethylaminopyridine (0.60 g, 4.95 mmol) to ethylene glycol dimethyl ether (1500 mL) at room temperature and react for 16 hours at room temperature. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the residue was slurried with isopropyl ether to obtain compound int.2_3. LC-MS (ESI): m / z=304[M+H-200] + .
[0664] Step 3: At room temperature, compound int.2_3 (30 g, 59.6 mmol) and lithium hydroxide solution (300 mL, 1 mol / L) were added to tetrahydrofuran (300 mL), and the temperature was raised to 30 ° C for reaction for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was adjusted to pH = 12 with lithium hydroxide solution (1 mol / L), BOC anhydride (80 g, 287 mmol) was added to the reaction solution, and the reaction was reacted at room temperature for 16 hours. LC-MS monitored the reaction to be complete, the reaction solution was adjusted to pH = 2 with dilute hydrochloric acid (1 mol / L), and then extracted with ethyl acetate (150 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by slurrying with petroleum ether at room temperature for 1 hour, and the compound int.2 was obtained after filtration. LC-MS (ESI): m / z = 279 [M+H-100] + .
[0665] Synthesis of intermediate 3 (compound int.3)
[0666]
[0667] Step 1: At room temperature, compound int.2 (15.5 g, 41.0 mmol) and tert-butyl trichloroacetimidate (26.8 g, 123 mmol) were added to dichloromethane (300 mL) and reacted at room temperature for 16 hours. LC-MS monitored the reaction to be complete, the reaction solution was adjusted to pH = 12 with lithium hydroxide solution (1 mol / L), BOC anhydride (80 g, 287 mmol) was added to the reaction solution, and the reaction was reacted at room temperature for 16 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (200 mL), extracted with ethyl acetate (100 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-20% tetrahydrofuran / petroleum ether), and then purified by reverse phase column (0-100% acetonitrile / water) to obtain compound int.3_1. LC-MS (ESI): m / z=335[M+H-100] + .
[0668] Step 2: Add compound int.3_1 (11.5 g, 26.6 mmol) and wet palladium carbon (1.61 g, 13.29 mmol) to methanol (120 mL) at room temperature, replace with hydrogen three times, and react at room temperature for 3 hours. LC-MS monitored the reaction to be complete, and the reaction solution was filtered and concentrated to obtain compound int.3. LC-MS (ESI): m / z = 301 [M+H] + .
[0669] Synthesis of intermediate 4 (compound int.4)
[0670]
[0671] At room temperature, int.4_1 (50 g, 227 mmol) was added to methanol (400 mL), cooled to 0°C, and thionyl chloride (135 g, 1136 mmol) was added under nitrogen protection. The reaction was allowed to react at room temperature for 5 hours. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, and the pH was adjusted to 8 with saturated sodium bicarbonate solution, extracted with ethyl acetate (300 mL*2), and the organic phase was dried with anhydrous sodium sulfate, filtered and concentrated to obtain compound int.4. LC-MS (ESI): m / z=233.8 / 235.8[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.67(d,J=2.0Hz,1H),7.99(d,J=5.1Hz,1H),3.96-3.88(m,3H).
[0672] Synthesis of intermediate 5 (compound int.5)
[0673]
[0674] Step 1: Add compound int.3 (5.5 g, 18.4 mmol), compound int.4 (5.5 g, 18.4 mmol) and N,N-diisopropylethylamine (4.76 g, 36.9 mmol) to dimethyl sulfoxide (100 mL) at room temperature, and heat to 100 ° C for 5 hours. LC-MS monitoring reaction is complete, the reaction solution is quenched with water (100 mL), extracted with ethyl acetate (50 mL * 3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, and the residue is separated and purified by column chromatography (0-10% tetrahydrofuran / petroleum ether) to obtain compound int.5_1. LC-MS (ESI): m / z = 514 [M + H] + .
[0675] Step 2: Add compound int.5_1 (13.5 g, 26.3 mmol) and lithium triethylborohydride solution (47.4 mL, 47.4 mmol) to tetrahydrofuran (140 mL) at room temperature and react at room temperature for 16 hours. LC-MS monitoring showed that the reaction was complete, the reaction solution was quenched with water (200 mL), extracted with ethyl acetate (150 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-20% tetrahydrofuran / petroleum ether) to obtain compound int.5_2. LC-MS (ESI): m / z=486.1 / 488.1[M+H] + .
[0676] Step 3: At 0°C, add compound int.5_2 (8.5 g, 17.6 mmol), compound int.1 (8.83 g, 26.3 mmol), triphenylphosphine (13.8 g, 52.6 mmol) and diisopropyl azodicarboxylate (10.6 g, 52.6 mmol) to tetrahydrofuran (170 mL), and warm to room temperature for 3 hours. TLC (petroleum ether:tetrahydrofuran = 3:1) shows that the raw material point disappears and new points are generated. The reaction solution is quenched with water (150 mL), extracted with ethyl acetate (100 mL*3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, and the residue is separated and purified by column chromatography (2-30% tetrahydrofuran / petroleum ether) to obtain compound int.5. 1 H NMR (400 MHz, DMSO-d 6)δ:8.93-8.78(m,2H),8.27(s,1H),7.56(s,1H),6.50(s,1H),5.58(br d,J=5.5Hz,2H),3.55(br d,J=11.9Hz,1H),3.21-3.04(m,2H),2.98(br t,J=10.9Hz,1H),2.14-2.00(m,2H),1.66(br d,J=12.8Hz,2H),1.39(s,9H),1.36-1.31(m,18H),1.20-1.14(m,9H).
[0677] Synthesis of intermediate 6 (compound int.6)
[0678]
[0679] Step 1: Add (R)-3-Boc-aminopiperidine (3.63 g, 18.16 mmol) to a mixed solution of int.4 (2.43 g, 12.11 mmol), triethylamine (4.35 mL, 31.41 mmol) and 1,4-dioxane (35 mL), heat to 100 ° C and stir for 3 hours to obtain a suspension. LC-MS detected that the raw material reaction was complete and the desired product was formed. The mixture was poured into water (20 mL) and extracted with ethyl acetate (60 mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 5:1) to obtain compound int.6_1. LC-MS m / z (ESI): 414.7 / 416.7 [M+2H] + . / [M+2H] + .
[0680] Step 2: At 0°C, 1M solution of lithium triethylborohydride in tetrahydrofuran (20 mL) was added dropwise to a mixture of int.6_1 (1.8 g 4.35 mmol) and tetrahydrofuran (15 mL), and the mixture was heated to room temperature and stirred for 2 hours to obtain a solution. LC-MS detected that the raw material was completely consumed and the desired product was formed. The reaction solution was quenched with saturated aqueous ammonium chloride solution (15 mL) and extracted with ethyl acetate (45 mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 4:1 to 2:1) to obtain compound int.6_2. LC-MS m / z(ESI):384.1 / 386.1[M+H] + . / [M+2H] + .
[0681] Step 3: Methanesulfonyl chloride (636.02 mg, 5.55 mmol) was added dropwise to a mixed solution of int.6_2 (1430 mg, 3.70 mmol), triethylamine (1123.78 mg, 11.11 mmol) and dichloromethane (25 mL), and stirred at room temperature for 2 hours to obtain a solution. LC-MS detected that the raw material reaction was complete and the desired product was formed. The mixture was poured into water (10 mL) and extracted with dichloromethane (30 mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain compound int.6_3. The crude product was not further purified and directly used in the next step. LC-MS m / z(ESI):463.4 / 465.4[M+H] + . / [M+2H] + .
[0682] Step 4: Add int.1 (1.26 g, 3.75 mmol) to a mixed solution of int.6_3 (1.45 g, 3.12 mmol), potassium carbonate (1.29 g, 9.37 mmol) and N,N-dimethylformamide (20 mL), heat to 100 ° C and stir for 3 hours to obtain a solution. LC-MS detected that the raw material reaction was complete and the desired product was formed. The mixture was poured into water (10 mL) and extracted with ethyl acetate (30 mL*2). The combined organic phase was washed with brine (10 mL*2), dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound int.6. LC-MS m / z (ESI): 702.6 / 704.6 [M+H] + . / [M+2H] + . 1 H NMR (400MHz, d 6 -CDCl 3 )δ:8.84(s,1H),8.13(s,1H),8.11(s,1H),6.83(s,1H),5.47(s,2H),3.82(s,1H),3.34-3.21(m,1H),3 .01-2.91(m,1H),2.86-2.76(m,1H),2.74-2.66(m,1H),1.92-1.78(m,4H),1.39(s,18H),1.35(s,9H).
[0683] Synthesis of intermediate 7 (compound int.7)
[0684]
[0685] Step 1: At room temperature, add (R)-3-Boc-aminopiperidine (3.09 g, 15.5 mmol), methyl 2-fluoro-5-bromobenzoate (3 g, 12.9 mmol) and N,N-diisopropylethylamine (3.33 g, 25.8 mmol) to dimethyl sulfoxide (60 mL). Heat to 110°C and react for 3 hours. LC-MS monitoring shows that the reaction is complete. The reaction solution is diluted with water (100 mL), extracted with ethyl acetate (100 mL*3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, and the residue is separated and purified by column chromatography (0-11.7% ethyl acetate / petroleum ether) to obtain compound int.7_1. LC-MS (ESI): m / z=413.1 / 415.1 [M+H] + .
[0686] Step 2: Add compound int.7_1 (3.6 g, 7.03 mmol) and tetrahydrofuran solution of lithium triethylborohydride (1.0 M, 14.5 mL, 14.5 mmol) to tetrahydrofuran (65 mL) at room temperature. React at room temperature for 16 hours. LC-MS monitoring reaction is complete, the reaction solution is diluted with water (60 mL), extracted with ethyl acetate (70 mL*3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, and the residue is separated and purified by column chromatography (11-15% tetrahydrofuran / petroleum ether) to obtain compound int.7_2. LC-MS (ESI): m / z=384.8 / 386.8[M+H] + .
[0687] Step 3: At room temperature, add compound int.7_2 (1.8 g, 4.67 mmol), int.1 (2.35 g, 7.01 mmol), triphenylphosphine (3.68 g, 14.0 mmol) to tetrahydrofuran (36 mL), add diisopropyl azodicarboxylate (2.83 g, 14.0 mmol) under nitrogen protection, replace with nitrogen 3 times, and react at room temperature for 3 hours. LC-MS monitoring reaction is complete, the reaction solution is diluted with water (60 mL), extracted with ethyl acetate (70 mL*3), the organic phase is dried with anhydrous sodium sulfate, filtered and concentrated, and the residue is separated and purified by column chromatography (0-24% ethyl acetate / petroleum ether) to obtain compound int.7. LC-MS (ESI): m / z=702.2 / 704.2[M+H] + .
[0688] Example 1: Preparation of Compound 1A Hydrochloride and Compound 1B Hydrochloride
[0689]
[0690] Step 1: Compound int.5 (200 mg, 0.25 mmol), trans-β-phenylvinylboronic acid (55.4 mg, 0.37 mmol), 1,1-bis(diphenylphosphino)ferrocenepalladium chloride (Pd(dppf)Cl) were added to dioxane (4 mL) at room temperature. 2 )(36.5mg, 0.05mmol) and cesium carbonate (244mg, 0.75mmol). Nitrogen was replaced 3 times, and the temperature was raised to 80℃ for 3 hours. LC-MS monitored that the reaction of raw material int.5 was complete, the reaction solution was diluted with water (20mL), extracted with ethyl acetate (30mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (19-39% tetrahydrofuran / petroleum ether) to obtain compound 1_1. LC-MS (ESI): m / z=827.5[M+H] + .
[0691] Step 2: Compound 1_1 (600 mg) was separated by SFC to obtain 1_1A and 1_1B. SFC method: Column: DAICELCHIRALCEL OJ (250 mm*30 mm, 10 um). Mobile phase: CO 2 -EtOH, gradient: 30%-30%, flow rate (ml / min): 80, the retention time of compound 1_1A is 0.984min; the retention time of compound 1_1B is 3.005min. "*" indicates that the corresponding position is a chiral carbon.
[0692] Step 3: At room temperature, add compound 1_1A (220 mg, 0.27 mmol) to dioxane hydrochloride (4 mL, 4 M), and then add hydrochloric acid (0.4 mL, 12 M). React at room temperature for 16 hours. LC-MS monitoring shows that the reaction is complete, the reaction solution is concentrated, and the residue is separated and purified by preparation (chromatographic column: Boston Green ODS150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 8%-48%, 9 min), and lyophilized to obtain compound 1A hydrochloride. LC-MS (ESI): m / z=471.0[M+H] + . 1 HNMR (400 MHz, DMSO-d 6)δ=8.46(s,1H),8.26-8.21(m,1H),8.21-8.15(m,1H),8.03-7.78(m,2H),7.60(br d,J=7.5Hz,2H),7.51(d,J=15.9Hz,1H),7.38-7.31(m,4H),7.30-7.24(m,1H),7.17(d,J=15.9Hz,1H),6.87(s,1H),5.69-5.48(m,2H),3.37(br s,1H),3.10-2.97(m,2H),2.95-2.84(m,1H),2.11-1.96(m,1H),1.94-1.77(m,2H),1.74-1.62(m,1H).
[0693] Step 4: At room temperature, add compound 1_1B (220 mg, 0.27 mmol) to dioxane hydrochloride (4 mL, 4 M), and then add hydrochloric acid (0.4 mL, 12 M). React at room temperature for 16 hours. LC-MS monitoring shows that the reaction is complete, the reaction solution is concentrated, and the residue is separated and purified by preparation (chromatographic column: Boston Green ODS150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 8%-48%, 9 min), and lyophilized to obtain the hydrochloride of compound 1B. LC-MS (ESI): m / z=471.0[M+H] + . 1 H NMR (400 MHz, METHANOL-d 4 )δ:8.67(s,1H),8.63-8.59(m,1H),8.45-8.41(m,1H),7.74(s,1H),7.64(dd,J=2.8,6.7Hz,2H),7.55 (s,1H),7.47-7.41(m,3H),7.25(d,J=16.5Hz,1H),6.18-5.92(m,2H),3.81(d,J=12.3Hz,1H),3.59(br d,J=12.3Hz,1H),3.50-3.41(m,1H),3.16-3.06(m,1H),2.44-2.31(m,1H),2.27-2.04(m,3H).
[0694] Example 2: Preparation of Compound 2
[0695]
[0696] Step 1: At room temperature, compound int.2 (5 g, 13.2 mmol), ammonium chloride (1.41 g, 26.4 mmol), N,N-diisopropylethylamine (4.27 g, 33.0 mmol) and O-(7-azabenzotriazole-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (5.53 g, 14.5 mmol) were added to N,N-dimethylformamide (40 mL) and reacted at room temperature for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (200 mL), extracted with ethyl acetate (100 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by slurrying (tetrahydrofuran / petroleum ether=1:4) to obtain compound 2_1. LC-MS (ESI): m / z=378.1[M+H] + .
[0697] Step 2: Add compound 2_1 (3 g, 7.95 mmol), wet palladium carbon (0.3 g, 2.47 mmol) and tetrahydrofuran (15 mL) to methanol (30 mL) at room temperature, replace with hydrogen three times, and react at room temperature for 3 hours. LC-MS monitored the reaction to be complete, and the reaction solution was filtered and concentrated to obtain compound 2_2. LC-MS (ESI): m / z = 244.1 [M+H] + .
[0698] Step 3: Add compound 2_2 (500 mg, 2.05 mmol), compound int.4 (818 mg, 3.49 mmol), and N,N-diisopropylethylamine (531 mg, 4.11 mmol) to dimethyl sulfoxide (5 mL) at room temperature, and react at 110°C for 3 hours. LC-MS monitored the reaction to be complete, quenched the reaction solution with water (30 mL), extracted with ethyl acetate (15 mL*3), dried the organic phase with anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-50% tetrahydrofuran / petroleum ether) to obtain compound 2_3. LC-MS (ESI): m / z=457.0[M+H] + .
[0699] Step 4: Add compound 2_3 (1 g, 2.19 mmol) and lithium triethylborohydride solution (6.56 mL, 6.56 mmol) to tetrahydrofuran (20 mL) at room temperature and react at room temperature for 2 hours. LC-MS monitoring showed that the reaction was complete, the reaction solution was quenched with water (60 mL), extracted with ethyl acetate (25 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (3-60% tetrahydrofuran / petroleum ether) to obtain compound 2_4. LC-MS (ESI): m / z=429.0[M+H] + .
[0700] Step 5: At 0°C, compound 2_4 (500 mg, 1.16 mmol), compound int.1 (586 mg, 1.75 mmol), triphenylphosphine (916 mg, 3.49 mmol), diisopropyl azodicarboxylate (706 mg, 3.49 mmol) were added to tetrahydrofuran (10 mL), and the atmosphere was replaced with nitrogen three times. The reaction was allowed to proceed at room temperature for 3 hours. The reaction was completed after LC-MS monitoring, and the reaction solution was concentrated. The residue was separated and purified by column chromatography (0-70% tetrahydrofuran / petroleum ether) to obtain compound 2_5. LC-MS (ESI): m / z=748.3[M+H] + .
[0701] Step 6: Add compound 2_5 (500 mg, 0.67 mmol), trifluoroacetic anhydride (422 mg, 2.01 mmol) and triethylamine (203 mg, 2.01 mmol) to tetrahydrofuran (1 mL) at 0°C, replace with nitrogen three times, and react at 0°C for 3 hours. LC-MS monitoring reaction is complete, the reaction solution is quenched with water (20 mL), extracted with ethyl acetate (15 mL*3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, and the residue is separated and purified by column chromatography (0-37% tetrahydrofuran / petroleum ether) to obtain compound 2_6. LC-MS (ESI): m / z=728.1[M+H] + .
[0702] Step 7: At room temperature, compound 2_6 (500 mg, 0.69 mmol), trans-β-phenylvinylboronic acid (152 mg, 1.03 mmol), cesium carbonate (671 mg, 2.06 mmol) and 1,1-bis(diphenylphosphino)ferrocenepalladium chloride (50.2 mg, 0.07 mmol) were added to dioxane (5 mL), replaced with nitrogen three times, and reacted at 80°C for 2 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (20 mL), extracted with ethyl acetate (15 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (2-40% tetrahydrofuran / petroleum ether) to obtain compound 2_7. LC-MS (ESI): m / z=752.5 [M+H] + .
[0703] Step 8: Add compound 2_7 (430 mg, 0.57 mmol) and concentrated hydrochloric acid (5 mL, 60.0 mmol) to dioxane (10 mL) at room temperature and react at room temperature for 16 hours. LC-MS monitored the reaction to be complete. After the reaction solution was cooled naturally, the reaction solution was concentrated. The crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-60%, 9min), and lyophilized to obtain compound 2. LC-MS (ESI): m / z=452.0[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.47(s,1H),8.27(s,1H),8.14(s,1H),7.59(d,J=7.2Hz,2H),7.48(d,J=15.9Hz,1H),7.37-7.30 (m,4H),7.27(d,J=7.1Hz,1H),7.17(d,J=16.0Hz,1H),6.68(s,1H),5.56(q,J=17.0Hz,2H),3.49(br d,J=11.6Hz,1H),3.19(br d,J=11.0Hz,1H),3.00-2.85(m,1H),2.84-2.71(m,3H),2.16(br d,J=12.7Hz,1H),2.01-1.82(m,2H),1.64-1.46(m,1H).
[0704] Example 3: Preparation of Compound 3
[0705]
[0706] Step 1: Dissolve compound 2_5 (450 mg, 0.60 mmol) and Lawesson's reagent (244 mg, 0.60 mmol) in tetrahydrofuran (10 mL) at room temperature and stir at room temperature for 16 hours. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, the sample was mixed, and the crude product was separated and purified by column chromatography (0-50% tetrahydrofuran / petroleum ether) to obtain compound 3_1. LC-MS (ESI): m / z=762.3[M+H] + .
[0707] Step 2: At room temperature, compound 3_1 (300 mg, 0.39 mmol) was dissolved in acetone (5 mL), and 40% chloroacetaldehyde aqueous solution (772 mg, 3.93 mmol) and potassium carbonate (163 mg, 1.18 mmol) were added respectively, and stirred at room temperature for 2 hours. LC-MS monitored the reaction to be complete, concentrated and diluted with water (10 mL), extracted with dichloromethane (10 mL*3), and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 3_2. LC-MS (ESI): m / z=804.3[M+H] + .
[0708] Step 3: At room temperature, compound 3_2 (300 mg, 0.37 mmol) was dissolved in dichloromethane (5 mL), triethylamine (113 mg, 1.12 mmol) and trifluoroacetic anhydride (157 mg, 0.75 mmol) were added respectively and stirred at room temperature for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (5 mL), extracted with dichloromethane (5 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, the sample was mixed, and the crude product was separated and purified by column chromatography (0-35% tetrahydrofuran / petroleum ether) to obtain compound 3_3. LC-MS (ESI): m / z=786.2[M+H] + .
[0709] Step 4: At room temperature, compound 3_3 (90 mg, 0.11 mmol) was dissolved in 1,4-dioxane (5 mL), and E-phenylvinylboronic acid (25.4 mg, 0.17 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (8.37 mg, 0.01 mmol) and cesium carbonate (112 mg, 0.34 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 80°C and stirred for 1 hour. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (5 mL), extracted with ethyl acetate (5 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by column chromatography (0-55% tetrahydrofuran / petroleum ether) to obtain compound 3_4. LC-MS (ESI): m / z=810.3[M+H] + .
[0710] Step 5: At room temperature, compound 3_4 (45 mg, 0.06 mmol) was dissolved in 1,4-dioxane (2 mL), and then hydrochloric acid (2 mL) was added. The reaction was allowed to react at room temperature for 1 hour. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, and the crude product was separated and purified by preparative (chromatographic column: Phenomenex Gemini NX 150*30mm*5um; mobile phase: [water (ammonium hydroxide v / v)-ACN]; B%: 23%-63%, 9min), and lyophilized to obtain compound 3. LC-MS (ESI): m / z=510.2[M+H] + . 1 H NMR (400MHz, DMSO-d6) δ: 8.42 (s, 1H), 8.26 (s, 1H), 8.14 (s, 1H), 7.77 (d, J = 3.3Hz, 1H), 7.62-7.56 (m, 3H), 7.47 (d, J = 15.9Hz, 1H),7.37-7.24(m,5H),7.16(d,J=15.9Hz,1H),6.79(s,1H),5.61-5.50(m,2H),3.18-3.11(m,1H),3.08-3.01(m,1H),2.91(br t,J=10.6Hz,1H),2.84-2.72(m,1H),2.27-2.06(m,2H),1.78(br t, J = 14.9 Hz, 2H).
[0711] Example 4: Preparation of Compound 4 Hydrochloride and Compound 4a Hydrochloride
[0712]
[0713] Step 1: Add compound int.3 (2 g, 6.70 mmol), 2-fluoro-5-bromo-benzoic acid methyl ester (2.34 g, 10.0 mmol) and N,N-diisopropylethylamine (1.73 g, 13.4 mmol) to dimethyl sulfoxide (40 mL) at room temperature, and heat to 110°C for 3 hours. LC-MS monitoring showed that a small amount of raw materials remained in the reaction. After the reaction solution was cooled naturally, it was quenched with water (80 mL), extracted with ethyl acetate (50 mL*3), and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by column chromatography (0-20% ethyl acetate / petroleum ether) to obtain compound 4_1. LC-MS (ESI): m / z=513.2[M+H] + .
[0714] Step 2: Add compound 4_1 (1.5 g, 2.93 mmol) and lithium triethylborohydride (4.98 mL, 4.98 mmol) to tetrahydrofuran (15 mL) at room temperature and react at room temperature for 16 hours. LC-MS monitoring showed that the reaction was complete, the reaction solution was quenched with water (20 mL), extracted with ethyl acetate (25 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (2-20% tetrahydrofuran / petroleum ether) to obtain compound 4_2. LC-MS (ESI): m / z=487.1[M+H] + .
[0715] Step 3: At 0°C, compound 4_2 (200 mg, 0.41 mmol), compound int.1 (208 mg, 0.62 mmol), triphenylphosphine (326 mg, 1.24 mmol) and diisopropyl azodicarboxylate (251 mg, 1.24 mmol) were added to tetrahydrofuran (3 mL), replaced with nitrogen three times, and heated to room temperature for 5 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (20 mL), extracted with ethyl acetate (25 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated by column chromatography (0-20% tetrahydrofuran / petroleum ether) to obtain a mixture of 4_3 and 4_3a. LC-MS (ESI): m / z=804.2[M+H] + .
[0716] Step 4: Compounds 4_3 and 4_3a (380 mg, 0.47 mmol), bis-pinacol borate (181 mg, 0.71 mmol), potassium acetate (140 mg, 1.42 mmol) and Pd(dppf)Cl were added to dioxane (6 mL) at room temperature. 2 (34.7 mg, 0.05 mmol), nitrogen replacement three times, heated to 80 ° C for 3 hours. LC-MS monitoring reaction is complete, the reaction solution is quenched with water (20 mL), extracted with ethyl acetate (25 mL * 3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, the residue is separated by column chromatography (0-20% tetrahydrofuran / petroleum ether) to obtain a mixture of 4_4 and 4_4a. LC-MS (ESI): m / z = 850.4 [M + H] + .
[0717] Step 5: Compounds 4_4 and 4_4a (280 mg, 0.33 mmol), 2-bromoquinoline (110 mg, 0.53 mmol), potassium carbonate (137 mg, 0.99 mmol), methanol (0.6 mL), water (0.15 mL) and tetrakis(triphenylphosphine)palladium (38.2 mg, 0.03 mmol) were added to toluene (0.6 mL) at room temperature, replaced with nitrogen three times, and heated to 80°C for 3 hours. The reaction was complete when monitored by LC-MS, and the reaction solution was quenched with water (20 mL), extracted with ethyl acetate (15 mL*3), and the organic phase was dried, filtered and concentrated with anhydrous sodium sulfate. The residue was separated by column chromatography (0-30% tetrahydrofuran / petroleum ether) to obtain compounds 4_5 and 4_5a. LC-MS (ESI): m / z=851.4 [M+H] + .
[0718] Step 6: Add compound 4_5 (140 mg, 0.16 mmol) and hydrochloric acid (2 mL, 24.0 mmol) to dioxane (4 mL) at room temperature and react at room temperature for 16 hours. LC-MS monitored the reaction to be complete, concentrated the reaction solution, and the crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 10%-50%, 9min), and lyophilized to obtain compound 4 hydrochloride. LC-MS (ESI): m / z=495.2[M+H] + . 1 H NMR (400 MHz, METHANOL-d 4 )δ:9.07(d,J=8.7Hz,1H),9.00(s,1H),8.50(s,1H),8.40(d,J=8.6Hz,1H),8.30(d,J=8.3Hz,1H) ,8.25(d,J=8.8Hz,1H),8.22-8.11(m,2H),8.01(d,J=2.2Hz,1H),7.98-7.89(m,1H),7.71(d,J=8. 6Hz,1H),6.15(d,J=15.4Hz,1H),5.94(d,J=15.4Hz,1H),3.77(d,J=12.2Hz,1H),3.62-3.49(m,1H ),3.44-3.34(m,1H),3.12-2.97(m,1H),2.48-2.30(m,1H),2.28-2.15(m,2H),2.14-1.96(m,1H).
[0719] Step 7: Add compound 4-5a (80 mg, 0.09 mmol) and hydrochloric acid (1 mL, 12.0 mmol) to dioxane (2 mL) at room temperature and react at room temperature for 16 hours. LC-MS monitored the reaction to be complete, concentrated the reaction solution, and the crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 9%-49%, 9min), and lyophilized to obtain compound 4a hydrochloride. LC-MS (ESI): m / z=495.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.53(s,1H),8.36(d,J=8.7Hz,1H),8.19-8.12(m,2H),7.93(d,J=7.6Hz,1H),7.86(d,J =8.7Hz,2H),7.73(dt,J=1.3,7.7Hz,1H),7.60-7.51(m,2H),7.37(d,J=8.6Hz,1H),6.43(br s,2H),6.09(br d,J=16.4Hz,1H),5.72(br d,J=16.3Hz,1H),3.50-3.41(m,1H),3.16-2.99(m,2H),2.80-2.64(m,1H),2.19-1.98(m,2H),1.92-1.70(m,2H).
[0720] Example 5: Preparation of Compound 5
[0721]
[0722] Step 1: At room temperature, compound 4_4 (80 mg, 0.09 mmol) was dissolved in toluene (0.6 mL), and 3-bromoisoquinoline (30.0 mg, 0.14 mmol), potassium carbonate (37.3 mg, 0.27 mmol), methanol (0.6 mL), water (0.15 mL) and tetrakis(triphenylphosphine)palladium (10.4 mg, 0.01 mmol) were added thereto, and nitrogen was replaced three times, and the reaction was carried out at 80°C for 5 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (20 mL), extracted with ethyl acetate (15 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by TLC (tetrahydrofuran / petroleum ether=1:1) to obtain compound 5_1. LC-MS (ESI): m / z=651.6[M+H-200] + .
[0723] Step 2: At room temperature, compound 5_1 (60 mg, 0.07 mmol) was dissolved in dioxane (4 mL) and concentrated hydrochloric acid (2 mL, 24.0 mmol) was added, and the mixture was reacted at room temperature for 16 hours. The reaction was completed after LC-MS monitoring, and the reaction solution was concentrated. The crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 13%-53%, 9 min), and lyophilized to obtain compound 5. LC-MS (ESI): m / z=495.3[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:9.34(s,1H),8.32(s,1H),8.25(d,J=4.0Hz,2H),8.17-8.06(m,3H),7.99(d,J=8.1Hz,1H),7. 85-7.75(m,1H),7.72-7.60(m,1H),7.45-7.31(m,3H),5.71-5.44(m,2H),3.22(brs,1H),2.99(br d,J=12.3Hz,1H),2.82-2.68(m,2H),2.08-1.93(m,1H),1.82(br d,J=13.4Hz,1H),1.77-1.55(m,2H).
[0724] Example 6: Preparation of Compound 6 Hydrochloride
[0725]
[0726] Step 1: At room temperature, 7-bromo-2-naphthol (2 g, 8.97 mmol) was dissolved in acetone (20 mL), and cesium carbonate (3.51 g, 10.76 mmol) was added thereto. At 0°C, iodomethane (1.4 g, 9.86 mmol) was slowly added dropwise to the reaction solution. The reaction was allowed to proceed at room temperature for 2 hours. The spot plate (petroleum ether: tetrahydrofuran = 2:1) showed that 7-bromo-2-naphthol was completely consumed, and new spots with a smaller polarity were generated. The reaction solution was concentrated to obtain compound 6_1. 1 H NMR (400 MHz, DMSO-d 6 )δ:8.08(s,1H),7.89-7.77(m,2H),7.46(dd,J=1.7,8.7Hz,1H),7.33(d,J=2.0Hz,1H),7.20(dd,J=2.4,9.0Hz,1H),3.87(s,3H).
[0727] Step 2: At room temperature, compound 6_1 (1 g, 4.22 mmol) was dissolved in dioxane (10 mL), and bis-pinacol borate (1.61 g, 6.33 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (308.6 mg, 0.42 mmol) and potassium acetate (1.24 g, 12.7 mmol) were added in sequence, and nitrogen was replaced 3 times, and the reaction was carried out at 110°C for 5 hours. LC-MS monitored the reaction to be complete. The reaction solution was diluted with water (30 mL) at room temperature, extracted with ethyl acetate (40 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-1% tetrahydrofuran / petroleum ether) to obtain compound 6_2. LC-MS (ESI): m / z=285.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.24(s,1H),7.86-7.78(m,2H),7.59-7.53(m,1H),7.44(d,J=2.4Hz,1H),7.22(dd,J=2.5,8.9Hz,1H),3.87(s,3H),1.33(s,12H).
[0728] Step 3: At room temperature, compound int.5 (500 mg, 0.62 mmol) was dissolved in dioxane (5 mL), and compound 6_2 (403 mg, 1.42 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (45.4 mg, 0.06 mmol) and cesium carbonate (808 mg, 2.48 mmol) were added in sequence, and nitrogen was replaced 3 times, and the reaction was carried out at 80°C for 16 hours. LC-MS monitored the reaction to be complete. The reaction solution was diluted with water (30 mL) at room temperature, extracted with ethyl acetate (50 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-29% tetrahydrofuran / petroleum ether) to obtain compound 6_3. LC-MS (ESI): m / z=781.4[M+H-100] + .
[0729] Step 4: At room temperature, compound 6_3 (300 mg, 0.34 mmol) was dissolved in dioxane (2 mL), hydrochloric acid (1 mL) was added, and the mixture was reacted at room temperature for 16 hours. LC-MS monitored the reaction to be complete. The reaction solution was concentrated, and the crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: water (NH4HCO3)-ACN; B%: 18%-58%, 9 min), and lyophilized to obtain compound 6 hydrochloride. LC-MS (ESI): m / z=525.1[M+H] + .1 H NMR (400 MHz, DMSO-d 6 )δ:8.60(s,1H),8.37(s,2H),8.26-8.20(m,1H),7.91-7.85(m,1H),7. 82(d,J=9.0Hz,2H),7.69-7.63(m,1H),7.39(s,3H),7.20-7.14(m,1H), 5.69-5.54(m,2H),3.89(s,3H),3.42(brs,1H),3.14-3.06(m,1H),2.99 -2.86(m,2H),2.11-1.98(m,1H),1.92-1.76(m,2H),1.74-1.61(m,1H).
[0730] Example 7: Preparation of Compound 7 Hydrochloride
[0731]
[0732] Step 1: Compound 2-5 (500 mg, 0.67 mmol), 2-naphthaleneboronic acid (184 mg, 1.07 mmol), cesium carbonate (655 mg, 2.01 mmol) and Pd(dppf)Cl were reacted at room temperature. 2 (49.0 mg, 0.07 mmol) was dissolved in dioxane (5 mL), replaced with nitrogen three times, and reacted at 80°C for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (20 mL), extracted with ethyl acetate (15 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-70% tetrahydrofuran / petroleum ether) to obtain compound 7_1. LC-MS (ESI): m / z=794.5[M+H] + .
[0733] Step 2: At room temperature, compound 7_1 (480 mg, 0.06 mmol) and concentrated hydrochloric acid (5 mL, 24.0 mmol) were dissolved in dioxane (10 mL) and reacted at room temperature for 16 hours. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, and the crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 3%-43%, 9 min), and lyophilized to obtain compound 7 hydrochloride. LC-MS (ESI): m / z=494.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:9.79-9.47(m,1H),9.12-8.82(m,1H),8.67(d,J=1.8Hz,2H),8.62(br s,2H),8.59(s,1H),8.48-8.37(m,1H),8.18(s,1H),8.04-7.95(m,3H),7.94-7.90(m,2H),7.58-7.50(m,3H),5.97(br d,J=16.5Hz,1H),5.78(d,J=16.5Hz,1H),3.72(br d,J=12.1Hz,1H),3.32(br d,J=11.7Hz,1H),3.19(br d,J=10.1Hz,1H),3.07-2.92(m,1H),2.25-2.01(m,3H),1.92-1.73(m,1H).
[0734] Example 8: Preparation of Compounds 8A and 8B
[0735]
[0736] Step 1: At room temperature, int.2 (10 g, 26.42 mmol) and methylamine hydrochloride (3.57 g, 52.85 mmol) were dissolved in N, N-dimethylformamide (140 mL), and O-(7-azabenzotriazole-1-yl)-N, N, N, N-tetramethyluronium hexafluorophosphate (13.06 g, 34.35 mmol) and N, N-diisopropylethylamine (13.66 g, 105.70 mmol) were added in sequence, and the reaction was carried out at room temperature for 3 hours. LC-MS monitored the reaction to be complete, and the reaction solution was quenched with water (300 mL) at room temperature, extracted three times with ethyl acetate (1500 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-45% tetrahydrofuran / petroleum ether) to obtain compound 8_1. LC-MS (ESI): m / z=392.2 [M+H] + .
[0737] Step 2: At room temperature, 8_1 (10 g, 25.54 mmol) was dissolved in anhydrous methanol (200 mL), palladium carbon (3.26 g, 30.65 mmol) was added under nitrogen atmosphere, hydrogen was replaced three times, and the reaction was carried out at room temperature for 1 hour. LC-MS monitored the reaction to be complete, and the reaction solution was filtered and concentrated at room temperature to obtain compound 8_2. LC-MS (ESI): m / z = 258.2 [M+H] + .
[0738] Step 3: At room temperature, 8_2 (6 g, 23.32 mmol) and methyl 5-bromo-2-fluorobenzoate (8.15 g, 34.97 mmol) were dissolved in dimethyl sulfoxide (67 mL), and then N, N-diisopropylethylamine (6.03 g, 46.63 mmol) was added and reacted at 110°C for 5 hours. LC-MS monitored the reaction to be complete. At room temperature, the reaction solution was quenched with water (200 mL), extracted three times with ethyl acetate (600 mL), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-43% tetrahydrofuran / petroleum ether) to obtain compound 8_3. LC-MS (ESI): m / z=470.1[M+H] + .
[0739] Step 4: At room temperature, 8_3 (8 g, 11.69 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL), replaced with nitrogen three times, and then lithium aluminum tetrahydride (4.68 mL, 11.69 mmol) was slowly added dropwise, and reacted at 0°C for 1 hour. LC-MS monitored the reaction to be complete, and sodium sulfate decahydrate was slowly added to the reaction solution at 0°C until quenching was complete, and anhydrous sodium sulfate was added to make the system uniform, filtered and concentrated, and the residue was separated and purified by column chromatography (0-32% tetrahydrofuran / petroleum ether) to obtain compound 8_4. LC-MS (ESI): m / z=444.1[M+H] + .
[0740] Step 5: At room temperature, compound triphenylphosphine (9.25 g, 35.27 mmol) was dissolved in tetrahydrofuran (5 mL), replaced with nitrogen 3 times, and diisopropyl azodicarboxylate (7.13 g, 35.27 mmol) was added dropwise at 0°C. After reacting at 0°C for 30 minutes, 8_4 (5.2 g, 11.76 mmol) and int.1 (4.34 g, 12.93 mmol) were added, and then the mixture was returned to room temperature and stirred for 2 hours. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the crude product was separated and purified by column chromatography (0-45% tetrahydrofuran / petroleum ether), and then separated and purified by reverse phase column (0-100% acetonitrile / water) to obtain compound 8_5. LC-MS (ESI): m / z=761.3 [M+H] + .
[0741] Step 6: At room temperature, compound 8_5 (720 mg, 0.95 mmol) was dissolved in 1,4-dioxane (10 mL), and bis-pinacol borate (385.07 mg, 1.52 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (69.35 mg, 0.09 mmol) and potassium acetate (279.03 mg, 2.84 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 80°C and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the crude product was separated and purified by column chromatography (0-46% tetrahydrofuran / petroleum ether) to obtain compound 8_6. LC-MS (ESI): m / z=807.5[M+H] + .
[0742] Step 7: At room temperature, compound 8_6 (720 mg, 0.77 mmol) was dissolved in toluene (5 mL), ethanol (5 mL) and water (2 mL), and 3-bromoisoquinoline (239.84 mg, 1.15 mmol), tetrakis(triphenylphosphine)palladium (88.81 mg, 0.08 mmol) and potassium carbonate (318.62 mg, 2.31 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 80°C and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, and the crude product was separated and purified by reverse phase column (0-100% acetonitrile / water) to obtain compound 8_7. LC-MS (ESI): m / z=808.4[M+H] + .
[0743] Step 8: Compound 8_7 (700 mg, 0.87 mmol) was dissolved in dichloromethane (6 mL) at room temperature, and then trifluoroacetic acid (3 mL) was added and reacted at room temperature for 0.5 hours. The reaction was completed after LC-MS monitoring, and the reaction solution was concentrated. The crude product was separated and purified by preparation (chromatographic column: Phenomenex Gemini NX 150×30 mm, 5 μm; mobile phase: [water (ammonia hydroxide v / v)-ACN]; B%: 18%-58%, 9 min). After purification, it was extracted three times with ethyl acetate (300 mL) and concentrated to obtain compound 8. LC-MS (ESI): m / z=508.3[M+H] + .
[0744] SFC separation: Compound 8 was separated by SFC to obtain compound 8A and compound 8B.
[0745] SFC method: Column: DAICEL CHIRALCEL OD (250mm*30mm, 10um). Chromatographic conditions: CO 2-MeOH, start B: 60%; end B: 60%, flow rate: (ml / min): 80, the retention time of compound 8A is 1.292 min; the retention time of compound 8B is 3.222 min.
[0746] Compound 8A: 1 H NMR (400 MHz, DMSO-d 6 )δ:9.31(s,1H),8.25(d,J=7.3Hz,2H),8.17(s,1H),8.12-8.05(m,3H),7.99-7.94(m,1H),7.92(d,J=2.0Hz ,1H),7.80-7.72(m,1H),7.66-7.59(m,1H),7.33(d,J=8.4Hz,1H),7.27(s,2H),5.65-5.52(m,2H),3.14(br d,J=11.2Hz,1H),2.95(br d,J=11.2Hz,1H),2.77(br d,J=11.0Hz,1H),2.70-2.61(m,4H),2.30(s,2H),2.05-1.88(m,2H),1.63(br d,J=8.8Hz,1H),1.49(br d,J=11.2Hz,1H).
[0747] Compound 8B: 1 H NMR (400 MHz, DMSO-d 6 )δ:9.31(s,1H),8.25(d,J=8.4Hz,2H),8.17(s,1H),8.08(br t,J=7.9Hz,3H),7.99-7.94(m,1H),7.93(d,J=1.5Hz,1H),7.76(t,J=7.4Hz,1H), 7.66-7.60(m,1H),7.33(d,J=8.6Hz,1H),7.28(s,2H),5.65-5.52(m,2H),3.14(br d,J=11.0Hz,1H),2.95(br d,J=10.8Hz,1H),2.81-2.72(m,1H),2.70-2.62(m,4H),2.05-1.89(m,2H),1.63(br d,J=8.6Hz,1H),1.54-1.43(m,1H).
[0748] Example 9: Preparation of Compound 9
[0749]
[0750] Step 1: At room temperature, compound 2_2 (2.8 g, 11.5 mmol) was dissolved in dimethyl sulfoxide (50 mL), and compound 5-bromo-2-fluorobenzoic acid methyl ester (4.02 g, 17.3 mmol) and N,N-diisopropylethylamine (4.46 g, 34.5 mmol) were added respectively, and the temperature was raised to 110°C and stirred for 3 hours. LC-MS monitored the reaction to be complete. The reaction solution was diluted with water (50 mL), extracted with ethyl acetate (50 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-45% tetrahydrofuran / petroleum ether) to obtain compound 9_1. LC-MS (ESI): m / z=458.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:7.76-7.70(m,1H),7.63(dd,J=2.3,8.7Hz,1H),7.39-7.27(m,1H),7.17-7.06(m,2H),6.51-6.37(m,1H),3.90-3.83( m,3H),3.31-3.24(m,2H),2.96-2.77(m,2H),1.99-1.89(m,1H),1.75-1.72(m,1H),1.71-1.57(m,2H),1.39-1.31(m,9H).
[0751] Step 2: At room temperature, compound 9_1 (2 g, 4.4 mmol) was dissolved in tetrahydrofuran (30 mL), replaced with nitrogen 3 times, and lithium triethylborohydride (13.15 mL, 13.2 mmol) was added dropwise at 0°C, and then returned to room temperature and stirred for 1 hour. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (50 mL), extracted with ethyl acetate (50 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by column chromatography (0-55% tetrahydrofuran / petroleum ether) to obtain compound 9_2. LC-MS (ESI): m / z=429.9[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:7.55(d,J=2.3Hz,1H),7.40-7.34(m,1H),7.12-7.01(m,2H),6.99-6.86(m,1H),6.62-6.55(m,1H),5.29-5.15(m,1H),4.61- 4.45(m,2H),3.22-2.96(m,2H),2.86-2.76(m,1H),2.65-2.55(m,1H),1.97-1.79(m,2H),1.73-1.52(m,2H),1.42-1.33(m,9H).
[0752] Step 3: At room temperature, compound triphenylphosphine (1.84 g, 7.0 mmol) was dissolved in tetrahydrofuran (5 mL), replaced with nitrogen 3 times, and diisopropyl azodicarboxylate (1.42 g, 7.0 mmol) was added dropwise at 0°C. After reacting at 0°C for 30 minutes, 9_2 (1 g, 2.3 mmol) and int.1 (0.94 g, 2.8 mmol) were added, and then the mixture was returned to room temperature and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the crude product was separated and purified by reverse phase column (0-100% acetonitrile / water), and lyophilized to obtain compound 9_3. LC-MS (ESI): m / z=745.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.93(s,1H),8.88-8.86(m,1H),7.44(dd,J=2.3,8.6Hz,1H),7.34-7.26(m,1H) ,7.20(d,J=8.6Hz,2H),7.13-7.07(m,1H),7.04-6.96(m,1H),5.67-5.46(m,2H),3. 31(s,1H),3.15-3.03(m,1H),2.93-2.82(m,1H),2.73-2.63(m,1H),2.14-2.03(m,1 H),1.97-1.86(m,1H),1.85-1.72(m,1H),1.68-1.58(m,1H),1.34(s,18H),1.25(br s,9H).
[0753] Step 4: At room temperature, compound 9_3 (200 mg, 0.27 mmol) was dissolved in 1,4-dioxane (5 mL), and bis-pinacol borate (102.16 mg, 0.40 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (19.63 mg, 0.03 mmol) and potassium acetate (78.97 mg, 0.80 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 80°C and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (5 mL), extracted with ethyl acetate (5 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-50% tetrahydrofuran / petroleum ether) to obtain compound 9_4. LC-MS (ESI): m / z=793.5[M+H] + .
[0754] Step 5: At room temperature, compound 9_4 (135 mg, 0.17 mmol) was dissolved in toluene (2 mL), ethanol (2 mL) and water (0.5 mL), and 3-bromoisoquinoline (53.15 mg, 0.26 mmol), tetrakis(triphenylphosphine)palladium (19.68 mg, 0.02 mmol) and potassium carbonate (70.60 mg, 0.51 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 80°C and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, the sample was mixed, and the crude product was separated and purified by column chromatography (0-53% tetrahydrofuran / petroleum ether) to obtain compound 9_5. LC-MS (ESI): m / z=794.6 [M+H] + .
[0755] Step 6: At room temperature, compound 9_5 (70 mg, 0.09 mmol) was dissolved in dichloromethane (3 mL), and then trifluoroacetic acid (1.5 mL) was added. The mixture was reacted at room temperature for 1 hour. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, and the crude product was separated and purified by preparative chromatography (chromatographic column: Phenomenex Gemini NX 150×30 mm, 5 μm; mobile phase: [water (ammonium hydroxide v / v)-ACN]; B%: 17%-57%, 9 min), and lyophilized to obtain compound 9. LC-MS (ESI): m / z=494.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:9.34-9.29(m,1H),8.29-8.27(m,1H),8.26-8.24(m,1H),8.18-8.15(m,1H),8.13-8.06(m,2H),7.98(d,J=8 .4Hz,1H),7.93(s,1H),7.77(t,J=7.6Hz,1H),7.67-7.61(m,1H),7.55-7.50(m,1H),7.37-7.33(m,1H),7.24(br s,2H),7.14-7.08(m,1H),5.63-5.53(m,2H),3.15(br d,J=11.0Hz,1H),2.98-2.90(m,1H),2.85-2.79(m,1H),2.74-2.63(m,1H),2.02-1.86(m,2H),1.68-1.60(m,1H),1.57-1.49(m,1H).
[0756] Example 10: Preparation of Compound 10
[0757]
[0758] Step 1: At room temperature, compound int.2 (12 g, 31.7 mmol) was dissolved in N, N-dimethylformamide (200 mL), and compound 2,2,2-trifluoroethylamine (4.71 g, 47.6 mmol), N, N-diisopropylethylamine (12.30 g, 95.1 mmol) and O-(7-azabenzotriazole-1-yl)-N, N, N, N-tetramethyluronium hexafluorophosphate (18.09 g, 47.6 mmol) were added respectively, and stirred at room temperature for 18 hours. TLC (petroleum ether / tetrahydrofuran = 1:1, phosphomolybdic acid color development) monitored the complete reaction of the raw materials, and a new spot with a smaller polarity was generated. The reaction solution was diluted with water (300 mL), extracted with ethyl acetate (150 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-35% tetrahydrofuran / petroleum ether) to obtain compound 10_1. LC-MS (ESI): m / z=404.1[M+H-56] + . 1 H NMR (400 MHz, DMSO-d 6)δ:8.40-8.16(m,1H),7.34(br s,5H),6.93-6.78(m,1H),5.27-4.75(m,2H),4.10(s,1H),3.79-3.67(m,1H), 2.97-2.76(m,1H),2.69(s,2H),1.90-1.74(m,2H),1.72-1.59(m,1H),1.42(br s,2H),1.39-1.18(m,9H).F NMR(376MHz,DMSO-d 6 )δ:-70.23(s),-70.57(s),-71.72(s).
[0759] Step 2: At room temperature, compound 10_1 (12.5 g, 27.2 mmol) was dissolved in methanol (100 mL), wet palladium carbon (5 g, 4.7 mmol) was added, hydrogen was replaced 3 times, and stirred at room temperature for 3 hours. TLC (petroleum ether: tetrahydrofuran = 2:1, phosphomolybdic acid color development) monitored the complete reaction of the raw material, and a new point with increased polarity was generated. Filtration and concentration gave compound 10_2. LC-MS (ESI): m / z = 326.0 [M+H] + .
[0760] Step 3: At room temperature, compound 10_2 (3 g, 9.22 mmol) was dissolved in dimethyl sulfoxide (50 mL), and compound 2-bromo-5-fluoroisonicotine methyl ester (2.59 g, 11.1 mmol) and N,N-diisopropylethylamine (3.58 g, 27.7 mmol) were added respectively, and the temperature was raised to 110°C and stirred for 18 hours. TLC (petroleum ether: tetrahydrofuran = 2:1, ninhydrin color development) monitored the complete reaction of the raw material, and a new point with a smaller polarity was generated. The reaction solution was diluted with water (50 mL), extracted with ethyl acetate (50 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-25% tetrahydrofuran / petroleum ether) to obtain compound 10_3. LC-MS (ESI): m / z = 539.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:8.41-8.16(m,2H),7.70-7.57(m,1H),6.66-6.18(m,1H),3.87(s,3H),3.85(d,J=3.3H z,1H),3.84-3.80(m,1H),3.38(d,J=12.8Hz,1H),3.31(s,1H),3.27-3.21(m,1H),3.00(br t,J=10.2Hz,1H),1.99-1.84(m,2H),1.75(d,J=3.3Hz,1H),1.53(br d,J=10.6Hz,1H),1.30(s,9H).F NMR(376MHz,DMSO-d 6 )δ:-70.26(s),-70.61(s),-71.72(s).
[0761] Step 4: At room temperature, compound 10_3 (2.8 g, 5.2 mmol) was dissolved in tetrahydrofuran (50 mL), replaced with nitrogen 3 times, and lithium triethylborohydride (15.57 mL, 15.6 mmol) was added dropwise at 0°C, and then returned to room temperature and stirred for 1 hour. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (50 mL), extracted with ethyl acetate (50 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-26% tetrahydrofuran / petroleum ether) to obtain compound 10_4. LC-MS (ESI): m / z=511.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.38-8.14(m,1H),8.07(s,1H),7.55(s,1H),6.89-6.60(m,1H),5.53-5.39(m, 1H),4.59-4.43(m,2H),3.94-3.76(m,2H),3.33(s,1H),3.19-3.10(m,1H),2.95(br d,J=10.6Hz,1H),2.81(br t,J=9.8Hz,1H),2.00-1.84(m,2H),1.64-1.55(m,1H),1.36(s,9H),1.29(br s,1H).F NMR(376MHz,DMSO-d 6 )δ:-70.25(s),-70.39(s),-70.59(s).
[0762] Step 5: At room temperature, compound triphenylphosphine (2.62 g, 9.9 mmol) was dissolved in tetrahydrofuran (10 mL), replaced with nitrogen 3 times, and diisopropyl azodicarboxylate (2.02 g, 9.9 mmol) was added dropwise at 0°C. After reacting at 0°C for 30 minutes, 10_4 (1.7 g, 3.3 mmol) and int.1 (1.23 g, 3.6 mmol) were added, and then the mixture was returned to room temperature and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the crude product was separated and purified by reverse phase column (0-100% acetonitrile / water), and lyophilized to obtain compound 10_5. LC-MS (ESI): m / z=828.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.93-8.83(m,2H),8.34-8.24(m,2H),7.32(br s,1H),6.74(s,1H),5.65-5.52(m,2H),3.96-3.77(m,2H),3.52(br d,J=11.7Hz,1H),3.25(br d,J=11.9Hz,1H),3.09(br d,J=9.0Hz,1H),2.93(br t,J=9.9Hz,1H),2.13-2.01(m,2H),1.83-1.72(m,1H),1.71-1.62(m,1H),1.34(s,18H),1.20(br d,J=4.0Hz,9H).F NMR (376 MHz, DMSO-d 6 )δ:-70.17(s),-70.53(s).
[0763] Step 6: At room temperature, compound 10_5 (300 mg, 0.36 mmol) was dissolved in 1,4-dioxane (5 mL), and naphthalene-2-ylboronic acid (93.39 mg, 0.54 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (26.49 mg, 0.04 mmol) and cesium carbonate (353.86 mg, 1.09 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 80°C and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (5 mL), extracted with ethyl acetate (5 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by reverse phase column (0-65% acetonitrile / water) to obtain compound 10_6. LC-MS (ESI): m / z=876.5[M+H] + .
[0764] Step 7: At room temperature, compound 10_6 (180 mg, 0.21 mmol) was dissolved in dichloromethane (3 mL), and then trifluoroacetic acid (1.5 mL) was added. The mixture was reacted at room temperature for 1 hour. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, and the crude product was separated and purified by preparative chromatography (chromatographic column: Phenomenex Gemini NX 150×30 mm, 5 μm; mobile phase: [water (ammonium hydroxide v / v)-ACN]; B%: 28%-68%, 9 min), and lyophilized to obtain compound 10. LC-MS (ESI): m / z=576.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.56(s,1H),8.40(s,1H),8.35(s,1H),8.17(s,1H),8.01-7.94(m,3H),7.90(br d,J=3.4Hz,1H),7.59(s,1H),7.56-7.50(m,2H),7.30(s,2H),5.68-5.53(m,2H),4.04-3.83(m,2H),3.31(br d,J=11.3Hz,1H),3.05(br d,J=10.5Hz,1H),2.94-2.81(m,2H),2.01(br d,J=8.9Hz,2H),1.66(br d,J=8.0Hz,1H),1.58(br d,J=7.8Hz,1H).FNMR(376MHz,DMSO-d 6 )δ:-70.66(br).
[0765] Example 11: Preparation of Compound 11
[0766]
[0767] Step 1: At room temperature, phenylboronic acid (3.30 g, 27.1 mmol) was dissolved in dichloromethane (65 mL), and 3-bromo-1,2,4-triazole (2 g, 13.5 mmol), pyridine (2.14 g, 27.0 mmol) and copper acetate (3.68 g, 20.3 mmol) were added respectively, and stirred at room temperature for 18 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (100 mL), extracted with dichloromethane (100 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-15% ethyl acetate / petroleum ether) to obtain compound 11_1. LC-MS (ESI): m / z=224.0[M+H] + .
[0768] Step 2: Compound int.7 (333 mg, 0.47 mmol), bis-pinacol boronate (181 mg, 0.71 mmol), potassium acetate (140 mg, 1.42 mmol) and Pd(dppf)Cl were added to dioxane (6 mL) at room temperature. 2 (34.7 mg, 0.05 mmol), nitrogen replacement three times, heated to 80 ° C for 3 hours. LC-MS monitoring reaction is complete, the reaction solution is quenched with water (20 mL), extracted with ethyl acetate (25 mL * 3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, the residue is separated and purified by column chromatography (0-20% tetrahydrofuran / petroleum ether) to obtain compound 11_2. LC-MS (ESI): m / z = 750.3 [M + H] + .
[0769] Step 3: At room temperature, compound 11_1 (300 mg, 0.40 mmol) was dissolved in 1,4-dioxane (5 mL) and water (1 mL), and compound 11_2 (134 mg, 0.60 mmol), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl) (2-amino-1,1'-biphenyl-2-yl) palladium (II) (33.9 mg, 0.04 mmol) and potassium phosphate (255 mg, 1.20 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 100°C and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (10 mL), extracted with ethyl acetate (10 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by reverse phase column (0-100% acetonitrile / water), and lyophilized to obtain compound 11_3. LC-MS (ESI): m / z = 767.3 [M+H] + .
[0770] Step 4: At room temperature, compound 11_3 (80 mg, 0.10 mmol) was dissolved in dichloromethane (5 mL), and then trifluoroacetic acid (0.5 mL, 6.71 mmol) was added. The reaction was allowed to react at room temperature for 1 hour. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, and the crude product was separated and purified by preparative chromatography (chromatographic column: Phenomenex Gemini NX 150×30 mm, 5 μm; mobile phase: [water (ammonium hydroxide v / v)-ACN]; B%: 28%-68%, 9 min), and lyophilized to obtain compound 11. LC-MS (ESI): m / z=467.2[M+H] +.1H NMR(400MHz,METHANOL-d4)δ:9.02(s,1H),8.27-8.24(m,1H),8.14-8.06(m,2H),7.86-7.77(m,3H),7.54(t,J =7.8Hz,2H),7.46-7.32(m,2H),5.60(s,2H),3.23-3.11(m,1H),3.05-2.90(m,2H),2.78-2.59(m,2H),1.94(br d,J=13.0Hz,1H),1.88-1.79(m,1H),1.68(td,J=9.8,13.3Hz,1H),1.35(br d,J=10.1Hz,1H).
[0771] Example 12: Preparation of Compound 12
[0772]
[0773] Step 1: At room temperature, compound 8_5 (300 mg, 0.39 mmol) was dissolved in 1,4-dioxane (10 mL), and 1-phenyl-1H-pyrazole-3-boronic acid pinacol ester (138.68 mg, 0.51 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (28.89 mg, 0.04 mmol) and cesium carbonate (385.99 mg, 1.18 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 80°C and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the crude product was separated and purified by reverse phase column (0-100% acetonitrile / water) to obtain compound 12_1. LC-MS (ESI): m / z=823.5[M+H] + .
[0774] Step 2: Compound 12_1 (80 mg, 0.10 mmol) was dissolved in dichloromethane (3 mL) at room temperature, and then trifluoroacetic acid (1.5 mL) was added and reacted at room temperature for 0.5 hours. The reaction was completed by LC-MS monitoring, and the reaction solution was concentrated. The crude product was separated and purified by preparative chromatography (chromatographic column: Phenomenex Gemini NX 150×30 mm, 5 μm; mobile phase: [water (ammonium hydroxide v / v)-ACN]; B%: 23%-63%, 9 min), and freeze-dried to obtain compound 12. LC-MS (ESI): m / z=523.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:8.51(d,J=2.4Hz,1H),8.23(s,1H),8.16(s,1H),8.11-8.05(m,1H),7.85-7.77(m,3H),7.57(d,J=1.5Hz,1H),7.51(t, J=7.9Hz,2H),7.34-7.30(m,1H),7.30-7.25(m,3H),6.84(d,J=2.6Hz,1H),5.61-5.47(m,2H),3.15-3.07(m,1H),2.89(br s,1H),2.74(br d,J=10.8Hz,1H),2.68-2.61(m,4H),2.03-1.85(m,2H),1.62(br d,J=9.9Hz,1H),1.54-1.45(m,1H).
[0775] Example 13: Preparation of Compound 13
[0776]
[0777] Step 1: At room temperature, compound int.2 (10 g, 26.4 mmol) was dissolved in N, N-dimethylformamide (150 mL), and dimethylamine hydrochloride (3.23 g, 39.6 mmol), N, N-diisopropylethylamine (10.25 g, 79.3 mmol) and HATU (15.07 g, 39.6 mmol) were added respectively, and stirred at room temperature for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (150 mL), extracted with ethyl acetate (150 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-42% tetrahydrofuran / petroleum ether) to obtain compound 13_1. LC-MS (ESI): m / z=406.2[M+H] + .
[0778] Step 2: At room temperature, compound 13_1 (8 g, 19.7 mmol) was dissolved in methanol (200 mL), wet palladium carbon (3 g, 2.8 mmol) was added, hydrogen was replaced 3 times, and stirred at room temperature for 18 hours. TLC (petroleum ether / tetrahydrofuran = 1:1, ninhydrin color development) monitored the complete reaction of the raw material, and a new point with increased polarity was generated. Filtration and concentration gave compound 13_2. LC-MS (ESI): m / z = 272.2 [M+H] + .
[0779] Step 3: At room temperature, compound 13_2 (3.85 g, 14.2 mmol) was dissolved in dimethyl sulfoxide (100 mL), and compound 2-fluoro-5-iodobenzoic acid methyl ester (3.97 g, 14.2 mmol) and N,N-diisopropylethylamine (5.50 g, 42.6 mmol) were added respectively, and the temperature was raised to 110°C and stirred for 18 hours. TLC (petroleum ether / tetrahydrofuran = 3:1, ninhydrin color development) monitored that the raw material reaction was complete, and a new point with a smaller polarity was generated. The reaction solution was diluted with water (150 mL), extracted with ethyl acetate (150 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-35% tetrahydrofuran / petroleum ether) to obtain compound 13_3. LC-MS (ESI): m / z = 532.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:7.86-7.78(m,1H),7.67(br d,J=8.6Hz,1H),6.91(br d,J=8.6Hz,1H),6.88-6.84(m,1H),3.82(s,3H),3.58(br d,J=1.3Hz,1H),3.19-2.73(m,9H),2.08(br d,J=12.8Hz,1H),1.95-1.81(m,1H),1.74-1.66(m,1H),1.49(br d,J=9.7Hz,1H),1.34-1.27(m,9H).
[0780] Step 4: At room temperature, compound 13_3 (2.49 g, 4.7 mmol) was dissolved in tetrahydrofuran (40 mL), replaced with nitrogen 3 times, and lithium triethylborohydride (11.73 mL, 11.7 mmol) was added dropwise at 0°C, and then returned to room temperature and stirred for 1 hour. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (50 mL), extracted with ethyl acetate (50 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the sample was mixed. The crude product was separated and purified by column chromatography (0-55% tetrahydrofuran / petroleum ether) to obtain compound 13_4. LC-MS (ESI): m / z=504.0[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:7.71(s,1H),7.52(br d,J=8.4Hz,1H),7.25(s,1H),6.88(br d,J=8.4Hz,1H),5.16(br t,J=6.1Hz,1H),4.58-4.37(m,2H),3.20(br s,1H),3.12-2.72(m,8H),2.64-2.57(m,1H),2.07-1.89(m,2H),1.66-1.53(m,2H),1.41-1.27(m,9H).
[0781] Step 5: At room temperature, triphenylphosphine (3.28 g, 12.5 mmol) was dissolved in tetrahydrofuran (10 mL), replaced with nitrogen 3 times, and diisopropyl azodicarboxylate (2.53 g, 12.5 mmol) was added dropwise at 0°C. After reacting at 0°C for 30 minutes, 13_4 (2.1 g, 4.2 mmol) and int.1 (1.54 g, 4.6 mmol) were added, and then the mixture was returned to room temperature and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the crude product was separated and purified by reverse phase column (0-100% acetonitrile / water), and lyophilized to obtain compound 13_5. LC-MS (ESI): m / z=821.2 [M+H] + . 1 H NMR (400 MHz, METHANOL-d 4 )δ:8.88(s,1H),8.77(s,1H),7.63(br d,J=8.6Hz,1H),7.46-7.34(m,1H),7.07(d,J=8.5Hz,1H),5.75-5.58(m,2H),3.54(br d,J=12.9Hz,1H),3.32-3.25(m,3H),3.20(br d,J=12.1Hz,1H),2.99(br s,4H),2.81(br t,J=10.6Hz,1H),2.30(br d,J=13.3Hz,1H),2.15-2.02(m,1H),2.00-1.92(m,1H),1.79(br d,J=13.8Hz,1H),1.39-1.32(m,27H).
[0782] Step 6: At room temperature, compound 13_5 (300 mg, 0.37 mmol) was dissolved in 1,4-dioxane (5 mL), and 1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (118.49 mg, 0.44 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (26.75 mg, 0.04 mmol) and cesium carbonate (357.29 mg, 1.10 mmol) were added respectively, and nitrogen was replaced 3 times, and the temperature was raised to 80°C and stirred for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (5 mL), extracted with ethyl acetate (5 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by reverse phase column (0-60% acetonitrile / water) to obtain compound 13_6. LC-MS (ESI): m / z = 837.8 [M+H] + .
[0783] Step 7: At room temperature, compound 13_6 (190 mg, 0.23 mmol) was dissolved in dichloromethane (3 mL), and then trifluoroacetic acid (3 mL) was added. The mixture was reacted at room temperature for 1 hour. LC-MS monitored the reaction to be complete, and the reaction solution was concentrated. The crude product was separated and purified by preparative chromatography (chromatographic column: C18 150*40 mm; mobile phase: [water (NH3H2O+NH4HCO3]; B%: 19%-59%, 9 min), and freeze-dried to obtain compound 13. LC-MS (ESI): m / z=537.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.50(d,J=2.6Hz,1H),8.22(s,1H),8.15(s,1H),7.83-7.78(m,3H),7.54-7.48(m,3H) ,7.33-7.28(m,2H),7.25(s,2H),6.82(d,J=2.6Hz,1H),5.55(s,2H),3.33(s,6H),3.14(br d,J=11.6Hz,1H),2.94-2.87(m,2H),2.67-2.57(m,1H),2.47-2.26(m,2H),1.95-1.73(m,3H),1.69-1.61(m,1H).
[0784] Example 14: Preparation of Compound 14A Hydrochloride and 14B Hydrochloride
[0785]
[0786] Step 1: Add compound int.5 (200 mg, 0.25 mmol), 2-naphthaleneboronic acid (64.4 mg, 0.37 mmol), Pd(dppf)Cl to dioxane (16 mL) at room temperature. 2 (18.3mg, 0.02mmol) and cesium carbonate (244mg, 0.75mmol). Nitrogen was replaced 3 times, and the temperature was raised to 80℃ for 3 hours. LC-MS monitored that the reaction of raw material int.5 was complete, the reaction solution was diluted with water (20mL), extracted with ethyl acetate (20mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-23% tetrahydrofuran / petroleum ether) to obtain compound 14_1. LC-MS (ESI): m / z=851.5[M+H] + .
[0787] Step 2: Compound 14_1 was separated by SFC to give 14_1A and 14_1B.
[0788] SFC method: Column: DAICEL CHIRALCEL OD-H (250mm*30mm, 5um), CO 2 -EtOH (0.1% NH 3 H 2 O), gradient: 45%-45%, flow rate (ml / min): 80, the retention time of compound 14_1A was 1.577 min; the retention time of compound 14_1B was 1.888 min.
[0789] Step 3: At room temperature, add compound 14_1A (175 mg, 0.21 mmol) to dioxane hydrochloride (4 mL, 4 M), and then add hydrochloric acid (0.4 mL, 12 M). React at room temperature for 16 hours. LC-MS monitoring shows that the reaction is complete, the reaction solution is concentrated, and the residue is separated and purified by preparation (chromatographic column: Boston Green ODS150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 0%-40%, 9 min), and lyophilized to obtain compound 14A hydrochloride. LC-MS (ESI): m / z=495.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:9.78-9.54(m,1H),9.06-8.81(m,4H),8.73-8.67(m,2H),8.64-8.59(m,1H),8.46-8.37(m,1H),8.03-7.88(m,4H),7.59-7 .49(m,3H),6.12-5.73(m,2H),3.62-3.41(m,2H),3.26-3.13(m,1H),3.07-2.89(m,1H),2.26-2.00(m,3H),1.90-1.76(m,1H).
[0790] Step 4: At room temperature, add compound 14_1B (190 mg, 0.22 mmol) to dioxane hydrochloride (4 mL, 4 M), and then add hydrochloric acid (0.4 mL, 12 M). React at room temperature for 16 hours. LC-MS monitoring shows that the reaction is complete, the reaction solution is concentrated, and the residue is separated and purified by preparation (chromatographic column: Boston Green ODS150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 0%-40%, 9 min), and lyophilized to obtain compound 14B hydrochloride. LC-MS (ESI): m / z=495.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:9.74-9.51(m,1H),9.05-8.83(m,4H),8.69(d,J=8.1Hz,2H),8.63-8.57(m,1H),8.45-8.3 8(m,1H),8.06-7.85(m,4H),7.59-7.45(m,3H),6.10-5.70(m,2H),3.61-3.40(m,2H),3.19(br d,J=11.7Hz,1H),3.08-2.94(m,1H),2.26-2.00(m,3H),1.89-1.77(m,1H).
[0791] Example 15: Preparation of Compound 15 Hydrochloride
[0792]
[0793] Step 1: Add compound 14_1 (235 mg, 0.28 mmol) and 1.0 M tetrahydrofuran solution of lithium triethylborohydride (1.38 mL, 1.38 mmol) to tetrahydrofuran (5 mL) at room temperature. Replace with nitrogen three times and react at room temperature for 16 hours. LC-MS monitoring shows that the reaction of raw material 14_1 is complete. The reaction solution is quenched with methanol (10 mL), and the reaction solution is concentrated. The crude product is separated and purified by preparation (chromatographic column: Phenomenex C18 75*30mm*3um; mobile phase: [water (HCl)-ACN]; B%: 39%-79%, 2min), and lyophilized to obtain compound 15_1. LC-MS (ESI): m / z=681.4[M+H-100] + .
[0794] Step 2: At room temperature, add compound 15_1 (30 mg, 0.05 mmol) to dioxane hydrochloride (1 mL, 4 M), and then add hydrochloric acid (0.1 mL, 12 M). React at room temperature for 16 hours. LC-MS monitoring shows that the reaction is complete, and the reaction solution is concentrated. The crude product is separated and purified by preparative method (chromatographic column: Boston Green ODS150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 5%-45%, 9 min), and lyophilized to obtain compound 15 hydrochloride. LC-MS (ESI): m / z=481.1[M-HCl+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:9.76-9.42(m,1H),9.08-8.82(m,1H),8.72-8.67(m,1H),8.66-8.58(m,2 H),8.47-8.40(m,1H),8.38-8.23(m,3H),8.05-7.90(m,4H),7.60-7.49(m,3H ),6.01-5.73(m,2H),3.73-3.65(m,2H),3.32-3.17(m,2H),3.15-3.04(m,1H) ,2.97-2.86(m,1H),2.17-2.02(m,1H),1.94-1.84(m,1H),1.82-1.66(m,2H).
[0795] Example 16: Preparation of Compound 16 Hydrochloride
[0796]
[0797] Step 1: At room temperature, 5-bromobenzofuran (2 g, 10.2 mmol), vinylboronic acid pinacol ester (1.56 g, 10.2 mmol), N,N-diisopropylethylamine (3.94 g, 30.4 mmol), tri-tert-butylphosphine (0.41 g, 2.03 mmol), tetrafluoroboric acid (0.18 g, 2.03 mmol), tris(dibenzylideneacetone)dipalladium (0.93 g, 1.02 mmol) were added to toluene (20 mL), nitrogen was replaced three times, and the mixture was heated to 95 ° C for 2 hours. LC-MS monitored the reaction to be complete, the reaction solution was cooled naturally, quenched with water (40 mL), extracted with ethyl acetate (30 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-5% tetrahydrofuran / petroleum ether) to obtain compound 16_1. LC-MS (ESI): m / z=271[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ=8.01(d,J=2.2Hz,1H),7.86(s,1H),7.59(s,2H),7.42(d,J=18.3Hz,1H),7.01-6.91(m,1H),6.12(d,J=18.5Hz,1H),1.39-1.11(m,12H).
[0798] Step 2: Compound int.5 (250 mg, 0.31 mmol), compound 16_1 (126 mg, 0.47 mmol), cesium carbonate (305 mg, 0.94 mmol) and Pd(dppf)Cl were added to dioxane (4 mL) at room temperature. 2 (22.8 mg, 0.03 mmol), nitrogen replacement three times, heated to 80 ° C for 16 hours. LC-MS monitoring reaction is complete, the reaction solution is cooled naturally, quenched with water (20 mL), extracted with ethyl acetate (15 mL * 3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, the residue is separated and purified by column chromatography (0-20% tetrahydrofuran / petroleum ether) to obtain compound 16_2. LC-MS (ESI): m / z = 867 [M + H] + .
[0799] Step 3: Add compound 16_2 (100 mg, 0.12 mmol) and hydrochloric acid (0.5 mL, 0.12 mmol) to dioxane (2 mL) at room temperature, and heat to 30°C for 16 hours. LC-MS monitored the reaction to be complete. After the reaction solution was cooled naturally, the reaction solution was concentrated, and the crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 15%-55%, 9min), and lyophilized to obtain compound 16 hydrochloride. LC-MS (ESI): m / z=511[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ8.46(s,1H),8.26(s,1H),8.20(s,1H),7.99(d,J=2.2Hz,1H),7.87(s,1H ),7.65–7.51(m,3H),7.37(s,2H),7.15(d,J=15.9Hz,1H),6.93(d,J=2.3Hz ,1H),6.83(s,1H),5.70–5.50(m,2H),3.36(s,1H),3.10–2.98(m,2H),2.89 (t,J=11.2Hz,1H),2.08–1.96(m,1H),1.94-1.78(m,2H),1.73-1.63(m,1H).
[0800] Example 17: Preparation of Compound 17 Hydrochloride
[0801]
[0802] Step 1: At room temperature, 6-bromobenzofuran (2 g, 10.2 mmol), vinylboronic acid pinacol ester (1.56 g, 10.2 mmol), N,N-diisopropylethylamine (3.94 g, 30.4 mmol), tri-tert-butylphosphine (0.41 g, 2.03 mmol), tetrafluoroboric acid (0.18 g, 2.03 mmol), Pd 2 (dba) 3 (0.93 g, 1.02 mmol), nitrogen replacement three times, heated to 95 ° C for 2 hours. LC-MS monitoring reaction is complete, the reaction solution is cooled naturally, quenched with water (20 mL), extracted with ethyl acetate (15 mL * 3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, the residue is separated and purified by column chromatography (0-5% tetrahydrofuran / petroleum ether) to obtain compound 17_1. LC-MS (ESI): m / z = 271 [M + H] + . 1H NMR (400 MHz, DMSO-d 6 )δ=8.12-7.95(m,1H),7.84(s,1H),7.71-7.59(m,1H),7.52(dd,J=0.9,8.1Hz,1H) ,7.42(d,J=18.4Hz,1H),7.01-6.93(m,1H),6.20(d,J=18.4Hz,1H),1.25(s,12H).
[0803] Step 2: Compound int.5 (250 mg, 0.31 mmol), compound 17_1 (126 mg, 0.47 mmol), cesium carbonate (305 mg, 0.94 mmol) and Pd(dppf)Cl were added to dioxane (4 mL) at room temperature. 2 (22.8 mg, 0.03 mmol), nitrogen replacement three times, heated to 80 ° C for 16 hours. LC-MS monitoring reaction is complete, the reaction solution is cooled naturally, quenched with water (20 mL), extracted with ethyl acetate (15 mL * 3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, the residue is separated and purified by column chromatography (0-20% tetrahydrofuran / petroleum ether) to obtain compound 17_2. LC-MS (ESI): m / z = 867 [M + H] + .
[0804] Step 3: Add compound 17_2 (100 mg, 0.12 mmol) and hydrochloric acid (0.5 mL, 0.12 mmol) to dioxane (2 mL) at room temperature, and heat to 30°C for 16 hours. The reaction was complete after LC-MS monitoring. After the reaction solution was cooled naturally, the reaction solution was concentrated, and the crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 15%-55%, 9min), and lyophilized to obtain compound 17 hydrochloride. LC-MS (ESI): m / z=511[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:8.47(s,1H),8.27(s,1H),8.20(s,1H),8.00(d,J=2.2Hz,1H),7.86(s,1H),7.6 5-7.58(m,2H),7.52(dd,J=8.3,1.4Hz,1H),7.37(s,2H),7.23(d,J=15.8Hz,1H),6. 94(d,J=1.3Hz,1H),6.82(s,1H),5.71-5.51(m,2H),3.32-3.25(m,1H),3.13-2.97( m,2H),2.95-2.85(m,1H),2.11-1.97(m,1H),1.95-1.79(m,2H),1.75-1.64(m,1H).
[0805] Example 18: Preparation of Compound 18 Hydrochloride
[0806]
[0807] Step 1: At room temperature, 6-methyl-2-naphthol trifluoromethanesulfonate (1 g, 3.45 mmol), bis-pinacol borate (1.57 g, 6.20 mmol), Pd(dppf)Cl 2 (0.50g, 0.69mmol) and potassium acetate (0.65g, 10.3mmol). Nitrogen was replaced 3 times, and the temperature was raised to 110℃ for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (15mL), extracted with ethyl acetate (20mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-4% ethyl acetate / petroleum ether) to obtain compound 18_1. LC-MS (ESI): m / z=269.2[M+H] + .
[0808] Step 2: Compound int.5 (300 mg, 0.37 mmol), 18_1 (301.0 mg, 1.12 mmol), Pd(dppf)Cl were added to dioxane (6 mL) at room temperature. 2 (54.76 mg, 0.07 mmol) and cesium carbonate (365.73 mg, 1.12 mmol). Nitrogen was replaced 3 times, and the temperature was raised to 80°C for 3 hours. LC-MS monitored that the reaction of raw material 18_1 was complete, the reaction solution was diluted with water (10 mL), extracted with ethyl acetate (15 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (28% tetrahydrofuran / petroleum ether) to obtain compound 18_2. LC-MS (ESI): m / z=865.5.[M+H] + .
[0809] Step 3: At room temperature, add compound 18_2 (220 mg, 0.15 mmol) to dioxane hydrochloride (2 mL, 4 M), and then add hydrochloric acid (0.2 mL, 12 M). React at room temperature for 16 hours. LC-MS monitoring shows that the reaction is complete, the reaction solution is concentrated, and the residue is separated and purified by preparation (chromatographic column: Boston Green ODS150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 10%-50%, 9 min), and lyophilized to obtain compound 18 hydrochloride. LC-MS (ESI): m / z=509.0[M-HCl+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ8.60(s,1H),8.33(d,J=13.8Hz,2H),8.23(s,1H),7.92(s,2H),7.82(d,J=8.3Hz,1H),7.74(s,1H),7.66(s,1H), 7.41-7.34(m,3H),5.65-5.54(m,2H),3.12-3.04(m,1H),2.97-2.88(m,2H),2.10-2.00(m,1H),1.90-1.63(m,3H).
[0810] Example 19: Preparation of Compound 19
[0811]
[0812] Step 1: At 0°C, add 6-bromo-2-naphthol (10 g, 44.8 mmol) and cesium carbonate (17.5 g, 53.8 mmol) to acetone (100 mL), slowly drop iodomethane (7.00 g, 49.3 mmol), warm to room temperature, and react for 3 hours. TLC (petroleum ether: tetrahydrofuran = 3:1) shows that the raw material point disappears and a new point is generated. After filtering the reaction solution, it is concentrated to obtain compound 19_1. 1 H NMR (400 MHz, DMSO-d 6 )δ:8.11(d,J=1.8Hz,1H),7.81(dd,J=8.9,13.9Hz,2H),7.57(dd,J=2.0,8.8Hz,1H),7.36(d,J=2.4Hz,1H),7.22(dd,J=2.6,8.9Hz,1H),3.88(s,3H).
[0813] Step 2: Compound 19-1 (3 g, 12.6 mmol), bis-pinacol borate (4.82 g, 19.0 mmol), potassium acetate (3.72 g, 38.0 mmol) and Pd(dppf)Cl were added to dioxane (20 mL) at room temperature. 2 (0.93 g, 1.27 mmol), nitrogen replacement three times, heated to 110 ° C for 3 hours. LC-MS monitoring reaction is complete, the reaction solution is cooled naturally, quenched with water (50 mL), extracted with ethyl acetate (30 mL * 3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, the residue is separated and purified by column chromatography (0-9% tetrahydrofuran / petroleum ether) to obtain compound 19_2. LC-MS (ESI): m / z = 285 [M + H] + .
[0814] Step 3: Compound int.5 (500 mg, 0.62 mmol), compound 19_2 (25.3 mg, 0.09 mmol), cesium carbonate (610 mg, 1.87 mmol) and Pd(dppf)Cl were added to dioxane (5 mL) at room temperature. 2 (45.6 mg, 0.06 mmol), nitrogen replacement three times, heated to 80 ° C for 16 hours. LC-MS monitoring reaction is complete, the reaction solution is cooled naturally, quenched with water (20 mL), extracted with ethyl acetate (15 mL * 3), the organic phase is dried over anhydrous sodium sulfate, filtered and concentrated, the residue is separated and purified by column chromatography (0-30% tetrahydrofuran / petroleum ether) to obtain compound 19_3. LC-MS (ESI): m / z = 881 [M + H] + .
[0815] Step 4: Compound 19_3 (200 mg, 0.23 mmol) and hydrochloric acid (3 mL, 36.0 mmol) were added to dioxane (6 mL) at room temperature and reacted for 16 hours at room temperature. The reaction was completed after LC-MS monitoring. After the reaction solution was cooled naturally, the reaction solution was concentrated and the crude product was prepared (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (NH 4 HCO 3 )-ACN]; B%: 16%-56%, 9min) was separated and purified, and freeze-dried to obtain compound 19. LC-MS (ESI): m / z=525[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ8.58(s,1H),8.39-8.35(m,2H),8.24(s,1H),7.96(dd,J=8.6,1.8Hz,1H),7.88(d d,J=11.8,8.9Hz,2H),7.65(s,1H),7.38(s,2H),7.33(d,J=2.5Hz,1H),7.18(dd,J= 8.9,2.5Hz,1H),5.67–5.55(m,2H),3.89(s,3H),3.40–3.37(m,1H),3.09(d,J=12.2 Hz,1H),2.96–2.88(m,2H),2.15-1.97(m,1H),1.92-1.71(m,2H),1.70-1.63(m,1H).
[0816] Example 20: Preparation of Compound 20
[0817]
[0818] Step 1: At room temperature, int.7 (400 mg, 0.57 mmol), 3-phenyl-1H-pyrazole (123 mg, 0.85 mmol), N,N-dimethylethylenediamine (80.9 mg, 0.57 mmol), cesium carbonate (556 mg, 1.71 mmol), cuprous iodide (54.2 mg, 0.28 mmol) were added to 1,4-dioxane (6 mL), nitrogen was replaced 3 times, the temperature was raised to 110 ° C and stirred for 18 hours. LC-MS monitoring reaction was complete, the reaction solution was diluted with water (10 mL), extracted with ethyl acetate (10 mL * 3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, the sample was mixed, the crude product was separated and purified by preparation (0-65% acetonitrile / water), and lyophilized to obtain compound 20_1. LC-MS (ESI): m / z = 566.3 [M + H-200] + .
[0819] Step 2: At room temperature, compound 20_1 (100 mg, 0.13 mmol) was added to 1,4-dioxane (3 mL), and then hydrochloric acid (1 mL, 12 mol / L) was added. The mixture was reacted at room temperature for 2 hours. LC-MS monitored the reaction to be complete, the reaction solution was concentrated, and the crude product was separated and purified by preparation (Phenomenex C18 75*30mm*3um; mobile phase: [water (ammonium hydroxide v / v)-ACN]; B%: 30%-70%, 9 min), and lyophilized to obtain compound 20. LC-MS (ESI): m / z=466.2[M+H] + . 1 H NMR (400 MHz, METHANOL-d 4)δ:8.27(s,1H),8.15-8.10(m,2H),7.86-7.82(m,2H),7.75(dd,J=2.6,8.6Hz,1H) ,7.62(d,J=2.6Hz,1H),7.45-7.30(m,4H),6.84(d,J=2.4Hz,1H),5.67-5.52(m,2H ),3.11(dd,J=3.0,10.9Hz,1H),3.05-2.96(m,1H),2.91-2.83(m,1H),2.74-2.57( m,2H),1.99-1.89(m,1H),1.84-1.74(m,1H),1.70-1.58(m,1H),1.40-1.27(m,1H).
[0820] Example 21: Preparation of Compound 21
[0821]
[0822] Step 1: Compound int.7 (300 mg, 0.43 mmol), 1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (150 mg, 0.56 mmol), cesium carbonate (417 mg, 1.28 mmol) and Pd(dppf)Cl were added to dioxane (5 mL) at room temperature. 2 (94.4 mg, 0.13 mmol), replaced with nitrogen 3 times, heated to 80°C, reacted for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was diluted with water (10 mL), extracted with ethyl acetate (10 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-38% tetrahydrofuran / petroleum ether) to obtain compound 21_1. LC-MS (ESI): m / z=766.4[M+H] + .
[0823] Step 2: At room temperature, compound 21_1 (200 mg, 0.13 mmol) was added to 1,4-dioxane (3 mL), and then hydrochloric acid (1 mL, 12 mol / L) was added. The mixture was reacted at room temperature for 2 hours. LC-MS monitored the reaction to be complete, and the reaction solution was concentrated. The crude product was separated and purified by preparation (Phenomenex C18 75*30mm*3um; mobile phase: [water (ammonium hydroxide v / v)-ACN]; B%: 29%-69%, 9 min), and lyophilized to obtain compound 21. LC-MS (ESI): m / z=466.2[M+H] + . 1 H NMR (400 MHz, METHANOL-d 4)δ:8.27(s,1H),8.19(d,J=2.4Hz,1H),8.08(s,1H),7.80–7.74(m,2H),7.68(d,J=1.3Hz,1H), 7.48(t,J=7.9Hz,2H),7.36-7.28(m,2H),6.74(d,J=2.3Hz,1H),5.56(d,J=1.6Hz,2H),3.11(br d,J=10.6Hz,1H),3.05-2.95(m,1H),2.92-2.84(m,1H),2.74-2.57(m,2H), 1.98-1.87(m,1H),1.83-1.74(m,1H),1.69-1.57(m,1H),1.40-1.26(m,1H).
[0824] Example 22: Preparation of Compound 22
[0825]
[0826] Step 1: Under nitrogen protection, 2-bromoquinoline (300 mg, 1.44 mmol) was dissolved in tetrahydrofuran (3 mL) solution, and n-butyl lithium (1.73 mL, 4.33 mmol, 2.5 M in hexane) was added dropwise to the reaction solution at -78 ° C. After reacting for 1 hour, tri-n-butyltin chloride (2.35 mL, 8.65 mmol) was quickly added dropwise to the reaction solution, and the temperature was raised to room temperature for 18 hours. LC-MS detected that the reaction was complete and compound 22_1 was generated. The reaction solution was poured into ice water (10 mL) and extracted with ethyl acetate (20 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain compound 22_1. LC-MS (ESI): m / z = 420.2 [M + H] + .
[0827] Step 2: Add toluene (3 mL) to compound 22_1 (200 mg, 0.28 mmol), compound int.6 (140.52 mg, 0.34 mmol), tetrakis(triphenylphosphine)palladium (16.42 mg, 0.01 mmol) and cuprous iodide (5.41 mg, 0.03 mmol), replace with nitrogen 3 times, heat to 100 ° C and stir for 3 hours to obtain a solution. LC-MS detected that the reaction was complete and compound 22_2 was generated. The reaction solution was poured into a saturated potassium fluoride solution (10 mL) and stirred at room temperature for 30 minutes, then extracted with ethyl acetate (15 mL x3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The residue was purified by gradient chromatography on a silica gel column (1%-20% ethyl acetate / petroleum ether) to obtain compound 22_2. LC-MS (ESI): m / z=752.4[M+H] + .
[0828] Step 3: Dissolve compound 22_2 (128.23 mg, 0.17 mmol) in 33% hydrobromic acid acetic acid solution (5 mL) and stir at room temperature for 20 minutes. Monitor the reaction to be complete by LC-MS. The reaction solution was spin-dried, methanol (2 mL) was added to dissolve the crude product, saturated sodium bicarbonate solution was added to adjust the solution pH to 7-8, and concentrated to dryness. The crude product was purified by reverse phase preparative HPLC (15%-45% (v / v) CH 3 CN-H 2 O-0.025% NH 4 HCO 3 ) gradient purification to obtain compound 22. LC-MS (ESI): m / z = 452.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.56(s,1H),8.43(t,J=4.3Hz,2H),8.30(s,1H),8.23(d,J=8.6Hz,1H),8 .05(d,J=8.5Hz,1H),7.87(s,1H),7.81(d,J=8.0Hz,1H),7.69(m,1H),7.52( m,1H),5.61(s,2H),5.56(d,J=3.4Hz,2H),3.22(m,1H),3.05(m,2H),2.86(m ,1H),2.71(m,1H),1.97(m,1H),1.87(m,1H),1.78–1.66(m,3H),1.31(m,1H).
[0829] Example 23: Preparation of Compound 23
[0830]
[0831] Step 1: Add 2-bromo-5-fluoroisonicotinic acid methyl ester (1.51 g, 6.47 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.24 g, 0.29 mmol) and cesium carbonate (2.88 g, 8.83 mmol) to a solution of 3-fluoro-4-methoxyphenylboronic acid (1 g, 5.88 mmol) in 1,4-dioxane (20 mL), respectively, heat to 100 ° C, and stir for 3 hours. LC-MS detected that the raw material reaction was complete and the product was the main one. The reaction solution was poured into water (10 mL) and extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated and purified by silica gel column chromatography (13%-20% ethyl acetate / petroleum ether) to obtain compound 23_1. LC-MS (ESI): m / z 280.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.86-8.74(m,1H),8.25(d,J=5.4Hz,1H),7.98-7.87(m,2H),7.32-7.24(m,1H),3.94(s,3H),3.91(s,3H).
[0832] Step 2: Add 3-(Boc-amino)pyrrolidine (800.39 mg, 4.30 mmol) and potassium carbonate (1.19 g, 8.59 mmol) to a solution of compound 23_1 (600 mg, 2.15 mmol) in N,N-dimethylformamide (10 mL), respectively, heat to 120 ° C and stir for 16 hours. LC-MS detected that the raw material reaction was complete and the product was the main one. Pour the reaction solution into water (10 mL), extract with ethyl acetate (30 mL*3), combine the organic phases, wash with saturated brine (10 mL*2), dry over anhydrous sodium sulfate, filter and concentrate. The crude product was separated and purified by silica gel chromatography (40%-40% ethyl acetate / petroleum ether gradient) to obtain compound 23_2. LC-MS (ESI): m / z 446.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:8.24(s,1H),7.86-7.74(m,3H),7.28-7.15(m,2H),4.13-4.04(m,1H),3.91-3.84(m,6H),3.46-3 .43(m,2H),3.35-3.30(m,1H),3.06-2.99(m,1H),2.15-2.05(m,1H),1.93-1.84(m,1H),1.38(s,9H).
[0833] Step 3: Add compound 23_2 (270 mg, 0.61 mmol) to a solution of tetrahydrofuran (5 mL), add lithium triethylborohydride (3.03 mL, 3.03 mmol, 1 mol / L) in batches under an ice bath, and stir at 25 ° C for 0.5 hours. LC-MS detected that the raw material reaction was complete and the product was the main one. Pour the reaction solution into water (5 mL), extract with ethyl acetate (15 mL*3), combine the organic phases, dry with anhydrous sodium sulfate, filter and concentrate. The crude product was separated and purified by silica gel chromatography (35%-40% ethyl acetate / petroleum ether gradient) to obtain compound 23_3. LC-MS (ESI): m / z 418.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.04(s,1H),7.83(s,1H),7.80-7.72(m,2H),7.26-7.18(m,2H),5.3 9-5.33(m,1H),4.59-4.52(m,2H),4.15-4.06(m,1H),3.88(s,3H),3.53
[0834] -3.46(m,1H),3.43-3.38(m,1H),3.32-3.27(m,1H),3.15-3.08(m,1H),2.17-2.05(m,1H),1.87-1.77(m,1H),1.40(s,9H).
[0835] Step 4: Add methanesulfonyl chloride (0.19 mL, 2.52 mmol) to a mixed solution of compound 23_3 (210 mg, 0.50 mmol), triethylamine (0.21 mL, 1.51 mmol) and dichloromethane (5 mL), stir at 25 ° C for 30 minutes to obtain a solution. TLC shows that the starting material is completely consumed, and a small polar spot is observed (PE: EA = 3: 1). The mixture is poured into water (5 mL) and extracted with dichloromethane (10 mL * 3), the organic phases are combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The crude product is separated and purified by silica gel column chromatography (15%-20% ethyl acetate / petroleum ether) to obtain compound 23_4.
[0836] Step 5: Potassium carbonate (75.30 mg, 0.54 mmol) was added to a solution of compound 23_4 (50 mg, 0.12 mmol) and int.1 (60 mg, 0.18 mmol) in N,N-dimethylformamide (2 mL), and the mixture was heated to 80 ° C and stirred for 16 hours to obtain a solution. The reaction of the raw material was complete and the product was the main product by LC-MS. The mixture was poured into water (5 mL) and extracted with ethyl acetate (10 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was separated and purified by silica gel chromatography (40%-60% ethyl acetate / petroleum ether gradient) to obtain compound 23_5. LC-MS (ESI): m / z 735.2 [M+H] + .
[0837] Step 6: Compound 23_5 (70 mg, 0.10 mmol) was dissolved in dichloromethane (0.75 mL), trifluoroacetic acid (0.25 mL) was added under ice bath, and stirred at 25 ° C for 1 hour. The reaction of the raw material was complete and the product was the main product by LC-MS. The reaction solution was concentrated, and the crude product was separated and purified by reverse phase preparative HPLC (eluent: 7% to 17% (v / v), 8 minutes, acetonitrile and water, 0.1% formic acid) to obtain compound 23 (3.34 mg). LC-MS (ESI): m / z 435.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.36(s,1H),8.28(s,1H),8.23(s,1H),8.12(s,1H),7.59(dd,J=13.1,2.0Hz,1H),7.42(dd,J=8.5Hz,1H),7.32(s,2H),7.21-7.14(m,1 H),6.97(s,1H),5.50(s,2H),3.83(s,3H),3.74-3.68(m,2H),3.34-3.29(m,1H),3.22-3.15(m,2H),2.24-2.12(m,1H),1.88-1.76(m,1H).
[0838] Example 24: Preparation of Compound 24 Formate
[0839]
[0840] Step 1: At room temperature, 23_1 (500 mg, 1.79 mmol), 3-(N-Boc-aminomethyl)pyrrolidine hydrochloride (847.8 mg, 3.58 mmol) and potassium carbonate (1.23 g, 8.95 mmol) were added to N,N-dimethylformamide (10 mL) respectively, and the temperature was raised to 120°C and stirred for 20 hours. TLC (petroleum ether / ethyl acetate = 2 / 1) showed that compound 23_1 was completely consumed and new spots with greater polarity were generated. The reaction solution was naturally cooled to room temperature, poured into water (10 mL), extracted with ethyl acetate (30 mL*2), the organic phases were combined and washed with saturated brine (10 mL*2), dried over anhydrous sodium sulfate, filtered, spin-dried, mixed, separated and purified by column chromatography (0-30% ethyl acetate petroleum ether solution) to obtain compound 24_1. LC-MS (ESI): m / z = 460.2 [M+H] + .
[0841] Step 2: Add 24_1 (340 mg, 0.74 mmol) to tetrahydrofuran (7 mL) at room temperature, stir and cool to 0°C. Add lithium triethylborohydride (3.7 mL, 3.7 mmol) dropwise at 0°C, return to room temperature and stir for 2 hours. TLC (petroleum ether / ethyl acetate = 1 / 1) shows that compound 24_1 is completely consumed and a new spot with high polarity is formed. Pour the reaction solution into water (10 mL), extract with ethyl acetate (30 mL*2), combine the organic phases, dry over anhydrous sodium sulfate, filter, spin dry, mix the sample, separate and purify by column chromatography (0-50% ethyl acetate petroleum ether solution) to obtain compound 24_2. LC-MS (ESI): m / z = 432.2 [M+H] + .
[0842] Step 3: At room temperature, 24_2 (300 mg, 0.7 mmol) and triethylamine (211.05 mg, 2.09 mmol) were added to dichloromethane (10 mL), stirred and cooled to 0°C. Methanesulfonyl chloride (398.16 mg, 3.48 mmol) was added dropwise at 0°C, returned to room temperature, and stirred for 1 hour. TLC (petroleum ether / ethyl acetate = 1 / 1) showed that 24_2 was completely consumed and a new spot with less polarity was formed. The mixture was quenched with sodium bicarbonate aqueous solution (5 mL), extracted with dichloromethane (15 mL*2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain crude compound 24_3, which was used directly in the next step without further post-treatment.
[0843] Step 4: At room temperature, 24_3 (354 mg, 0.69 mmol), int.1 (349.45 mg, 1.04 mmol) and potassium carbonate (288.01 mg, 2.08 mmol) were added to N,N-dimethylformamide (8 mL), the temperature was raised to 80°C, and the mixture was stirred for 2 hours. TLC (petroleum ether / ethyl acetate = 1 / 1) showed that compound 24_3 was completely consumed and a new spot with greater polarity was formed. The reaction solution was poured into water (10 mL), extracted with ethyl acetate (30 mL*2), the organic phases were combined, washed with saturated brine (10 mL*2), dried over anhydrous sodium sulfate, filtered, spin-dried, mixed, and separated and purified by column chromatography (0-30% ethyl acetate petroleum ether solution) to obtain compound 24_4. LC-MS (ESI): m / z = 749.4 [M+H] + .
[0844] Step 5: Add 24_4 (160 mg, 0.21 mmol) to a mixed solution of dichloromethane and trifluoroacetic acid (1:1, 4 mL + 4 mL) and stir at room temperature for 1 hour. LC-MS detected that the reaction of the raw material was complete. Spin dry, and the crude product was prepared (8-95% ACN in 0.1% FA / H 2 O) was separated and purified, and freeze-dried to obtain compound 24 formate (44.18 mg). LC-MS (ESI): m / z = 449.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ:8.39(s,2H),8.26(s,1H),8.20(s,1H),8.12(s,1H),7.5 9(dd,J=13.1,2.0Hz,1H),7.40(d,J=9.7Hz,1H),7.32(s,2H),7.17(t,J=8.8Hz,1H ),6.96(s,1H),5.49(q,J=16.5Hz,2H),3.82(s,3H),3.47-3.36(m,10H),3.31-3.2 4(m,5H),2.88(s,2H),2.12(dd,J=11.8,5.7Hz,1H),1.73(dd,J=12.1,7.4Hz,1H).
[0845] Example 25: Preparation of Compound 25
[0846]
[0847] Step 1: Add (R)-3-Boc-aminopiperidine (3.63 g, 18.16 mmol) to a mixed solution of int.4 (2.43 g, 12.11 mmol), triethylamine (4.35 mL, 31.41 mmol) and 1,4-dioxane (35 mL), heat to 100 ° C and stir for 3 hours to obtain a suspension. LC-MS detected that the raw material reaction was complete and the desired product was formed. The mixture was poured into water (20 mL) and extracted with ethyl acetate (60 mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 5:1) to obtain compound 25_1. LC-MS m / z (ESI): 414.7 / 416.7 [M+2H] + / [M+2H] + .
[0848] Step 2: At 0°C, 1M solution of lithium triethylborohydride in tetrahydrofuran (20 mL) was added dropwise to a mixture of compound 25_1 (1.8 g 4.35 mmol) and tetrahydrofuran (15 mL), and the mixture was heated to room temperature and stirred for 2 hours to obtain a solution. LC-MS detected that the raw material was completely consumed and the desired product was formed. The reaction solution was quenched with saturated aqueous ammonium chloride solution (15 mL) and extracted with ethyl acetate (45 mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 4:1 to 2:1) to obtain compound 25_2. LC-MS m / z (ESI): 384.1 / 386.1 [M+H] + / [M+2H] + .
[0849] Step 3: Methanesulfonyl chloride (636.02 mg, 5.55 mmol) was added dropwise to a mixed solution of 25_2 (1430 mg, 3.70 mmol), triethylamine (1123.78 mg, 11.11 mmol) and dichloromethane (25 mL), and stirred at room temperature for 2 hours to obtain a solution. LC-MS detected that the raw material reaction was complete and the desired product was formed. The mixture was poured into water (10 mL) and extracted with dichloromethane (30 mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain 25_3 (1580 mg). The crude product was not further purified and was used directly in the next step. LC-MS m / z (ESI): 463.4 / 465.4 [M+H] + . / [M+2H] + .
[0850] Step 4: Add int.1 (1.26 g, 3.75 mmol) to a mixed solution of 25_3 (1.45 g, 3.12 mmol), potassium carbonate (1.29 g, 9.37 mmol) and N,N-dimethylformamide (20 mL), heat to 100 ° C and stir for 3 hours to obtain a solution. LC-MS detected that the raw material reaction was complete and the desired product was formed. The mixture was poured into water (10 mL) and extracted with ethyl acetate (30 mL*2). The combined organic phase was washed with brine (10 mL*2), dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 25_4. LC-MS m / z (ESI): 702.6 / 704.6 [M+H] + . / [M+2H] + . 1 H NMR (400MHz, d 6 -CDCl 3 )δ:8.84(s,1H),8.13(s,1H),8.11(s,1H),6.83(s,1H),5.47(s,2H),3.82(s,1H),3.34-3.21(m,1H),3 .01-2.91(m,1H),2.86-2.76(m,1H),2.74-2.66(m,1H),1.92-1.78(m,4H),1.39(s,18H),1.35(s,9H).
[0851] Step 5: Compound 25_4 (200 mg, 0.28 mmol), phenylacetylene (0.5 mL, 4.55 mmol), triethylamine (1 mL, 7.21 mmol) and N,N-dimethylformamide (5 mL) were added to a microwave tube, and then bis(triphenylphosphine)palladium(II) chloride (55 mg, 0.08 mmol) and N 2 Air was blown and microwaved at 100 ° C for 2 hours, then cooled to room temperature. LC-MS detected that the raw material reacted completely and formed the desired product. The mixture was poured into water (5 mL) and extracted with ethyl acetate (15 mL * 2). The organic phases were combined, washed with brine (5 mL * 2), dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 2: 1 to 1: 1) to obtain compound 25_5. LC-MSm / z (ESI): 725.8 [M + H] + .
[0852] Step 6: Add hydrobromic acid in acetic acid solution (3 mL, 33%) to 25_5 (115 mg, 0.16 mmol) and stir at room temperature for 1 hour to obtain a solution. LC-MS detected that the raw material reaction was complete and the desired product was formed. The reaction mixture was quenched with saturated sodium bicarbonate solution (5 mL) and extracted with ethyl acetate (15 mL*3). The combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (chromatographic column (eluent: (2%-32%) CH 3 CN and H 2 O, containing 0.1% HCOOH) to obtain compound 25. LC-MS m / z (ESI): 425.2 [M+H] + . 1 H NMR (400MHz, d 6 -DMSO)δ:8.40(d,J=14.5Hz,2H),8.26(s,1H),8.14(s,1H),7.55-7.48(m,2H),7.44-7.31(m,5H),6.79(s,1H),5.48(s,2H) ),3.07(m,J=12.5Hz,2H),2.95-2.83(m,2H),2.82-2.74(m,2H),1.89(s,2H),1.68(m,J=9.2Hz,1H),1.41(m,J=8.4Hz,1H).
[0853] Example 26: Preparation of Compound 26
[0854]
[0855] Step 1: Pd(dppf)Cl 2 .CH 2 Cl 2 (11.61 mg, 0.01 mmol) was added to a mixed solution of compound int.5 (200 mg, 0.28 mmol), cesium carbonate (138.91 mg, 0.43 mmol), styrene boronic acid pinacol ester (68.68 mg, 0.30 mmol) and 1,4-dioxane (4 mL), replaced with nitrogen 3 times, and stirred at 100 ° C for 3 hours under nitrogen protection. The raw material reaction was complete and the product was the main one detected by LC / MS. The reaction solution was dried and separated and purified by column chromatography (ethyl acetate / petroleum ether (0 / 100 to 100 / 0) to obtain compound 26_1. LC-MS (ESI): m / z 727.3 [M+H] + .
[0856] Step 2: Compound 26_1 (120 mg, 0.17 mmol) was added to a hydrobromic acid acetic acid solution (3 mL, 33%), and the mixture was stirred at 25°C for 1 hour. LC / MS showed that the reaction of the starting material was complete and the product was the main product. The reaction solution was concentrated and the crude product was purified by reverse preparative HPLC (7-27% ACN in 0.1% HCl / H 2 O) gradient separation and purification to obtain compound product 26. LC-MS (ESI): m / z 427.4 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.37(s,1H),8.31-8.27(m,1H),8.20-8.13(m,3H),6.97-6.88(m,3H),6.87-6.79(m,2H),6.44(s ,1H),5.53-5.34(m,2H),4.52-4.39(m,2H),3.23-3.14(m,1H),2.92-2.70(m,4H),1.95-1.80(m,2H),1.67-1.54(m,2H).
[0857] Example 27: Preparation of Compound 27 Hydrochloride and Compound 27a Hydrochloride
[0858]
[0859] Step 1: At room temperature, a mixture of 4_3 and 4_3a (800 mg, 1.00 mmol) was dissolved in dioxane (3 mL), 3-phenyl-1H-pyrazole (216.05 mg, 1.50 mmol), cuprous iodide (190.26 mg, 1.00 mmol), cesium carbonate (976.48 mg, 3.00 mmol) and N,N-dimethylethylenediamine (176.12 mg, 2.00 mmol) were added, and the temperature was raised to 110°C for 16 hours. The reaction was complete after LC-MS monitoring, the reaction solution was cooled naturally, filtered and concentrated, and the residue was purified by reverse phase column (0-100% acetonitrile / water) to obtain compounds 27_1 and 27_1a. LC-MS (ESI): m / z=866.4 [M+H] + .
[0860] Step 2: At room temperature, 27_1 (100 mg, 0.12 mmol) was dissolved in dioxane (2 mL), concentrated hydrochloric acid (2 mL, 12 M) was added, and the mixture was reacted at room temperature for 3 hours. The reaction was completed after LC-MS monitoring, and the reaction solution was concentrated. The residue was separated by prep-HPLC (chromatographic column: C18 150×30 mm; mobile phase: [water (HCl)-MeCN]; B%: 15%-55%, 9 min) to prepare compound 27 hydrochloride. LC-MS (ESI): m / z=510.3[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:9.43(br s,1H),8.91(br s,3H),8.61(s,2H),8.43(d,J=2.6Hz,1H),7.88-7.76(m,3H),7.55-7.40(m ,4H),7.39-7.31(m,1H),6.98(d,J=2.6Hz,1H),5.94-5.81(m,1H),5.72(br d,J=15.8Hz,1H),3.41-3.21(m,2H),2.99(br d,J=11.7Hz,1H),2.82(br d,J=10.3Hz,1H),2.17-1.99(m,3H),1.78(br s,1H).
[0861] Step 3: At room temperature, 27_1a (100 mg, 0.12 mmol) was dissolved in dioxane (2 mL), concentrated hydrochloric acid (2 mL, 12 M) was added, and the mixture was reacted at room temperature for 3 hours. The reaction was completed after LC-MS monitoring, and the reaction solution was concentrated. The residue was separated by prep-HPLC (chromatographic column: C18 150×30 mm; mobile phase: [water (HCl)-MeCN]; B%: 13%-53%, 9 min) to prepare compound 27a hydrochloride. LC-MS (ESI): m / z=510.3[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:8.92(br s,3H),8.81(s,1H),8.76(s,1H),8.40(s,1H),7.83(br d,J=7.7Hz,1H),7.76(br d,J=7.9Hz,2H),7.52-7.39(m,4H),7.39-7.32(m,1H),7.17(br s,1H),6.97(d,J=1.5Hz,1H),6.36(br d,J=16.9Hz,1H),6.05(br d,J=16.3Hz,1H),3.41-3.33(m,2H),3.15(br d,J=11.0Hz,1H),2.88-2.77(m,1H),2.33(br s,1H),2.14-2.02(m,2H),1.80(br d,J=12.1Hz,1H).
[0862] Example 28: Preparation of Compound 28
[0863]
[0864] Step 1: At room temperature, N,N-diisopropylethylamine (1.2 mL, 8.52 mmol) was added to tetrahydrofuran (4 mL), the atmosphere was replaced with nitrogen three times, the temperature was lowered to -78°C, n-butyllithium (3.41 mL, 8.52 mmol) was added dropwise, and then stirred at -78°C for 30 minutes, a solution of 5-fluoro-2-bromopyridine (1 g, 5.68 mmol) in tetrahydrofuran (2 mL) was added dropwise, and then stirred at -78°C for 30 minutes, and then stirred at -20°C for 30 minutes, a solution of N-methoxy-N-methylacetamide (0.7 g, 6.82 mmol) in tetrahydrofuran (2 mL) was added dropwise at -78°C, and then stirred at -78°C for 1 hour, and then stirred at room temperature for 30 minutes. TLC (petroleum ether / ethyl acetate = 10 / 1) showed that 5-fluoro-2-bromopyridine was completely consumed, and a new spot with greater polarity was generated. The reaction solution was poured into water (5 mL), then extracted with ethyl acetate (20 mL*2). The organic phases were combined, dried over an appropriate amount of anhydrous sodium sulfate, filtered, spin-dried, and purified by column chromatography (0-7% EA in PE) to obtain compound 28_1.
[0865] Step 2: At room temperature, 28_1 (300 mg, 1.38 mmol), (R)-3-Boc-aminopiperidine (551.15 mg, 2.75 mmol) and potassium carbonate (760.63 mg, 5.5 mmol) were added to N,N-dimethylformamide (3 mL) respectively, and the mixture was heated to 100°C and stirred for 2 hours. TLC (petroleum ether / ethyl acetate = 5 / 1) showed that compound 28_1 was completely consumed and a new spot with high polarity was formed. The reaction solution was poured into water (5 mL), then extracted with ethyl acetate (15 mL*2), the combined organic phases were washed with saturated brine (5 mL*2), dried over anhydrous sodium sulfate, filtered, and dried by column chromatography (0-40% EAin PE) to obtain compound 28_2. LC-MS (ESI): m / z = 398 / 400 [M+H] + . / [M+2H] + .
[0866] Step 3: At room temperature, 28_2 (310 mg, 0.78 mmol), 3-fluoro-4-methoxyphenylboronic acid (145.5 mg, 0.86 mmol), Pd(dppf)Cl were added to 1,4-dioxane (8 mL) respectively. 2 .CH 2 Cl 2 (31.78mg, 0.04mmol) and cesium carbonate (381.21mg, 1.17mmol), nitrogen replacement 3 times, the reaction temperature was raised to 100℃ and stirred for 3 hours. TLC (petroleum ether / ethyl acetate = 5 / 1) showed that compound 28_2 was completely consumed and new spots with greater polarity were generated. The reaction solution was naturally cooled to room temperature, filtered, and the filtrate was poured into water (10mL), extracted with ethyl acetate (30mL*2), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and spin-dried. Compound 28_3 was obtained by column chromatography (0-30% EAin PE). LC-MS (ESI): m / z = 444.2 [M+H] + .
[0867] Step 4: At room temperature, add compound 28_3 (268 mg, 0.6 mmol) to methanol (3 mL), add sodium borohydride (114.3 mg, 3.02 mmol) in batches under an ice-water bath, warm to room temperature and stir for 1 hour. TLC (petroleum ether / ethyl acetate = 2 / 1) shows that compound 28_3 is completely consumed and a new spot with greater polarity is formed. The reaction solution is spin-dried, poured into water (5 mL), extracted with ethyl acetate (15 mL*2), and the combined organic phases are dried over an appropriate amount of anhydrous sodium sulfate, filtered, and spin-dried to obtain compound 28_4. LC-MS (ESI): m / z = 446.2 [M+H] + .
[0868] Step 5: At room temperature, 28_4 (219 mg, 0.49 mmol) and triethylamine (149.22 mg, 1.47 mmol) were added to dichloromethane (3 mL), stirred and cooled to 0 ° C, methanesulfonyl chloride (281.5 mg, 2.46 mmol) was added dropwise, warmed to room temperature, and stirred for 1 hour. TLC (petroleum ether / ethyl acetate = 2 / 1) showed that compound 28_4 was completely consumed and a new spot with less polarity was formed. The reaction mixture was quenched with sodium bicarbonate solution (5 mL), extracted with dichloromethane (15 mL * 2), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, spin-dried, and wet column chromatography (0-50% EA in PE) to obtain compound 28_5.
[0869] Step 6: At room temperature, 28_5 (215 mg, 0.41 mmol), int.1 (206.55 mg, 0.62 mmol) and potassium carbonate (170.24 mg, 1.23 mmol) were added to N,N-dimethylformamide (3 mL) respectively, and the mixture was heated to 80°C and stirred for 2 hours. TLC (petroleum ether / ethyl acetate = 1 / 1) showed that compound 28_5 was completely consumed and a new spot with greater polarity was formed. The reaction solution was poured into water (5 mL), extracted with ethyl acetate (15 mL*2), the organic phases were combined, washed with saturated brine (5 mL*2), dried over an appropriate amount of anhydrous sodium sulfate, filtered, and dried by column chromatography (0-30% EAin PE) to obtain compound 28_6. LC-MS (ESI): m / z = 763.4 [M+H] + .
[0870] Step 7: To a solution of hydrobromic acid in acetic acid (33%, 4.5 mL) was added 28_6 (130 mg, 0.17 mmol) at room temperature, and the mixture was stirred at room temperature for 1 hour. The reaction was completed after monitoring by LC-MS. The mixture was spin-dried and the crude product was separated and purified by a preparative chromatography column (14-24% ACN in 0.1% FA / H2O) and lyophilized to obtain compounds 28A and 28B.
[0871] 28A, LC-MS(ESI): m / z=463.2[M+H] + . 1H NMR(400MHz,DMSO-d6)δ:8.54(s,1H),8.48(s,1H),8.40(s,1H),8.11(s, 1H),7.87(s,1H),7.85(s,1H),7.79(s,1H),7.27(d,J=12.0Hz,4H),6.25( d,J=7.0Hz,1H),3.88(s,3H),3.17(s,2H),2.87-2.82(m,1H),2.70(d,J=2 6.5Hz,2H),1.95(d,J=7.1Hz,3H),1.83(s,2H),1.59(s,1H),1.39(s,1H).
[0872] 28B, LC-MS(ESI): m / z=463.2[M+H] + , 1 H NMR(400MHz, DMSO-d6)δ:8.52-8.51(m,1H),8.47-8.46(m,1H),8.41-8.38(m,1H),8.17-8. 16(m,1H),7.94-7.93(m,1H),7.92-7.88(m,1H),7.83(d,J=8.7Hz,1H),7.33-7.21(m,4H),6 .27(d,J=7.1Hz,1H),3.89-3.88(m,3H),3.10(d,J=9.0Hz,2H),2.88(s,1H),2.78(d,J=8.3H z,1H),2.67(s,1H),1.93-1.90(m,3H),1.82(s,1H),1.73(s,1H),1.63(s,1H),1.40(s,1H).
[0873] Example 29: Preparation of Compound 29
[0874]
[0875] Step 1: At room temperature, methyl 2-fluorobenzoate (1 g, 6.49 mmol), (R)-3-Boc-aminopiperidine (2.6 g, 12.98 mmol) and potassium carbonate (3.59 g, 25.95 mmol) were added to N,N-dimethylformamide (10 mL) respectively, and the reaction temperature was raised to 100 ° C and stirred for 16 hours. TLC (petroleum ether / ethyl acetate = 5 / 1) showed that methyl 2-fluorobenzoate was completely consumed and new spots with greater polarity were generated. The reaction solution was naturally cooled to room temperature, poured into water (10 mL), extracted with ethyl acetate (30 mL*2), the organic phases were combined and washed with saturated brine (10 mL*2), dried over anhydrous sodium sulfate, filtered, and dried by column chromatography (0-20% EAin PE) to obtain compound 29_1. LC-MS (ESI): m / z = 335.2 [M+H] + .
[0876] Step 2: Add compound 29_1 (615 mg, 1.84 mmol) to tetrahydrofuran (10 mL) at room temperature, stir and cool to 0°C, add lithium triethylborohydride (9.2 mL, 9.2 mmol) dropwise, then warm to room temperature and stir for 0.5 hours. TLC (petroleum ether / ethyl acetate = 5 / 1) shows that compound 29_1 is completely consumed and a new spot with high polarity is formed. The reaction solution is poured into water (10 mL), extracted with ethyl acetate (30 mL*2), the organic phases are combined, dried over anhydrous sodium sulfate, filtered, spin-dried, and column chromatography (0-20% EA in PE) is performed to obtain compound 29_2. LC-MS (ESI): m / z = 307 [M+H] + .
[0877] Step 3: At room temperature, 29_2 (50 mg, 0.16 mmol), compound int.1 (82.09 mg, 0.24 mmol) and tri-n-butylphosphine (99.04 mg, 0.49 mmol) were added to tetrahydrofuran (3 mL) respectively, replaced with nitrogen 3 times, cooled to 0°C, and diisopropyl azodicarboxylate (98.99 mg, 0.49 mmol) was added dropwise, and the mixture was returned to room temperature after the addition, and stirred for 1 hour. TLC (petroleum ether / ethyl acetate = 1 / 1) showed that compound 29_2 was completely consumed and a new spot with greater polarity was formed. The reaction solution was poured into water (5 mL), extracted with ethyl acetate (15 mL*2), the combined organic phases were dried over an appropriate amount of anhydrous sodium sulfate, filtered, and spin-dried, and column chromatography (0-30% EAin PE) was performed to obtain compound 29_3. LC-MS (ESI): m / z = 624.4 [M+H] + .
[0878] Step 4: Add 29_3 (46 mg, 0.07 mmol) to a solution of hydrobromic acid in acetic acid (33%, 2 mL) at room temperature and stir for 1 hour. LC-MS showed that the reaction of the starting material was complete. Concentrate and prepare the crude product (16-95% ACN in 0.1% NH 4 HCO 3 / H 2 O) was separated and purified, and freeze-dried to obtain compound 29. LC-MS (ESI): m / z=324 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ: 8.39 (s, 1H), 8.14 (s, 2H), 7.31-7.24 (m, 3H), 7.20 (d, J = 7.5Hz, 1H), 7.03 (t, J = 7.2Hz, 1H), 6.83 (d, J = 7.3Hz, 1H), 5.44 (s,2H),3.11(d,J=10.9Hz,2H),2.83(s,1H),2.68(dd,J=4.3,2.5Hz,2H),1.83(d,J=20.3Hz,2H),1.64(d,J=9.0Hz,1H),1.45(d,J=6.6Hz,1H).
[0879] Example 30: Preparation of Compound 30
[0880]
[0881] Compound int.6 (282 mg, 0.40 mmol) was dissolved in a 33% hydrobromic acid and acetic acid solution and stirred at room temperature for 20 minutes. The reaction was monitored by LC-MS. The reaction solution was dried and methanol (2 mL) was added to dissolve the crude product. Saturated sodium bicarbonate solution was added to adjust the solution pH to 7-8. The crude product was purified by reverse phase preparative HPLC (8%-18% (v / v) CH 3 CN-H 2 O-0.1% HCOOH) gradient purification to obtain compound 30. LC-MS (ESI): m / z=403.0 / 405.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.28(s,1H),8.23(s,2H),7.37(s,2H),6.74(s,1H),5.47(d,J=4.9Hz,2H), 3.22(m,2H),3.00(m,2H),2.84(m,3H),1.87(m,2H),1.66(m,1H),1.41(m,1H).
[0882] Example 31: Preparation of Compound 31
[0883]
[0884] Step 1: Potassium carbonate (1.27 g, 9.16 mmol) was added to a solution of 3-hydroxypyridine-4-carboxylic acid methyl ester (0.72 mL, 6.11 mmol) and 2-methylpropyl [(3-bromopropyl) amino] formate (1453.91 mg, 6.11 mmol) in N,N-dimethylformamide (10 mL). Stir at 60 ° C for 2 hours. LC / MS detected that the raw material reaction was complete and the main product was produced. The reaction solution was poured into water (10 mL) and extracted with ethyl acetate (30 mL*3), and the combined organic phases were washed with saturated brine (10 mL*2), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography (0%-100% ethyl acetate / petroleum ether gradient) to obtain compound 31_1. LC-MS (ESI): m / z333.2[M+23] + .
[0885] Step 2: Under nitrogen protection at 0°C, lithium triethylborohydride (30.60 mL, 1 mol / L) was slowly added dropwise to a mixed solution of compound 31_1 (1.9 g, 6.12 mmol) and tetrahydrofuran (30 mL). Stir at 25°C for 1 hour. LC / MS detected that the raw material was completely consumed and the main product was generated. Water (30 mL) was slowly added dropwise to quench, and extracted with ethyl acetate (80 mL*2). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography: 0%-100% ethyl acetate / petroleum ether gradient to obtain compound 31_2. LC-MS (ESI): m / z 283.2 [M+H] + .
[0886] Step 3: At 0°C, add methylsulfonyl chloride (0.55 mL, 7.08 mmol) dropwise to a mixed solution of compound 31_2 (400 mg, 1.42 mmol), triethylamine (0.59 mL, 4.25 mmol) and dichloromethane (8 mL). Stir at 25°C for 1 hour. LC / MS showed that the raw material was completely consumed and the product was mainly generated. The reaction solution was spin-dried and mixed, and purified by silica gel column: 0%-5% dichloromethane / methanol gradient to obtain compound 31_3. Directly proceed to the next step. LC-MS (ESI): m / z 361.2 [M+H] + .
[0887] Step 4: Potassium carbonate (345.09 mg, 2.50 mmol) was added to a mixed solution of compound int.1 (418.70 mg, 1.25 mmol), 31_3 (300 mg) and N,N-dimethylformamide (10 mL), and stirred at 80°C for 1 hour. LC / MS detected that the raw material was completely consumed and the main product was produced. The reaction solution was poured into water (10 mL) and extracted with ethyl acetate (30 mL*2). The combined organic phases were washed with saturated sodium chloride solution (10 mL*2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography: 0%-100% ethyl acetate / petroleum ether gradient to obtain compound 31_4. LC-MS (ESI): m / z 600.4 [M+H] + .
[0888] Step 5: Add compound 31_4 (238 mg, 0.40 mmol) to hydrobromic acid acetic acid solution (2 mL, 33%). Stir at 25°C for 1 hour. LC / MS showed that the starting material was completely consumed and the product was mainly generated. The reaction solution was concentrated and the crude product was purified by reverse preparative HPLC (3-7% ACN in 0.1% NH 4 HCO 3 / H 2 O) gradient purification to obtain compound 31. LC-MS (ESI): m / z 300.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.39-8.34(m,1H),8.21-8.18(m,1H),8.15-8.08(m,2H),7.29(s,2H ),6.84-6.77(m,1H),5.38(s,2H),4.30-4.22(m,2H),3.01-2.91(m,2H),2.06-1.95(m,2H).
[0889] Example 32: Preparation of Compound 32
[0890]
[0891] Step 1: 2-methylpropan-2-yl {[2-(methylamino)ethyl]amino}formate (1.89 g, 10.87 mmol) was added to a mixed solution of 3-fluoropyridine-4-carboxylic acid methyl ester (1.21 g, 7.77 mmol), potassium carbonate (3.33 g, 24.08 mmol) and N,N-dimethylformamide (20 mL), and the mixture was heated to 100 ° C and stirred for 20 hours to obtain a solution. LC-MS detected that the raw material reaction was complete and the desired product was formed. The mixture was poured into water (20 mL) and extracted with ethyl acetate (60 mL*2). The combined organic phases were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 5:1 to 2:1) to obtain compound 32_1. LC-MS m / z (ESI): 310.0 [M+H] + .
[0892] Step 2: A 1M solution of lithium triethylborohydride in tetrahydrofuran (26.40 mL, 26.40 mmol) was added dropwise to a mixed solution of 32_1 (1420 mg, 4.59 mmol) and tetrahydrofuran (12 mL) at 0°C, warmed to room temperature and stirred for 2 hours to obtain a solution. LC-MS detected that the raw material reaction was complete and the desired product was formed. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (30 mL) and extracted with ethyl acetate (80 mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 32_2. LC-MS m / z(ESI):282.0[M+H] + .
[0893] Step 3: At 0°C, methanesulfonyl chloride (317.53 mg, 2.77 mmol) was added dropwise to a mixed solution of 32_2 (650 mg, 2.31 mmol), triethylamine (935.08 mg) and dichloromethane (15 mL), returned to room temperature and stirred for 1 hour to obtain a solution. LC-MS detected that the raw material was completely consumed and the desired product was formed. The reaction mixture was quenched with saturated sodium bicarbonate solution (10 mL) and extracted with dichloromethane (30 mL*2). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain compound 32_3. The crude product was not further purified and was used directly in the next step.
[0894] Step 4: Add int.1 (682.96 mg, 2.04 mmol) to a mixed solution of compound 32_3 (610 mg, 1.70 mmol), potassium carbonate (703.61 mg, 5.09 mmol) and N,N-dimethylformamide (15 mL), heat to 80 ° C and stir for 3 hours to obtain a solution. LC-MS detected that the raw material reacted completely and formed the desired product. The mixture was poured into water (15 mL) and extracted with ethyl acetate (45 mL*2), the combined organic phases were washed with brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 32_4. LC-MS m / z (ESI): 599.3 [M+H] + .
[0895] Step 5: Trifluoroacetic acid (1.5 mL, 20.13 mmol) was added dropwise to a mixture of compound 32_4 (150 mg, 0.25 mmol) and dichloromethane (5 mL), and the mixture was reacted at room temperature for 1 hour. LC-MS showed that the reaction of the raw material was complete and the product was mainly generated. The reaction solution was concentrated to obtain a residue. The residue was purified by preparative HPLC (chromatographic column (eluent: (5%) CH 3 CN and H 2 O, containing 0.1% NH 4 HCO 3 ) was separated and purified to obtain compound 32. LC-MS m / z (ESI): 299.1 [M+H] + . 1 H NMR (400MHz, d 6 -DMSO)δ:8.58(s,1H),8.32(s,1H),8.27(d,J=5.0Hz,1H),8.18(s,1H),7.43(s,2H),6. 77(d,J=5.0Hz,1H),5.58(s,2H),3.37-3.33(m,2H),3.12(t,J=6.0Hz,2H),2.74(s,3H).
[0896] Example 33: Preparation of Compound 33
[0897]
[0898] Compound 30 (40 mg, 0.10 mmol) was dissolved in methanol (2 mL), and 5% wet palladium carbon was added. The mixture was stirred at room temperature for 3 hours under the condition of full hydrogen. The reaction was monitored by LC-MS, which showed that all the starting materials were consumed and 70% of the product was generated. The reaction solution was filtered, the filter cake was rinsed with 3 mL of methanol, and vacuum concentrated to obtain a crude product. The crude product was purified by reverse phase preparative high performance liquid chromatography (acetonitrile: water from 2% to 2% (v / v) containing 0.025% hydrochloric acid) gradient to obtain compound 33. LC-MS (ESI): m / z = 325.1 [M+H] + .1H-NMR (400MHz, DMSO-d 6 )δ:8.66(s,1H),8.60(s,1H),8.49(s,1H),8.43(m,2H),8.41(s,1H),7.08(d,J=5 .6Hz,1H),6.03-5.77(m,2H),3.45(m,3H),3.08(m,4H),1.99(m,2H),1.71(m,2H).
[0899] Example 34: Preparation of Compound 34
[0900]
[0901] Step 1: To a solution of 2-bromo-5-fluoropyridinecarboxaldehyde (3g, 14.71mmol) in N,N-dimethylformamide (40ml), piperidine-3-carboxylic acid ethyl ester (3.43mL, 22.06mmol) and triethylamine (4.08mL, 29.41mmol) were added respectively, and the mixture was heated to 100°C and stirred for 16 hours. LC-MS detected that the raw material reaction was complete and the main product was produced. The reaction solution was poured into water (40mL) and extracted with ethyl acetate (100mL*3). The organic phases were combined, washed with water (20mL) and saturated brine (20mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was separated by a silica gel column: 10%-10% ethyl acetate / petroleum ether gradient to obtain 34_1. LC-MS (ESI): m / z 341.0 / 343.0 [M+H] + . / [M+2H] + .
[0902] Step 2: Add [1,1'-bis(diphenylphosphino)ferrocene[1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (160.84 mg, 0.22 mmol) to a mixed solution of compound 34_1 (1500 mg, 4.40 mmol), cesium carbonate (4.30 g, 13.19 mmol), (3-fluoro-4-methyloxyphenyl)boranediol (747.14 mg, 4.40 mmol) and 1,4-dioxane (10 mL), purge with nitrogen 3 times, and stir at 100 ° C for 3 hours under nitrogen protection. LC-MS detected that the raw material reaction was complete and the main product was generated. The mixture was concentrated to dryness to obtain a crude product. The residue was purified by silica gel chromatography: 16%-18% ethyl acetate / petroleum ether gradient to obtain compound 34_2. LC-MS (ESI): m / z 387.2 [M+H] + .
[0903] Step 3: Sodium borohydride (0.13 g, 3.42 mmol) was added in batches to a mixture of compound 34_2 (1.32 g, 3.42 mmol), tetrahydrofuran (10 mL) and methanol (5 mL) at 0°C, and stirred at 0°C for 10 minutes to obtain a colorless solution. The reaction of the raw material was complete and the main product was detected by LC-MS. The mixture was poured into water (5 mL) and extracted with ethyl acetate (30 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The residue was purified by silica gel chromatography column: 40%-50% ethyl acetate / petroleum ether gradient to obtain compound 34_3. LC-MS (ESI): m / z=389.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.32(s,1H),7.93(s,1H),7.86-7.77(m,2H),7.27(d,J=8.8Hz,1H),5.4 6-5.33(m,1H),4.57(d,J=5.7Hz,2H),4.14-4.06(m,2H),3.89(s,3H),3.23 -3.15(m,1H),3.02-2.93(m,2H),2.84-2.76(m,1H),2.74-2.66(m,1H),1.9 2-1.84(m,1H),1.84-1.75(m,1H),1.69-1.58(m,2H),1.20(t,J=7.1Hz,3H).
[0904] Step 4: To a mixed solution of compound 34_3 (200 mg, 0.51 mmol) and dichloromethane (3 mL) was added thionyl chloride (0.07 mL, 1.03 mmol) at 0°C and stirred at 25°C for 30 minutes to obtain a solution. TLC showed that the starting material was completely consumed and a small polar spot was observed (PE:EA=2:1, R f =0.7). The reaction solution was concentrated, and the residue was purified by silica gel column chromatography: 6%-6% ethyl acetate / petroleum ether gradient to obtain compound 34_4.
[0905] Step 5: Add N,N-dimethylformamide (4 mL) to compound 34_4 (190 mg, 0.47 mmol), int.1 (234.90 mg, 0.70 mmol) and cesium carbonate (234.90 mg, 0.70 mmol), warm to 80 ° C and stir for 16 hours to obtain a solution. LC-MS detected that the raw material reaction was complete and the main product was produced. The mixture was poured into water (5 mL) and extracted with ethyl acetate (15 mL*3). The combined organic phases were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was purified by silica gel chromatography: 50%-50% ethyl acetate / petroleum ether gradient to obtain compound 34_5. LC-MS (ESI): m / z=706.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.81(s,1H),8.75(s,1H),8.54(s,1H),7.68-7.62(m,1H),7.61-7.56(m,1H) ,7.27(s,1H),7.22-7.16(m,1H),5.76(s,2H),4.14-4.06(m,2H),3.86(s,3H),3 .27-3.22(m,1H),3.11-2.98(m,2H),2.91-2.83(m,1H),2.79-2.72(m,1H),1.96 -1.88(m,1H),1.82-1.75(m,1H),1.67-1.56(m,2H),1.34(s,18H),1.17(d,3H).
[0906] Step 6: Add water (0.5 mL), tetrahydrofuran (0.5 ml) and ethanol (0.5 ml) to compound 34_5 (80 mg, 0.11 mmol) and sodium hydroxide (22.5 67 mg, 0.57 mmol), respectively, heat to 80 ° C and stir for 20 minutes to obtain a solution. LC-MS detected that the raw material reaction was complete and the main product was produced. The reaction solution was spin-dried, adjusted to pH 6-7 with saturated citric acid aqueous solution, and extracted with ethyl acetate (10 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product compound 34_6. The product was used directly in the next step without further purification. LC-MS (ESI): m / z=678.3[M+H] + .
[0907] Step 7: Compound 34_6 (80 mg, 0.12 mmol) was added to a mixed solution of dichloromethane (0.75 mL) and trifluoroacetic acid (0.25 mL), and stirred at 25 ° C for 30 minutes to obtain a solution. The reaction of the raw material was complete and the main product was detected by LC-MS. The mixture was concentrated to dryness to obtain a crude product. The crude product was purified by preparative HPLC (eluent: 19% to 45% (v / v) 8.5 minutes, acetonitrile and water, 10mmoL / L ammonium bicarbonate) to obtain compound 34. LC-MS (ESI): m / z=478.3[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.50(s,1H),8.24(s,1H),8.12(s,1H),7.71-7.63(m,1H),7.56-7.47(m,1H),7.36-7.14(m,4H),5.57-5.41(m,2H),3.85(s,3H), 3.25-3.18(m,2H),3.08-2.99(m,2H),2.88-2.82(m,1H),2.69-2.64(m,1H),1.97-1.88(m,1H),1.85-1.77(m,1H),1.71-1.55(m,2H).
[0908] Example 35: Preparation of Compound 35
[0909]
[0910] Step 1: Compound int.6 (500 mg, 0.71 mmol), 4-chloro-trans-β-phenylvinylboronic acid pinacol ester (225.59 mg, 0.85 mmol), Pd(dppf)Cl were added to 1,4-dioxane (2.5 mL) at room temperature. 2(26.00mg, 0.04mmol) and cesium carbonate (694.57mg, 2.13mmol), nitrogen replacement 3 times, heating to 100℃ and stirring for 5 hours to obtain a solution. LC-MS detection shows that compound int.6 is completely consumed and compound 35_1 is generated. Cool to room temperature, add saturated brine (10mL), extract with ethyl acetate (30mL*2), combine the organic phases, dry over anhydrous sodium sulfate, filter, spin dry, mix the sample, separate and purify by column chromatography (1% to 5% dichloromethane / methanol) to obtain compound 35_1. LC-MS (ESI): m / z=761.4[M+H] + .
[0911] Step 2: Dissolve compound 35_1 (280 mg, 0.37 mmol) in 33% hydrobromic acid acetic acid solution (5 mL) and stir at room temperature for 1 hour. Monitor the reaction to completion by LC-MS. Concentrate to dryness, add methanol (2 mL) to dissolve the crude product, and adjust the solution pH to 7-8 with sodium bicarbonate. The crude product is purified by reverse phase preparative HPLC (29%-59% (v / v) CH 3 CN-H 2 O-0.025% NH 4 HCO 3 ) gradient purification to obtain compound 35. LC-MS (ESI): m / z = 461.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ8.39(s,1H),8.24(d,J=10.6Hz,1H),8.12(d,J=4.0Hz,1H),7.61(d,J=8.4Hz ,2H),7.44(d,J=15.9Hz,1H),7.37(d,J=8.4Hz,2H),7.28(s,2H),7.17(d,J=15 .9Hz,1H),6.69(d,J=5.0Hz,1H),5.45(s,2H),3.17(s,2H),3.05(s,1H),2.90( s,1H),2.79(m,1H),2.56(s,2H),1.83(m,2H),1.67(s,1H),1.38-1.09(m,1H).
[0912] Example 36: Preparation of Compound 36
[0913]
[0914] Step 1: At room temperature, 4-bromopyridine (200 mg, 1.03 mmol), vinylboronic acid pinacol ester (174.25 mg, 1.13 mmol), Pd 2 (dba) 3 (47.09 mg, 0.05 mmol), tri-tert-butylphosphine tetrafluoride (29.84 mg, 0.1 mmol) and N,N-diisopropylethylamine (398.8 mg, 3.09 mmol), heated to 100 ° C and stirred for 3 hours. TLC (petroleum ether / ethyl acetate = 10 / 1) showed that a small amount of 4-bromopyridine remained, and new spots with greater polarity were generated. The reaction solution was naturally cooled to room temperature, poured into water (5 mL), extracted with ethyl acetate (15 mL*2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried, and separated and purified by column chromatography (0-15% EAin PE) to obtain compound 36_1. LC-MS (ESI): m / z: 232 [M+H] + .
[0915] Step 2: Int.6 (137.9 mg, 0.2 mmol), 36_1 (49.82 mg, 0.22 mmol), cesium carbonate (95.78 mg, 0.29 mmol) and Pd(dppf)Cl were added to 1,4-dioxane (3 mL) at room temperature. 2 (7.17 mg, 0.01 mmol), nitrogen replacement 3 times, heating to 100 ° C and stirring for 3 hours. TLC (dichloromethane / methanol = 10 / 1) shows that compound 36_1 is completely consumed and a new spot with high polarity is formed. Cool to room temperature, pour into water (5 mL), extract with ethyl acetate (15 mL * 2), combine the organic phases, dry over anhydrous sodium sulfate, spin dry, mix the sample, separate and purify by column chromatography (0-20% MeOH in DCM) to obtain compound 36_2. LC-MS (ESI): m / z: 728.4 [M+H] + .
[0916] Step 3: At room temperature, add 36_2 (74 mg, 0.1 mmol) to a solution of hydrobromic acid in acetic acid (3 mL, 33%) and stir at room temperature for 1 hour. LC-MS detected that the reaction of the raw material was complete. Spin dry, and the crude product was prepared (5-35% ACN in 0.1% NH 4 HCO 3 / H 2 O) was separated and purified, and freeze-dried to obtain compound 36. LC-MS (ESI): m / z: 428.2 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ:8.50-8.48(m,2H),8.43-8.42(m,1H),8.25-8.23(m,1H),8. 13-8.11(m,1H),7.56-7.54(m,2H),7.44-7.42(m,2H),7.31-7.29(m,2H),6.77-6.74( m,1H),5.48-5.46(m,2H),3.20(d,J=11.1Hz,2H),3.08(d,J=11.7Hz,1H),2.81(s,1H) ,2.63-2.57(m,1H),1.89-1.81(m,2H),1.67(d,J=9.9Hz,1H),1.23(d,J=10.5Hz,1H).
[0917] Example 37: Preparation of Compound 37
[0918]
[0919] Step 1: Pd(dppf)Cl was added to a mixed solution of compound int.6 (410 mg, 0.58 mmol), 2-naphthaleneboronic acid pinacol ester (222.13 mg, 0.87 mmol), cesium carbonate (569.55 mg, 1.75 mmol) and 1,4-dioxane (10 mL). 2 (42.64mg, 0.06mmol), heated to 100℃ under nitrogen protection for 3 hours, and turned into a black solution. LC-MS detected that the raw material was completely consumed and the generated product was the main one. The mixture was poured into water (10mL) and extracted with ethyl acetate (30mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain compound 37_1. LC-MS m / z(ESI):751.4[M+H] + .
[0920] Step 2: Add a solution of hydrobromic acid in acetic acid (5 mL, 33%) dropwise to compound 37_1 and stir at room temperature for 1 hour to obtain an emulsion. LC-MS detected that the reaction of the raw material was complete and the desired product was formed. The reaction solution was concentrated to obtain a residue. The residue was purified by preparative HPLC (chromatographic column (eluent: (15%-25%) CH 3 CN and H 2 O, containing 0.1% HCOOH) to obtain compound 37. LC-MS m / z (ESI): 451.2 [M+H] + . 1 H NMR (400MHz, d6 -DMSO)δ:8.56(s,1H),8.37(s,2H),8.31(s,1H),8.18(s,1H),8.02-7.93(m,3H),7.93-7.89(m,1H),7.60-7.47(m,3H),7.30(s,2H ),5.56(s,2H),3.30-3.22(m,2H),3.09-3.02(m,1H),2.93-2.82(m,2H),1.95-1.81(m,2H),1.69-1.60(m,1H),1.48-1.40(m,1H).
[0921] Example 38: Preparation of Compound 38 Hydrochloride
[0922]
[0923] Step 1: Add compound int.5 (389 mg, 0.48 mmol), 7-methyl-2-naphthaleneboronic acid pinacol ester (100 mg, 0.37 mmol), Pd(dppf)Cl to dioxane (10 mL) at room temperature. 2 (54.6mg, 0.07mmol) and cesium carbonate (365mg, 1.12mmol). Nitrogen was replaced 3 times, and the temperature was raised to 80℃ for 6 hours. LC-MS monitored that the raw material 7-methyl 2-naphthaleneboronic acid pinacol ester reacted completely, the reaction solution was diluted with water (15mL), extracted with ethyl acetate (20mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-28% tetrahydrofuran / petroleum ether) to obtain compound 38_1. LC-MS (ESI): m / z=865.4[M+H] + .
[0924] Step 2: Add compound 38_1 (220 mg, 0.15 mmol) to dioxane hydrochloride (2 mL, 4 M) at room temperature, and then add hydrochloric acid (0.2 mL, 12 M). React at room temperature for 16 hours. LC-MS monitoring shows that the reaction is complete, the reaction solution is concentrated, and the residue is separated and purified by preparation (chromatographic column: Boston Green ODS150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 10%-50%, 9 min), and lyophilized to obtain compound 38 hydrochloride. LC-MS (ESI): m / z=509.0[M-HCl+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:8.60(s,1H),8.35(s,1H),8.32(s,1H),8.23(s,1H),7.96-7.88(m,2H),7.82(d,J=8.4Hz,1H),7.74(s,1H),7.66(s ,1H),7.40-7.34(m,3H),5.59(d,J=5.4Hz,2H),3.15-2.84(m,4H),2.48(s,3H),2.11-1.99(m,1H),1.89-1.62(m,3H).
[0925] Example 39: Preparation of Compound 39
[0926]
[0927] Step 1: Vinylboronic acid pinacol ester (1.07 mL, 6.33 mmol) and 3-bromopyridine (0.61 mL, 6.33 mmol) were added to a toluene (8 mL) solution at room temperature, and tri(2-methylprop-2-yl)phosphine tetrafluoro-λ5-borane (183.65 mg, 0.63 mmol), Pd 2 (dba) 3 (289.83 mg, 0.32 mmol) and N, N-diisopropylethylamine (1.05 mL, 6.33 mmol), nitrogen replacement 3 times, and heated to 95 ° C under nitrogen protection and stirred for 4 hours. LC-MS showed that the reaction was complete. Cooled to room temperature, the mixture was filtered and the solid was washed with ethyl acetate (5 mL x3), and the filtrate was concentrated to dryness under reduced pressure to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: EtOAc = 80:20) to obtain compound 39_1. LC-MS (ESI): m / z = 232.1 [M+H] + .
[0928] Step 2: Compound 39_1 (147.80 mg, 0.64 mmol), Pd(dppf)Cl were added to a mixed solution of compound int.6 (300 mg, 0.43 mmol), water (1 mL) and 1,4-dioxane (5 mL) at room temperature. 2 (31.20 mg, 0.04 mmol) and cesium carbonate (416.74 mg, 1.28 mmol), replaced with nitrogen 3 times, and heated to 100 ° C under nitrogen protection and stirred for 16 hours. LC-MS showed that the reaction was complete. Cooled to room temperature, the mixture was filtered and the solid was washed with ethyl acetate (10 mL x 3), and the filtrate was concentrated to dryness under reduced pressure to obtain compound 39_2. LC-MS (ESI): m / z=528.4[M+H-200] + .
[0929] Step 3: At room temperature, compound 39_2 (350 mg, 0.34 mmol) was added to a 33% hydrobromic acid acetic acid solution (5 mL) and stirred at 25°C for 2 hours. LC-MS showed that the reaction of the raw material was complete. The mixture was concentrated to obtain a crude product. The crude product was purified by preparative high performance liquid chromatography (column: Atlantis TM T 3 Prep OBDTM 5μm, 19*150mm; flow rate: 15mL / min; mobile phase: A: 0.1% FA / H 2 O; B: ACN; UV wavelength: 220nm / 254nm) to separate and purify compound 39. LC-MS (ESI): m / z=428.2[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:9.88-9.72(m,1H),9.10(s,1H),8.79(d,J=5.5Hz,1H),8.72(d,J=11.7H z,2H),8.61-8.49(m,5H),8.03-7.98(m,1H),7.74(d,J=16.2Hz,1H),7.60( d,J=16.2Hz,1H),6.91(s,1H),5.89(s,1H),5.76(d,J=17.3Hz,1H),3.47(s ,2H),3.18-3.10(m,1H),3.06(s,2H),2.06-1.93(m,2H),1.80-1.63(m,2H).
[0930] Example 40: Preparation of Compound 40
[0931]
[0932] Step 1: Add tetrahydrofuran (5mL) solution to a mixture of cuprous chloride (0.01mL, 0.29mmol), sodium tert-butoxide (55.92mg, 0.58mmol) and bis(2-diphenylphosphinophenyl) ether (78.34mg, 0.15mmol), replace with nitrogen three times, react at room temperature for 10 minutes, then add diboric acid pinacol ester (0.90mL, 3.49mmol) and react at room temperature for 20 minutes. After the reaction is completed, 2-alkynylpyridine (0.29mL, 2.91mmol) is dissolved in methanol (0.14mL) and added dropwise to the reaction solution, and reacted at room temperature for 18 hours to obtain a solution. LC-MS detection shows that 2-alkynylpyridine is completely consumed and compound 40_1 is generated. Cool to room temperature, filter, wash the filter cake with ethyl acetate (10mL), and concentrate the filtrate to dryness under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (1% to 6% ethyl acetate / petroleum ether) to obtain compound 40_1. LC-MS (ESI): m / z = 232.2 [M+H] + .
[0933] Step 2: Compound 40_1 (197.06 mg, 0.85 mmol), int.6 (500 mg, 0.71 mmol), cesium carbonate (694.57 mg, 2.13 mmol) and Pd(dppf)Cl 2 (26.00mg, 0.04mmol) were dissolved in a mixed solvent of 1,4-dioxane (5mL) and water (1mL), replaced with nitrogen 3 times, heated to 80°C and stirred for 4 hours. The reaction was monitored by LC-MS. The reaction solution was filtered, concentrated to dryness, diluted with water (10mL), and extracted with ethyl acetate (20mL x3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by gradient chromatography on a silica gel column (5%-30% ethyl acetate / petroleum ether) to obtain compound 40_2. LC-MS (ESI): m / z=728.4[M+H] + .
[0934] Step 3: Dissolve compound 40_2 (300 mg, 0.41 mmol) in 33% hydrobromic acid acetic acid solution (5 mL) and stir at room temperature for 20 minutes. Monitor the reaction to completion by LC-MS. Concentrate the reaction solution to dryness, add methanol (2 mL) to dissolve, add sodium bicarbonate to adjust the solution pH to 7-8, and concentrate to dryness. The crude product was purified by reverse phase preparative HPLC (16%-46% (v / v) CH 3 CN-H 2 O-0.025% NH 4 HCO 3) gradient purification to obtain compound 40. LC-MS (ESI): m / z=428.2 [M+H] + . 1 HNMR (400 MHz, DMSO-d 6 )δ:8.52(m,1H),8.42(s,1H),8.25(m,1H),8.13(m,1H),7.73(m,1H),7.59(d,J=7.8Hz,1H),7.50–7.41(m,2H),7.29(s,2H),7.25–7.21(m ,1H),6.82(s,1H),5.46(s,2H),3.17(m,2H),3.08(m,2H),2.89(m,1H),2.79(m,1H),2.56(m,1H),1.84(m,2H),1.66(m,1H),1.18(m,1H).
[0935] Example 41: Preparation of Compound 41
[0936]
[0937] Step 1: trans-β-phenylvinylboronic acid pinacol ester (200 mg, 0.87 mmol), compound int.6 (509.64 mg, 0.72 mmol), Pd(dppf)Cl 2 (16.62 mg, 0.02 mmol) and cesium carbonate (707.97 mg, 2.17 mmol) were dissolved in a mixed solution of 1,4-dioxane (10 mL) and water (2 mL), respectively; nitrogen was purged 3 times, the temperature was raised to 80 ° C and stirred for 3 hours to obtain a solution. LC-MS detected that the reaction was complete and compound 41_1 was generated. The reaction solution was filtered, the filtrate was concentrated to dryness under reduced pressure, the residue was poured into water (20 mL), and extracted with ethyl acetate (20 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by gradient chromatography on a silica gel column (10%-30% ethyl acetate / petroleum ether) to obtain compound 41_1. LC-MS (ESI): m / z=727.4[M+H] + .
[0938] Step 2: Compound 41_1 (350 mg, 0.48 mmol) was dissolved in methanol (2 mL), wet palladium carbon (0.10 mL, 0.96 mmol, 5%) was added, hydrogen was replaced three times, and the reaction was carried out at room temperature for 3 hours. LC-MS detected that the reaction was complete and compound 41_2 was generated. The reaction solution was filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain compound 41_2. LC-MS (ESI): m / z = 729.6 [M+H] + .
[0939] Step 3: Compound 41_2 (280 mg, 0.38 mmol) was dissolved in 33% hydrobromic acid acetic acid solution (5 mL) and stirred at room temperature for 20 minutes. The reaction was complete and the product was generated by LC-MS. The reaction solution was concentrated to dryness, methanol (2 mL) was added to dissolve the crude product, saturated sodium bicarbonate solution was used to adjust the solution pH to 7-8, and concentrated to dryness. The crude product was purified by reverse phase preparative HPLC (18%-48% (v / v) CH 3 CN-H 2 O-0.025% NH 4 HCO 3 ) gradient purification to obtain compound 41. LC-MS (ESI): m / z = 429.3 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.30(s,1H),8.12(m,2H),7.28(s,2H),7.15(m,2H),7.11-7.03(m,3H),6.48(s,1H),5.39(s,2H),3.19(m,1H),3.07 (m,1H),2.97(m,1H),2.84(m,5H),2.71(m,1H),2.51(m,1H),2.47(m,1H),1.86-1.75(m,2H),1.62(m,1H),1.16(m,1H).
[0940] Example 42: Preparation of Compound 42
[0941]
[0942] Step 1: int.6 (500 mg, 0.71 mmol), Pd(dppf)Cl 2 (16.62 mg, 0.02 mmol) and triethylamine (26.00 mg, 0.04 mmol) were dissolved in methanol (7 mL) respectively; replaced with carbon monoxide 3 times, heated to 70 ° C and stirred for 3 hours to obtain a solution. LC-MS detected that the reaction was complete and compound 42_1 was generated. The reaction solution was filtered, washed with ethyl acetate (10 mL), and the filtrate was concentrated to dryness under reduced pressure. The residue was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain a crude product. The residue was purified by gradient chromatography on a silica gel column (10%-50% ethyl acetate / petroleum ether) to obtain compound 42_1. LC-MS (ESI): m / z=583.3[M-100+H] + .
[0943] Step 2: Dissolve compound 42_1 (300 mg, 0.51 mmol) in methanol (5 mL) and water (1 mL), add lithium hydroxide (0.07 mL, 2.57 mmol), and react at room temperature for 5 hours. LC-MS detection shows that the reaction is complete and compound 42_2 is generated. Filter the reaction solution, wash the filter cake with ethyl acetate (15 mL), and concentrate the filtrate to dryness under reduced pressure to obtain compound 42_2. LC-MS (ESI): m / z=569.2[M-100+H] + .
[0944] Step 3: Compound 42_2 (200 mg, 0.35 mmol), aniline (38.54 μL, 0.42 mmol, Anaiji), N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (147.30 mg, 0.52 mmol) and N-methylimidazole (84.12 μL, 1.06 mmol) were dissolved in acetonitrile (3 mL) and stirred at room temperature for 4 hours to obtain a solution. LC-MS detected that the reaction was complete and compound 42_3 was generated. Concentrate to dryness, pour the residue into water (20 mL), extract with ethyl acetate (20 mL x 3), combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to dryness to obtain a crude product. The residue was purified by gradient chromatography on a silica gel column (50%-90% ethyl acetate / petroleum ether) to obtain compound 42_3. LC-MS (ESI): m / z=644.4[M-100+H] + .
[0945] Step 4: Dissolve compound 42_3 (100 mg, 0.16 mmol) in 33% hydrobromic acid acetic acid solution (5 mL) and stir at room temperature for 20 minutes. Monitor the reaction to be complete by LC-MS. The reaction solution was spin-dried, methanol (2 mL) was added to dissolve the crude product, saturated sodium bicarbonate solution was adjusted to pH = 7-8, and concentrated to dryness. The crude product was purified by reverse phase preparative HPLC (15%-45% (v / v) CH 3 CN-H 2 O-0.025% NH 4 HCO 3 ) gradient purification to obtain compound 42. LC-MS (ESI): m / z = 444.2 [M+H] + . 1 HNMR (400 MHz, DMSO-d 6)δ:9.81(s,1H),8.39(m,2H),7.78(m,2H),7.70(m,2H),7.35(m,2H),7.12(m,1H),5.62(s,2H),5.50(m,2H),3.2 7(m,1H),3.13(m,2H),2.89(m,1H),2.74(m,1H),2.08–1.98(m,1H),1.92(m,1H),1.82–1.65(m,3H),1.35(m,1H).
[0946] Example 43: Preparation of Compound 43 Hydrochloride
[0947]
[0948] Step 1: At room temperature, 2-naphthol (1.5 g, 10.40 mmol) was dissolved in dichloromethane (8 mL), replaced with nitrogen three times, tert-butyl chloride (2.02 g, 21.85 mmol) and aluminum chloride (0.14 g, 1.04 mmol) were added, and the temperature was raised to 40 ° C for 6 hours. LC-MS monitored the reaction to be complete, the reaction solution was naturally cooled to room temperature, concentrated under reduced pressure, the residue was dissolved in 10 mL of 5% sodium hydroxide solution, heated to 80 ° C and stirred for 2 hours. Cooled to room temperature, diluted with water (20 mL), and extracted with dichloromethane (20 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by column chromatography (0-10% ethyl acetate / petroleum ether) to obtain compound 43_1. LC-MS (ESI): m / z=201.1[M+H] + . 1 H NMR(400MHz,CHLOROFORM-d)δ:7.77-7.71(m,2H),7.66(d,J=8.6Hz,1H),7.56(dd, J=2.0,8.8Hz,1H),7.14(d,J=2.2Hz,1H),7.10(dd,J=2.4,8.8Hz,1H),1.43(s,9H).
[0949] Step 2: At 0°C, 43_1 (0.8 g, 3.99 mmol) was dissolved in dichloromethane (3 mL), replaced with nitrogen 3 times, triethylamine (1.21 g, 11.98 mmol) was added, stirred for 0.5 hours, then trifluoromethanesulfonic anhydride (1.35 g, 4.79 mmol) was dissolved in dichloromethane (3 mL) and slowly added dropwise to the reaction system, and reacted at 0°C for 2 hours. TLC (petroleum ether: tetrahydrofuran = 5:1) monitored the disappearance of the raw material point and the generation of a new point with low polarity. The reaction solution was quenched with saturated ammonium chloride (50 mL) and extracted with dichloromethane (50 mL*2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 43_2.1 H NMR(400MHz,CHLOROFORM-d)δ:7.91(d,J=9.0Hz,1H),7.87-7.82(m,2H),7.76-7.68(m,2H),7.37(dd,J=2.4,9.0Hz,1H),1.44(s,9H).F NMR(376MHz,CHLOROFORM-d)δ:-72.75(s).
[0950] Step 3: 43_2 (1.2 g, 3.61 mmol), bis-pinacol borate (1.38 g, 5.42 mmol) and potassium acetate (1.06 g, 10.83 mmol) were dissolved in dioxane (15 mL) at room temperature and Pd(dppf)Cl was added. 2 (0.26 g, 0.36 mmol), nitrogen replacement 3 times, heating to 100 ° C for 3 hours. TLC (petroleum ether: ethyl acetate = 10: 1) monitored the disappearance of the raw material point, and a new point with less polarity was generated. Water (15 mL) was added for dilution and ethyl acetate was extracted (15 mL * 2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by column chromatography (0-3% ethyl acetate / petroleum ether) to obtain compound 43_3. 1 H NMR (400MHz, CHLOROFORM-d) δ: 8.34 (s, 1H), 7.88-7.76 (m, 4H), 7.59 (dd, J = 1.9, 8.7Hz, 1H), 1.43 (d, J = 9.5Hz, 21H).
[0951] Step 4: At room temperature, int.5 (300 mg, 0.37 mmol), 43_3 (127.69 mg, 0.41 mmol), tetrakis(triphenylphosphine)palladium (43.24 mg, 0.04 mmol) and sodium carbonate (118.97 mg, 1.12 mmol) were dissolved in ethanol (2 mL), water (2 mL) and toluene (4 mL), replaced with nitrogen 3 times, and heated to 100 ° C for 5 hours. LC-MS monitored the reaction to be complete, the reaction solution was cooled and concentrated, diluted with water (50 mL), and extracted with ethyl acetate (50 mL*3). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by column chromatography (0-30% ethyl acetate / petroleum ether) to obtain compound 43_4. LC-MS (ESI): m / z=907.5[M+H] + .
[0952] Step 5: At room temperature, compound 43_4 (200 mg, 0.22 mmol) was dissolved in dioxane (3 mL), concentrated hydrochloric acid (3 mL, 36.00 mmol) was added, and the mixture was reacted at 30°C for 16 hours. The reaction was completed after LC-MS monitoring, and the reaction solution was concentrated. The residue was separated and purified by preparative chromatography (chromatographic column: C18 150×30 mm; mobile phase: water (HCl)-MeCN; B%: 22%-62%, 9 min) to obtain compound 43 hydrochloride. LC-MS (ESI): m / z=551.4[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:9.59(br s,1H),8.88(br s,3H),8.68(d,J=5.1Hz,2H),8.60(s,1H),8.38(s,1H),8.03-7.88(m,3H),7.82(s,1H),7.65(dd,J=1.7,8.7Hz,1H),7.51(s,1H),6.01(br d,J=16.7Hz,1H),5.80(d,J=16.5Hz,1H),3.56(br d,J=12.1Hz,1H),3.44(br d,J=11.7Hz,1H),3.18(br d,J=12.1Hz,1H),2.99(br t,J=10.7Hz,1H),2.22-2.04(m,3H),1.83(br d,J=11.9Hz,1H),1.37(s,9H).
[0953] Example 44: Preparation of Compound 44
[0954]
[0955] Step 1: At room temperature, compound int.6 (300 mg, 0.43 mmol) was dissolved in anhydrous dioxane (5 mL) and water (1 mL), and indolin-2-one-5-boronic acid pinacol ester (143.6 mg, 0.55 mmol), tetrakis(triphenylphosphine)palladium (49.3 mg, 0.03 mmol) and sodium carbonate (135.6 mg, 1.28 mmol) were added in sequence, and nitrogen was replaced three times, and the reaction was carried out at 100°C for 1 hour. LC-MS monitored the reaction to be complete. The reaction solution was filtered and concentrated, and the residue was separated and purified by reverse column (0-100% acetonitrile / water) to obtain compound 44_1. LC-MS (ESI): m / z=756.4[M+H] + .
[0956] Step 2: Compound 44_1 (50 mg, 0.07 mmol) was dissolved in anhydrous dichloromethane (1 mL) and trifluoroacetic acid (0.5 mL) at room temperature and reacted for 1 hour. LC-MS monitored the reaction to be complete. The reaction solution was filtered and concentrated, and the crude product was separated and purified by preparative method (mobile phase: [water (ammonia hydroxide v / v)-ACN]; B%: 9%-49%, 9 min), and lyophilized to obtain compound 44. LC-MS (ESI): m / z = 456.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:10.49(br d,J=3.5Hz,1H),8.47-8.37(m,1H),8.27(s,1H),8.12(s,1H),7.69-7.57(m,2H),7 .30(s,2H),7.12(s,1H),6.84(d,J=8.1Hz,1H),5.48(s,2H),3.51(s,2H),3.14(br d,J=9.5Hz,1H),3.03(brd,J=11.2Hz,1H),2.95-2.85(m,1H),2.82-2.69(m,1H ),2.61-2.56(m,1H),1.93-1.74(m,2H),1.70-1.56(m,1H),1.28-1.11(m,1H).
[0957] Example 45: Preparation of Compound 45
[0958]
[0959] Step 1: At room temperature, 2-methyl-3-bromo-aniline (5 g, 26.9 mmol) and hydroxylamine hydrochloride (11.2 g, 161 mmol) were first dissolved in hydrochloric acid (6.72 mL) and water (30 mL) and stirred evenly to obtain a mixed solution 1. Secondly, chloral hydrate (5.33 g, 32.3 mmol) and sodium sulfate (20.2 g, 142.4 mmol) were dissolved in water (82 mL) and stirred evenly to obtain a mixed solution 2. Finally, the mixed solution 1 was added to the mixed solution 2, first reacted at 35°C for 1 hour, heated to 50°C for 1.5 hours, and finally heated to 75°C for 1 hour. LC-MS monitored the reaction to be complete, and the reaction solution was filtered and concentrated to obtain compound 45_1. LC-MS (ESI): m / z=257.0[M+H] + .
[0960] Step 2: At 60°C, compound 45_1 (450 mg, 1.75 mmol) was added to (5 mL) concentrated sulfuric acid, heated to 90°C, and reacted for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was cooled naturally, poured into (20 mL) ice water, and filtered to obtain compound 45_2. LC-MS (ESI): m / z = 240.0 [M+H] + .
[0961] Step 3: At room temperature, compound 45_2 (400 mg, 1.67 mmol) was dissolved in hydrazine hydrate (5 mL), and the temperature was raised to 130°C for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was cooled naturally, hydrochloric acid (10 mL) was added dropwise at 0°C, and compound 45_3 was obtained by filtration. LC-MS (ESI): m / z = 225.9 [M+H] + .
[0962] Step 4: Compound 45_3 (200 mg, 0.88 mmol), bis-pinacol borate (336.98 mg, 1.33 mmol), potassium acetate (260.47 mg, 2.65 mmol) and Pd(dppf)Cl were reacted at room temperature. 2 (64.73 mg, 0.09 mmol) was dissolved in dioxane (5 mL), replaced with nitrogen 3 times, and heated to 110°C for 3 hours. The reaction was complete after LC-MS monitoring. The reaction solution was cooled naturally, filtered and concentrated, and the residue was purified by column chromatography (0-40% tetrahydrofuran / petroleum ether) to obtain compound 45_4. LC-MS (ESI): m / z = 274.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:10.37(s,1H),7.26(d,J=7.3Hz,1H),7.02(br d,J=7.3Hz,1H),3.95(s,2H),2.35(s,3H),1.29(s,12H).
[0963] Step 5: At room temperature, int.6 (500 mg, 0.71 mmol), compound 45_4 (194.09 mg, 0.71 mmol), sodium carbonate (225.95 mg, 2.13 mmol) and tetrakis(triphenylphosphine)palladium (82.12 mg, 0.07 mmol) were dissolved in dioxane (2.5 mL) and water (0.5 mL), replaced with nitrogen three times, and heated to 100 ° C for 2 hours. LC-MS monitored the reaction to be complete, the reaction solution was cooled naturally, diluted with water (10 mL), extracted with ethyl acetate (15 mL), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was subjected to column chromatography (0-70% tetrahydrofuran / petroleum ether) to obtain compound 45_5. LC-MS (ESI): m / z=770.5[M+H] + .
[0964] Step 6: At room temperature, 45_5 (200 mg, 0.26 mmol) was dissolved in dichloromethane (0.5 mL), trifluoroacetic acid (0.25 mL) was added, and the mixture was reacted at room temperature for 1 hour. The reaction was completed after LC-MS monitoring, and the reaction solution was concentrated. The residue was prepared (chromatographic column: Phenomenex Gemini NX 150×30 mm, 5 μm; mobile phase: water (ammonium hydroxide v / v)-ACN; B%: 9%-49%, 9 min) to obtain compound 45. LC-MS (ESI): m / z=470.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:10.39(brs,1H),8.44(s,1H),8.32-8.22(m,1H),8.11(s,1H),7.32(br s,2H),7.02(d,J=7.7Hz,1H),6.78(d,J=7.7Hz,1H),6.49(s,1H),5.51(s,2H),3.47(s,2H),3.20-3.16(m,1H),3.09(br d,J=11.7Hz,1H),2.93(br s,1H),2.82(br t,J=9.8Hz,1H),2.60(br t,J=9.0Hz,1H),1.94-1.77(m,5H),1.68(br d,J=9.7Hz,1H),1.22(br d,J=9.5Hz,1H).
[0965] Example 46: Preparation of Compound 46
[0966]
[0967] Step 1: Compound int.2 (5 g, 13.2 mmol) was dissolved in N, N-dimethylformamide (20 mL) at room temperature, potassium carbonate (5.48 g, 39.6 mmol) was added thereto, nitrogen was replaced three times, and the mixture was stirred at room temperature for 10 minutes. The reaction solution was cooled to 0°C, iodomethane (2.81 g, 19.8 mmol) was added dropwise thereto, and the mixture was reacted at room temperature for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (80 mL), filtered and concentrated, and the residue was purified by slurrying with water (100 mL) to obtain compound 46_1. LC-MS (ESI): m / z=293.1[M+H-100] + .
[0968] Step 2: Compound 46_1 (3.4 g, 8.66 mmol) was dissolved in tetrahydrofuran (50 mL) at 0°C, and lithium triethylborohydride solution (26.0 mL, 26.0 mmol) was added thereto, and the atmosphere was replaced with nitrogen three times, and the reaction was carried out at room temperature for 2 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (80 mL), extracted with ethyl acetate (25 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-50% tetrahydrofuran (0.5% ammonia water) / petroleum ether) to obtain compound 46_2. LC-MS (ESI): m / z=365.1[M+H] + .
[0969] Step 3: At 0°C, compound 46_2 (5.4 g, 14.8 mmol) was dissolved in tetrahydrofuran (10 mL), and 50% sodium hydroxide solution (20 mL), tetrabutylammonium hydrogen sulfate (1.0 g, 2.96 mmol) and iodomethane (9.22 mL, 148 mmol) were added thereto, and the mixture was reacted at room temperature for 16 hours. LC-MS monitored the reaction to be complete, the reaction solution was quenched with water (50 mL), extracted with ethyl acetate (30 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (0-50% tetrahydrofuran / petroleum ether) to obtain compound 46_3. LC-MS (ESI): m / z=379.2[M+H] + .
[0970] Step 4: At room temperature, compound 46_3 (7.0 g, 18.5 mmol) was dissolved in methanol (100 mL), wet palladium carbon (5 g, purity: 10%) was added, hydrogen was replaced three times, and the reaction was carried out at room temperature for 3 hours. LC-MS monitored the reaction to be complete, and the reaction solution was filtered and concentrated to obtain compound 46_4. LC-MS (ESI): m / z = 188.6 [M+H-56] + .
[0971] Step 5: At room temperature, compound 46_4 (4.3 g, 17.6 mmol) was dissolved in dimethyl sulfoxide (80 mL), methyl 2-fluoro-5-iodobenzoate (5.91 g, 21.1 mmol) and N,N-diisopropylethylamine (4.55 g, 35.2 mmol) were added thereto, and the mixture was heated to 110°C for 16 hours. The reaction was complete after LC-MS monitoring. After the reaction solution was cooled naturally, it was quenched with water (200 mL), extracted with ethyl acetate (50 mL*3), and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by column chromatography (0-25% tetrahydrofuran / petroleum ether) to obtain compound 46_5. LC-MS (ESI): m / z=504.9[M+H] + .
[0972] Step 6: At 0°C, compound 46_5 (4.3 g, 8.53 mmol) was dissolved in tetrahydrofuran (15 mL), and lithium triethylborohydride (25.6 mL, 25.6 mmol) was added thereto. The atmosphere was replaced with nitrogen three times and the reaction was carried out at room temperature for 1 hour. The reaction was complete after LC-MS monitoring. The reaction solution was quenched with water (200 mL), extracted with ethyl acetate (50 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by column chromatography (2-40% tetrahydrofuran / petroleum ether) to obtain compound 46_6. LC-MS (ESI): m / z=477.1[M+H] + .
[0973] Step 7: At 0°C, triphenylphosphine (3.30 g, 12.6 mmol) was dissolved in tetrahydrofuran (5 mL), diisopropyl azodicarboxylate (2.55 g, 12.6 mmol) was added thereto, nitrogen was replaced three times, and the mixture was stirred at 0°C for 30 minutes. Compound 46_6 (2 g, 4.20 mmol) and compound int.1 (1.69 g, 5.04 mmol) were added thereto, and the mixture was heated to room temperature for 3 hours. The reaction was complete after LC-MS monitoring, and the reaction solution was concentrated. The residue was separated and purified by reverse phase column (0-100% acetonitrile / water) to obtain compound 46_7. LC-MS (ESI): m / z=794.3[M+H] + .
[0974] Step 8: Compound 46-7 (150 mg, 0.19 mmol) was dissolved in dioxane (2 mL) at room temperature, and 1-phenyl-1H-pyrazole-3-boronic acid pinacol ester (102 mg, 0.38 mmol), cesium carbonate (185 mg, 0.57 mmol) and Pd(dppf)Cl were added thereto. 2(13.8 mg, 0.02 mmol), replaced with nitrogen three times, heated to 80°C for 3 hours. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the residue was separated and purified by reverse phase column (0-100% acetonitrile / water) to obtain compound 46_8. LC-MS (ESI): m / z = 810.5 [M+H] + .
[0975] Step 9: Compound 46_8 (108 mg, 0.13 mmol) was dissolved in dichloromethane (2 mL) at room temperature, trifluoroacetic acid (2 mL, 26.8 mmol) was added, and the mixture was reacted at 30°C for 2 hours. The reaction was completed after LC-MS monitoring, and the reaction solution was concentrated. The crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (ammonia hydroxid)-ACN]; B%: 31%-71%, 9 min), and lyophilized to obtain compound 46. LC-MS (ESI): m / z=510.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6 )δ:8.50(d,J=2.6Hz,1H),8.22(s,1H),8.17(s,1H),7.87-7.74(m,3H),7.56-7.44(m,3H),7.36-7.20(m,4H) ,6.81(d,J=2.4Hz,1H),5.59-5.41(m,2H),3.39(brd,J=8.4Hz,1H),3.26(s,3H),3.23-3.17(m,1H),2.86(br d,J=11.2Hz,1H),2.83-2.72(m,2H),2.63(br d,J=10.8Hz,1H),1.87-1.68(m,3H),1.66-1.50(m,2H),1.41-1.31(m,1H).
[0976] Example 47: Preparation of Compound 47
[0977]
[0978] Step 1: Compound 46-7 (350 mg, 0.44 mmol) was dissolved in dioxane (3 mL) at room temperature, and bis-pinacol borate (224 mg, 0.88 mmol), potassium acetate (120 mg, 1.32 mmol) and Pd(dppf)Cl were added thereto. 2(32.3 mg, 0.044 mmol), nitrogen replacement three times, 80 ° C for 3 hours. LC-MS monitoring reaction completion, the reaction solution was filtered and concentrated, the residue was separated and purified by reverse phase column (0-100% acetonitrile / water) to obtain compound 47_1. LC-MS (ESI): m / z = 794.3 [M+H] + .
[0979] Step 2: At room temperature, compound 47_1 (108 mg, 0.136 mmol) was dissolved in toluene (0.4 mL), 3-bromoisoquinoline (42.5 mg, 0.204 mmol), potassium carbonate (56.4 mg, 0.408 mmol), water (0.1 mL), ethanol (0.4 mL) and tetrakis(triphenylphosphine)palladium (15.7 mg, 0.013 mmol) were added thereto, nitrogen was replaced three times, and the reaction was carried out at 80°C for 5 hours. LC-MS monitored the reaction to be complete, the reaction solution was filtered and concentrated, and the residue was separated and purified by reverse phase column (0-100% acetonitrile / water) to obtain compound 47_2. LC-MS (ESI): m / z=795.3[M+H] + .
[0980] Step 3: At room temperature, compound 47_2 (80 mg, 0.01 mmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (1 mL, 13.4 mmol) was added, and the mixture was reacted at 30°C for 2 hours. The reaction was completed by LC-MS monitoring, and the reaction solution was concentrated. The crude product was separated and purified by preparative chromatography (chromatographic column: Boston Prime C18 150*30mm*5um; mobile phase: [water (ammonium hydroxide)-ACN]; B%: 27%-67%, 9 min), and lyophilized to obtain compound 47. LC-MS (ESI): m / z=495.1[M+H] + . 1 H NMR (400 MHz, DMSO-d 6)δ:9.31(s,1H),8.24(d,J=5.9Hz,2H),8.16(s,1H),8.13-8.05(m,2H),7.97(d,J=8.1Hz,1H),7.88(s,1H) ,7.77(t,J=7.6Hz,1H),7.68-7.60(m,1H),7.34(d,J=8.6Hz,1H),7.25(s,2H),5.61-5.49(m,2H),3.41(br d,J=8.6Hz,1H),3.26(s,3H),3.21(br d,J=8.8Hz,1H),2.90(br d,J=11.0Hz,1H),2.87-2.75(m,2H),2.67(br d,J=11.0Hz,1H),1.83(br d,J=2.0Hz,3H),1.68-1.51(m,2H),1.43-1.32(m,1H).
[0981] Example 48: Preparation of Compound 48
[0982]
[0983] Step 1: At room temperature, compound int.2 (5 g, 13.2 mmol) was dissolved in N, N-dimethylformamide (100 mL), and ethylamine hydrochloride (1.62 g, 19.8 mmol), N, N-diisopropylethylamine (5.12 g, 39.6 mmol) and HATU (7.54 g, 19.8 mmol) were added respectively, and stirred at room temperature for 3 hours. TLC (petroleum ether: tetrahydrofuran = 2:1, phosphomolybdic acid color development) monitored the complete reaction of the raw materials, and a new point with a smaller polarity was generated. The reaction solution was diluted with water (150 mL), extracted with ethyl acetate (150 mL*3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by column chromatography (0-35% tetrahydrofuran / petroleum ether) to obtain compound 48_1. LC-MS (ESI): m / z = 406.1 [M+H] + .
[0984] Step 2: At room temperature, compound 48_1 (4.6 g, 11.3 mmol) was dissolved in methanol (100 mL), wet palladium carbon (1.5 g, 1.41 mmol) was added, hydro...
Claims
1. Compounds of formula (I): or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably a deuterated compound), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof, in: Ring A is a benzene ring or a 5-6 membered heteroaryl group; L is a direct key, C 1-6 Alkylene, -C 1-6 Alkylene-O-, or -OC 1-6 Alkylene-; L 1 For direct keys, O, S, C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -SC 1-6 Alkylene-, -C 1-6 Alkylene-S-, -NH-CO- or -CO-NH-; R 1 H or C 1-6 alkyl; R 2 H or C 1-6 alkyl; R 3 H, halogen, OH, NH2, CN, NO2 or part; Ring B is C 3-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl or 3-10 membered heterocyclyl; R b OH, NH2, halogen, CN, NO2, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -NR 4 C(=O)CR 6 =C(R 6 )2 or -(CR 4 R 5 ) l -NR 4 -C(=O)-R 7 , wherein the C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted by 1, 2, 3 or more independently selected from OH, NH2, halogen, CN, NO2, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Substitution of haloalkyl groups; Ring C is a 9-10 membered heteroaryl group having 2, 3, 4 or 5 nitrogen heteroatoms; R c C 1-6 Alkyl or -OC 1-6 alkyl; R is: (1) -OC optionally substituted by 1, 2 or more substituents independently selected from halogen, OH, NH2, CN, NO2 and COOH 1-6 alkyl; (2)-NR e R f , where R e and R f are each independently H, or C optionally substituted by 1, 2, 3 or more substituents independently selected from halogen, OH, NH2, CN, NO2 and COOH 1-6 alkyl; (3)–(CH2) w -O-(CH2) v -C 6-10 aryl; or (4) part, in: Ring D is a 5-6 membered heterocycloalkyl group containing 1 nitrogen heteroatom and 0 or 1 O or S heteroatoms; R a1 For: COOH, -NR g R h 、COOR g ,CONR g R h , or -C 1-6 Alkylene-NR g R h ; Each R a2 Independently for: (1) Halogen, OH, NH2, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C 1-6 Alkylene-SR g , -C 1-6 Halogenated alkylene -OR g , -C 1-6 Halogenated alkylene-SR g , -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C 1-4 Alkylene-S(O)-C 1-6 Alkyl, -C 1-6 Alkylene-S(O)2-C 1-6 Alkyl, -C(C 1-6 alkyl)=NO(C 1-6 alkyl), -C(O)-C 1-6 Alkyl, or -C(O)-NR g R h ;or (2)-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 , where R 14 For-OC 1-6 Alkyl, C 3-7 Cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, the C 3-7 The cycloalkyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl are each independently unsubstituted or substituted with C 1-6 Alkyl or -OC 1-6 Alkyl substitution; or (3)-(CR 11 R 12 ) t -C(O)-NR 15 R 16 , where R 15 is hydrogen or C 1-6 Alkyl, R 16 For hydrogen, C 1-6 Alkyl, or 5-6 membered heterocyclic group; or R 15 and R 16 Together with the nitrogen atom to which they are attached, they form an unsubstituted or C 1-6 an alkyl-substituted 5-6 membered heterocyclic group; or (4) 5-10 membered heterocyclic group, or -C 1-6 Alkylene-(5-10 membered heterocyclyl), wherein each of the 5-10 membered heterocyclyl is unsubstituted or replaced by C 1-6 Alkyl substitution; or (5) 5-10 membered heteroaryl, or -C 1-6 Alkylene-(5-10 membered heteroaryl), wherein each of the 5-10 membered heteroaryl is unsubstituted or substituted with: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene-OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, halogen, OH, CN, -C(O)NH2, -C 1-6 Alkylene -C(O)NH2, -C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C 1-6 Alkyl, -C(O)N(C 1-6 Alkyl)2, -C 1-6 Alkylene-C(O)N(C 1-6 Alkyl)2, or -C 3-7 Cycloalkyl; R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from halogen, OH, NH2, CN, NO2, -OC 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The substituents of aryl and 5-10 membered heteroaryl are substituted with C 1-6 alkyl; R 4 , R 5 , R 6 , R 11 , R 12 and R 13 Each time it appears, it is independently H, C 1-6 Alkyl or C 3-7 Cycloalkyl; R 7 C 1-6 Alkyl or C 1-6 Haloalkyl; l, m, n, p, q, w, v and s are each independently 0, 1, 2, 3 or 4; t is independently 1, 2, 3 or 4; and in: When the R 1 and R 2 are all H, the ring C is The ring A is a pyridyl ring, the L and L 1 are all direct bonds, and the R is the part, the ring D is a piperidinyl ring, and the R a1 and R a2 When at least one of is NH2, the following conditions are met: (1) If p is not 0, then R a1 With at least one R a2 Connect to the same location; (2) If n is 1, then R b Not halogen; (3) If n is greater than 1, then R b Not all halogen; and (4) The compound of formula (I) is not any compound disclosed in international patent application WO2021026803.
2. Compounds of formula (I): or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably a deuterated compound), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate or pharmaceutically acceptable salt thereof, in: Ring A is a benzene ring or a 5-6 membered heteroaryl group; L is a direct key, C 1-6 Alkylene, -C 1-6 Alkylene-O-, or -OC 1-6 Alkylene-; L 1 For direct keys, O, S, C 1-6 Alkylene, C 2-6 Alkenylene, C 2-6 Alkynylidene, -OC 1-6 Alkylene-, -C 1-6 Alkylene-O-, -SC 1-6 Alkylene-, -C 1-6 Alkylene-S-, -NH-CO- or -CO-NH-; R 1 H or C 1-6 alkyl; R 2 H or C 1-6 alkyl; R 3 H, halogen, OH, NH2, CN, NO2 or part; Ring B is C 3-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl or 3-10 membered heterocyclyl; R b OH, NH2, halogen, CN, NO2, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -NR 4 C(=O)CR 6 =C(R 6 )2 or -(CR 4 R 5 ) l -NR 4 -C(=O)-R 7 , wherein the C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted by 1, 2, 3 or more independently selected from OH, NH2, halogen, CN, NO2, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Substitution of haloalkyl groups; Ring C is a 9-10 membered heteroaryl group having 2, 3, 4 or 5 nitrogen heteroatoms; R c C 1-6 Alkyl or -OC 1-6 alkyl; R is: (1) -OC optionally substituted by 1, 2 or more substituents independently selected from halogen, OH, NH2, CN, NO2 and COOH 1-6 alkyl; (2)-NR e R f , where R e and R f are each independently H, or C optionally substituted by 1, 2, 3 or more substituents independently selected from halogen, OH, NH2, CN, NO2 and COOH 1-6 Alkyl; or (3) part, in: Ring D is a 5-6 membered heterocycloalkyl group containing 1 nitrogen heteroatom and 0 or 1 O or S heteroatoms; R a1 For: COOH, -NR g R h , or -C 1-6 Alkylene-NR g R h ; Each R a2 Independently for: (1) Halogen, OH, NH2, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C 1-6 Alkylene-SR g , -C 1-6 Halogenated alkylene -OR g , -C 1-6 Halogenated alkylene-SR g , -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C 1-4 Alkylene-S(O)-C 1-6 Alkyl, -C 1-6 Alkylene-S(O)2-C 1-6 Alkyl, -C(C 1-6 alkyl)=NO(C 1-6 alkyl), -C(O)-C 1-6 Alkyl, or -C(O)-NR g R h ;or (2)-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 , where R 14 C 3-7 Cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, the C 3-7 The cycloalkyl, 5-6 membered heterocyclyl and 5-6 membered heteroaryl are each independently unsubstituted or substituted with C 1-6 Alkyl or -OC 1-6 Alkyl substitution; or (3)-(CR 11 R 12 ) t -C(O)-NR 15 R 16 , where R 15 is hydrogen or C 1-6 Alkyl, R 16 For hydrogen, C 1-6 Alkyl or 5-6 membered heterocyclic group; or R 15 and R 16 Together with the nitrogen atom to which they are attached, they form an unsubstituted or C 1-6 an alkyl-substituted 5-6 membered heterocyclic group; or (4) 5-10 membered heterocyclic group, or -C 1-6 Alkylene-(5-10 membered heterocyclyl), wherein each of the 5-10 membered heterocyclyl is unsubstituted or replaced by C 1-6 Alkyl substitution; or (5) 5-10 membered heteroaryl, or -C 1-6 Alkylene-(5-10 membered heteroaryl), wherein each of the 5-10 membered heteroaryl is unsubstituted or substituted with: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, halogen, OH, CN, -C(O)NH2, -C 1-6 Alkylene -C(O)NH2, -C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C 1-6 Alkyl, -C(O)N(C 1-6 Alkyl)2, -C 1-6 Alkylene-C(O)N(C 1-6 Alkyl)2, or -C 3-7 Cycloalkyl; R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from halogen, OH, NH2, CN, NO2, -OC 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 The substituents of aryl and 5-10 membered heteroaryl are substituted with C 1-6 alkyl; R 4 , R 5 , R 6 , R 11 , R 12 and R 13 Each occurrence is independently H or C 1-6 alkyl; R 7 C 1-6 Alkyl or C 1-6 Haloalkyl; l, m, n, p, q and s are each independently 0, 1, 2, 3 or 4; t is independently 1, 2, 3 or 4; and in: When the R 1 and R 2 are all H, the ring C is The ring A is a pyridyl ring, the L and L 1 are all direct bonds, and the R is the part, the ring D is a piperidinyl ring, and the R a1 and R a2 When at least one of is NH2, the following conditions are met: (1) If p is not 0, then R a1 With at least one R a2 Connect to the same location; (2) If n is 1, then R b Not halogen; (3) If n is greater than 1, then R b Not all halogen; and (4) The compound of formula (I) is not any of the compounds disclosed in Examples 1-325 of international patent application WO2021026803, in particular not the following compounds, or their stereoisomers, tautomers, diastereomers, racemates, cis-trans isomers, isotope-labeled compounds, N-oxides, metabolites, esters, prodrugs, crystalline forms, hydrates, solvates or pharmaceutically acceptable salts:
3. The compound according to claim 1 or 2, wherein: R is: (1) -OC optionally substituted by 1 or 2 substituents independently selected from F, Cl, OH, NH2, CN, NO2 and COOH 1-6 Alkyl; preferably -OC optionally substituted by 1 or 2 substituents independently selected from NH2 and COOH 1-4 Alkyl; more preferably -O-(CH2)2-NH2, -O-(CH2)3-NH2 or -O-(CH2)2-CH(COOH)-NH2; or (2)-NR e R f , where R e and R f are each independently H, or C optionally substituted by 1, 2, 3 or more substituents independently selected from F, Cl, OH, NH2, CN, NO2 and COOH 1-6 Alkyl; R e and R f Preferably each independently is H, or C optionally substituted by 1, 2 or 3 substituents independently selected from F, Cl, OH, NH2 and CN. 1-4 Alkyl; R e and R f More preferably, each independently is CH3, or -(CH2)2-NH2; preferably, -NR e R f is -N(CH3)-(CH2)2-NH2; or (3)–(CH2) w -O-(CH2) v -C 6-10 Aryl, wherein w and v are preferably each independently 0, 1 or 2; preferably, w and v are both 1; preferably, the -(CH2) w -O-(CH2) v -C 6-10 C in aromatic groups 6-10 Aryl is phenyl; more preferably, –(CH2) w -O-(CH2) v -C 6-10 Aryl is –(CH2)-O-(CH2)-phenyl; or (4) part; Preferably, R is part; and / or R 3 H, Br, OH, NH2, CN, NO2 or part; Preferably, R 3 H, Br, OH, NH2, NO2 or part; Preferably, R 3 is H, Br or part; More preferably, R 3 For the part.
4. The compound according to any one of claims 1 to 3, wherein the compound has a structure shown in formula (I-0):
5. A compound according to any one of claims 1 to 4, wherein: R 1 H or C 1-3 Alkyl, preferably H; and / or R 2 H or C 1-3 Alkyl, preferably H; and / or The ring C is a 9-10 membered heteroaryl group having 2, 3, 4 or 5 nitrogen heteroatoms; preferably, the ring C is a 9 membered heteroaryl group containing 2, 3 or 4 nitrogen heteroatoms; preferably, the ring C is a structure shown in the following formula: wherein X is N or CH, Y is N or CH; more preferably, the ring C is Best and / or The R c C 1-6 Alkyl or -OC 1-6 Alkyl; preferably, R c C 1-4 Alkyl or -OC 1-4 Alkyl; and / or Said m is 0, 1, 2, 3 or 4; preferably, m is 0 or 1, and more preferably, m is 0.
6. The compound according to any one of claims 1 to 5, wherein the compound has a structure shown by formula (I-1), formula (I-2), formula (I-3) or formula (I-4):
7. A compound according to any one of claims 1 to 6, wherein: The ring A is a benzene ring or a 6-membered nitrogen-containing heteroaryl group; Preferably, the ring A is a benzene ring or a 6-membered heteroaryl group containing 1, 2 or 3 nitrogen heteroatoms; More preferably, the ring A is a benzene ring or a 6-membered heteroaryl group containing 1 or 2 nitrogen heteroatoms; More preferably, the ring A is a benzene ring, a pyridyl ring or a pyridazinyl ring; More preferably, the ring A is: Where the bond identified by "a" is connected to L, the bond identified by "b" is connected to R, and the bond identified by "c" is connected to L 1 ; Most preferably, the ring A is: and / or L is a direct key, C 1-6 Alkylene, -C 1-6 Alkylene-O-, or -OC 1-6 Alkylene-; Preferably, L is a direct bond, C 1-3 Alkylene, -C 1-3 Alkylene-O-, or -OC 1-3 Alkylene-; Preferably, L is C 1-2 Alkylene; More preferably, L is -CH2- or -CH(CH)3-; More preferably, L is -CH2-.
8. The compound according to any one of claims 1 to 7, wherein the compound has a structure shown in formula (I-5), formula (I-6) or formula (I-7):
9. The compound according to any one of claims 1 to 8, wherein the ring D is pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl, preferably pyrrolidinyl or piperidinyl, more preferably More preferred 10. A compound according to any one of claims 1 to 9, wherein: R a1 COOH, -NR g R h 、COOR g ,CONR g R h , or -C 1-3 Alkylene-NR g R h ; Preferably, R a1 COOH, -NR g R h 、COOR g ,CONR g R h , or -C 1-2 Alkylene-NR g R h ; More preferably, R a1 For-NR g R h ; and / or R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2 or 3 independently selected from F, Cl, OH, NH2, CN, NO2 and -OC 1-3 Alkyl substituents substituted C 1-3 alkyl; Preferably, R g and R h H independently at each occurrence; Preferably, R a1 It is COOH, NH2, -NH-CH2CH2-OH, COOCH(CH3)2, CONHCH3, or -CH2-NH2, preferably CONHCH3 or NH2.
11. A compound according to any one of claims 1 to 10, wherein: Said Parts are: in particular or in particular or in particular Best where p is independently 0 or 1 at each occurrence.
12. A compound according to any one of claims 1 to 11, wherein: The compound has a structure shown in formula (I-8): Where: X 1 N or CH, Y 1 is N or CH, r is 0 or 1, and p is 0 or 1; Preferred structures are those represented by formula (I-9), formula (I-10), formula (I-11), formula (I-12) or formula (I-13): wherein p is independently 0 or 1 at each occurrence; or the compound has a structure shown in formula (I-14): Where: X 1 N or CH, Y 1 is N or CH, r is 0 or 1, and p is 0 or 1; The structure shown in formula (I-15) or formula (I-16) is preferred: wherein p is independently 0 or 1 at each occurrence; or the compound has a structure shown in formula (I-17): Where: X 1 N or CH, Y 1 is N or CH, r is 0 or 1, and p is 0 or 1; The preferred structure is: Or the compound has a structure shown in formula (I-19): Where: X 1 N or CH, Y 1 is N or CH, r is 0 or 1, and p is 0 or 1; The preferred structure is:
13. A compound according to any one of claims 1 to 12, wherein: Each R a2 Independently: halogen, NH2, CN, NO2, COOH, C 1-6 Alkyl, C 2-6 Alkynyl, -C 1-6 Alkylene-OR g , -C 1-6 Alkylene-OC 3-8 Cycloalkyl, -C 1-6 Alkylene-NR g R h , -C 1-6 Alkylene -CN, -C(O)-NR g R h 、-(CR 11 R 12 ) q -C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 or a 5-10 membered heteroaryl group, wherein each of the 5-10 membered heteroaryl groups is unsubstituted or substituted by: C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C 1-6 Alkylene -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, OH, CN, -C(O)NH2, -C 1-6 Alkylene -C(O)NH2, -C(O)NH-C 1-6 Alkyl, -C 1-6 Alkylene-C(O)NH-C 1-6 Alkyl, -C(O)N(C 1-6 Alkyl)2, -C 1-6 Alkylene-C(O)N(C 1-6 Alkyl)2, or -C 3-7 Cycloalkyl; Preferably, each R a2 Independently: F, Cl, NH2, CN, NO2, COOH, C 1-3 Alkyl, C 2-4 Alkynyl, -C 1-3 Alkylene-OR g , -C 1-3 Alkylene-NR g R h , -C 1-3 Alkylene -CN, -C(O)-NR g R h 、-C(=O)-OR 13 or -C(=O)-(CR 11 R 12 ) s R 14 or a 5-10 membered heteroaryl group, wherein each of the 5-10 membered heteroaryl groups is unsubstituted or substituted by: C 1-3 Alkyl, halogenated C 1-3 Alkyl, -C 1-3 Alkylene -OH, -OC 1-3 Alkyl, -OC 1-3 Haloalkyl, OH, CN, -C(O)NH2, -C 1-3 Alkylene -C(O)NH2, -C(O)NH-C 1-3 Alkyl, -C 1-3 Alkylene-C(O)NH-C 1-3 Alkyl, -C(O)N(C 1-3 Alkyl)2, -C 1-3 Alkylene-C(O)N(C 1-3 Alkyl)2, or -C 3-7 Cycloalkyl; Preferably, each R a2 Independently: CN, COOH, -C(O)-NR g R h , -C 1-6 Alkylene-OR g 、-(CR 11 R 12 ) q -C(=O)-OR 13 or unsubstituted 5-10 membered heteroaryl; Preferably, each R a2 Independently: CN, COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 , 5-6 membered heteroaryl; Preferably, R a2 For: CN, COOH, -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 or -C(O)-NR g R h ; or unsubstituted 5-membered heteroaryl, preferably oxazolyl, isoxazolyl, thiazolyl or isothiazolyl; Preferably, each R a2 Independently: COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 ; and / or R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2, 3 or more independently selected from F, Cl, OH, NH2, CN, NO2, C 1-3 Alkyl, -OC 1-3 Alkyl, C 3-6 Cycloalkyl, C 6-10 The C substituted with aryl, 5-10 membered heteroaryl or 3-6 membered heterocyclic group 1-4 alkyl; Preferably, R g and R h is independently H at each occurrence, or is optionally substituted by 1, 2 or 3 independently selected from halogen, -OH, C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-10 Cycloalkyl, C 6-10 The C substituted by the substituent of the aryl group or the 3-10 membered heterocyclic group 1-6 alkyl; Preferably, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2 or 3 independently selected from F, Cl, OH, NH2, CN, NO2, C 1-3 Alkyl, -OC 1-3 Alkyl, C 3-6 C substituted by a cycloalkyl group, a phenyl group, or a 3-6-membered heterocyclic group 1-3 alkyl; Preferably, R g and R h is independently H at each occurrence, or is optionally replaced by 1, 2 or 3 independently selected from F, Cl, -OH, C 1-3 Alkyl, -OC 1-3 Alkyl, C 3-6 C substituted by a cycloalkyl group, a phenyl group, or a 3-6-membered heterocyclic group 1-3 alkyl; More preferably, R g and R h is independently H at each occurrence, or C optionally substituted by 1, 2 or 3 substituents independently selected from F, Cl, OH, methyl, -O-CH3, cyclopropyl, phenyl 1-2 alkyl; More preferably, R g and R h Each occurrence is independently H, CH3, -CH2CH3, -C(CH3)3, -CH2CH2-OH, -CH2-OCH3, -CH2CH2-OCH3, -CH2F, -CHF2, -CF3, -CH2CF3, -CH2-cyclopropyl, -CH2CH2-cyclopropyl, -CH2-phenyl, More preferably, R g and R h is independently H, CH3, -CH2CH3, -CH2CF3, -CH2CH2-OH, -CH2-cyclopropyl, -CH2-phenyl at each occurrence; and / or R 13 C 3-6 Cycloalkyl or C 1-6 alkyl; Preferably, R 13 are independently methyl, ethyl, isopropyl, n-propyl, tert-butyl or cyclopentyl; preferably, isopropyl or tert-butyl; Preferably, each R a2 are independently: F, Cl, OH, NH2, CN, NO2, COOH, -CH2-OH, -CH2-O-CH3, -C(O)NH2, -C(O)NHCH3, -C(O)NH-CH2CH3, -C(O)N(CH3)2, -C(O)NH-CH2CH2-OH, -C(O)NH-CH2CH2-OCH3, -C(O)NH-CH2CF3, -C(O)NH-CH2-cyclopropyl, -C(O)OCH(CH3)2, -C(O)OC(CH3)3, ethynyl, -C(O)O-cyclopentyl, -C(O)CH2OCH3, -C(O)NH-C(CH3)3, -CH2-OCH2-phenyl; or unsubstituted 5- or 6-membered heteroaryl, preferably unsubstituted 5-membered heteroaryl, more preferably oxazolyl, isoxazolyl, thiazolyl (preferably ) or isothiazolyl; Preferably, each R a2 are independently: COOH, -CH2-OH, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -C(O)NH-CH2CH3, -C(O)NH-CH2CF3, -C(O)NH-CH2-cyclopropyl, -C(O)NH-CH2CH2-OH, -C(O)OCH(CH3)2, -C(O)OC(CH3)3, -CH2-O-CH3, -CH2-OCH2-phenyl; and / or p is independently 0 or 1 at each occurrence.
14. The compound according to claim 12 or 13, wherein: Parts are: Preferably, or Part of 15. A compound according to any one of claims 1 to 14, wherein: L 1 For direct keys, O, S, C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 Alkynylidene, -OC 1-3 Alkylene-, -C 1-3 Alkylene-O-, -SC 1-3 Alkylene-, -C 1-3 Alkylene-S-, -NH-CO- or -CO-NH-; Preferably, L 1 For direct keys, C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 Alkyne, -NH-CO- or -CO-NH-; Preferably, L 1 For direct key or C 2-3 alkenylene; Preferably, L 1 For direct keys, O, C 1-2 Alkylene, -CH=CH-, -C≡C-, -O-CH2-, -CH2-O-, -NH-CO- or -CO-NH-; More preferably, L 1 For direct keys, C 1-2 Alkylene, -CH=CH-, -C≡C-, -NH-CO- or -CO-NH-; More preferably, L 1 is a direct bond, -CH2CH2-, -CH=CH-, -C≡C-, -NH-CO- or -CO-NH-; More preferably, L 1 is a direct bond or -CH=CH-; and / or The ring B is C 5-10 Cycloalkyl (preferably C 5-10 Cycloalkyl), C 6-10 Aryl, 5-10 membered heteroaryl or 5-10 membered heterocyclyl; Preferably, the ring B is a benzo-fused C 5-6 Monocyclic cycloalkyl (preferably benzo-fused C 5-6 monocyclic cycloalkyl), pyrido-fused C 5-6 Monocyclic cycloalkyl (preferably pyrido-fused C 5-6 Monocyclic cycloalkyl), C 6-10 aryl, a 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, a 9-10 membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a benzo-fused 5- or 6-membered monocyclic heterocyclyl; Preferably, the ring B is C 6-10 aryl, 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, 9-10 membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, benzo-fused 5 or 6 membered monocyclic heterocyclyl; More preferably, the ring B is tetrahydronaphthyl, phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl (e.g. 1,2,3-triazole, 1,2,4-triazole), pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzofuranyl, benzothiophenyl, naphthyridinyl, indolyl, isoindolyl, indolyl, benzimidazolyl, benzopyrazolyl, benzopyridinyl (e.g. quinoline, isoquinoline), benzopyrrolyl, pyridocyclohexyl or indolonyl; More preferably, the ring B is phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, benzofuranyl, indolyl, benzopyrazolyl, benzopyridinyl, benzopyrrolyl, pyridocyclohexyl; and / or, n is 0, 1 or 2; and / or Parts are: Preferably, Preferably, and / or R b OH, NH2, halogen, CN, NO2, C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, -OC 1-4 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-6 Cycloalkyl), C 6-10 Aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the C 6-10 Aryl, 5-10 membered heteroaryl, C 3-6 The cycloalkyl or 3-6 membered heterocyclyl is optionally substituted by 1, 2, 3 or more independently selected from OH, NH2, F, Cl, CN, NO2, C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl and -OC 1-4 Substitution of haloalkyl groups; Preferably, R b For halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-10 Cycloalkyl), C 3-10 Cycloalkyl and C 6-10 Aryl, wherein the C 6-10 Aryl is optionally substituted by 1, 2, 3 or more independently selected from halogen and -OC 1-6 Substitution of alkyl groups; Preferably, R b For halogen, CN, C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, -OC 1-4 Haloalkyl, -O-(C 6-10 Aryl), -O-(C 3-6 wherein the phenyl group is optionally substituted by 1, 2 or 3 groups independently selected from halogen and -OC 1-4 The alkyl group is substituted with a substituent; preferably, R b For halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OC 1-4 Alkyl, -OC 1-4 haloalkyl, -O-cyclopentyl or phenyl, wherein the phenyl is optionally substituted by 1 or 2 independently selected from halogen and -OC 1-4 Substitution of alkyl groups; Preferably, R b is OH, NH2, F, Cl, CN, NO2, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, CF3, -O-CF3, -O-CH3, -O-CH2CH3, -O-phenyl, -O-cyclopentyl, phenyl, cyclopentyl or cyclohexyl, wherein the phenyl, cyclopentyl or cyclohexyl is optionally substituted with 1 or 2 substituents independently selected from OH, NH2, F, Cl, CN, NO2, -O-CH3 and -O-CH2CH3; Preferably, R b is F, Cl, CN, -CF3, -OCF3, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH3, -O-CH2CH3, -O-phenyl, -O-cyclopentyl or phenyl, wherein the phenyl is optionally substituted with 1 or 2 substituents independently selected from F, Cl, -O-CH3 and -O-CH2CH3; More preferably, R b is F, Cl, CN, CF3, -O-CF3, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -O-CH3, -O-CH2CH3, -O-phenyl, -O-cyclopentyl, Preferably, the Parts are: Preferably, 16. A compound according to any one of claims 1 to 15, wherein the compound has a structure shown in formula (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (II-I), (II-J), (II-K), (II-L), (II-M), (II-N): in, x is selected from 0, 1, 2 or 3; ring Q is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl; R Q Selected from OH, NH2, halogen, CN, NO2, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl and -OC 1-6 Haloalkyl; X 1 , Y 1 , B, R b ,n,r,R a2 , p is as defined in any one of claims 1-15.
17. The compound according to claim 16, wherein In formula (II-A) and (II-B), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 Selected from CH, Y 1 is selected from N; r is selected from 0 or 1, preferably, r is selected from 1; Ring B is selected from C 6-10 Aryl, 5-10 membered heteroaryl; preferably, ring B is selected from C 6-10 aryl, 5- or 6-membered monocyclic heteroaryl having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, 9-10-membered bicyclic heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; p is selected from 0 or 1, preferably, in formula (II-B), p is selected from 0; n is selected from 0, 1 or 2; R a2 Selected from CN, -COOH, -C(O)-NR g R h 、-C(=O)-OR 13 , 5-6 membered heteroaryl; preferably, in formula (II-A), R a2 Selected from CN, -COOH, -C(O)-NR g R h 、-C(=O)-OR 13 , 5-6 membered heteroaryl; More preferably, in formula (II-A), R a2 is selected from CN, -COOH, 5-6 membered heteroaryl; R b Selected from halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl; In formula (II-C), (II-D), (II-E), (II-F), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 Selected from CH, Y 1 is selected from N; r is selected from 0 or 1, preferably, r is selected from 1; p is selected from 0 or 1, preferably, p is selected from 0; Ring B is selected from C 6-10 Aryl, 5-10 membered heteroaryl; preferably, ring B is selected from C 6-10 Aryl; R a2 Selected from CN, -COOH, -C(O)-NR g R h 、-C(=O)-OR 13 , preferably, R a2 Selected from -COOH, -C(O)-NR g R h 、-C(=O)-OR 13 ; n is selected from 0, 1 or 2; R b Selected from halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl; In formula (II-G), (II-H), (II-I), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 Selected from CH, Y 1 Select from N, or X 1 and Y 1 are CH; r is selected from 0 or 1, preferably, r is selected from 1; W1 and W2 are each independently selected from CH or N; preferably, W1 and W2 are simultaneously selected from N, or one of W1 and W2 is selected from CH and the other is selected from N; p is selected from 0 or 1; preferably, in formula (II-H) and (II-I), p is selected from 0; R a2 Selected from COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 Preferably, R a2 Selected from COOH, -C(O)-NR g R h ; n is selected from 0, 1 or 2, preferably, n is selected from 0 or 1; R b For halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl; In formula (II-J) and (II-K), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 and Y 1 are CH; W1, W2, W3 and W4 are each independently selected from CH or N; preferably, one of W1 and W2 is selected from CH and the other is selected from N, or W1 and W2 are simultaneously selected from CH; one of W3 and W4 is selected from CH and the other is selected from N; r is selected from 0 or 1, preferably, r is selected from 1; p is selected from 0 or 1, preferably, p is selected from 1; R a2 Selected from COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 Preferably, R a2 Selected from -C(O)-NR g R h , -C 1-3 Alkylene-OR g ; n is selected from 0, 1 or 2, preferably, n is selected from 0 or 1; R b For halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl; In formula (II-L), (II-M), (II-N), X 1 and Y 1 are each independently selected from CH or N; preferably, X 1 and Y 1 and CH; r is selected from 0 or 1, preferably, r is selected from 1; Ring B is selected from a 5-membered heteroaryl group, preferably, Ring B is selected from a 5-membered heteroaryl group having 1, 2 or 3 nitrogen heteroatoms and 0 or 1 oxygen or sulfur heteroatoms, more preferably, Ring B is selected from a 5-membered heteroaryl group having 1, 2 or 3 nitrogen heteroatoms, such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl; preferably, Selected from Wherein the bond marked by "*" is connected to the Q ring; the ring Q is selected from C 6-10 Aryl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, 5-10 membered heteroaryl; preferably, ring Q is selected from C 6-10 Aryl; x is selected from 0, 1 or 2; R Q Selected from OH, halogen, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 haloalkyl; p is selected from 0 or 1, preferably, in formula (II-M) and (II-N), p is preferably 0; R a2 Selected from CN, COOH, -C(O)-NR g R h , -C 1-3 Alkylene-OR g 、-C(=O)-OR 13 Preferably, R a2 Selected from COOH, -C(O)-NR g R h ; R g , R h , R 13 As defined in any one of claims 1 to 16.
18. The compound according to any one of claims 1 to 17, wherein the compound is selected from:
19. A pharmaceutical composition comprising a compound according to any one of claims 1 to 18, or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystalline form, hydrate, solvate or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
20. A pharmaceutical combination comprising a compound according to any one of claims 1 to 18, or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotope-labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystalline form, hydrate, solvate or pharmaceutically acceptable salt thereof, and one or more additional therapeutically active agents, wherein the one or more additional therapeutically active agents are anticancer agents, analgesics or anti-inflammatory agents.
21. Use of a compound according to any one of claims 1 to 18, or a stereoisomer, tautomer, diastereomer, racemate, cis-trans isomer, isotopically labeled compound (preferably deuterated), N-oxide, metabolite, ester, prodrug, crystalline form, hydrate, solvate or pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 19, or a pharmaceutical combination according to claim 20 in the preparation of a medicament for treating a disease, disorder or condition mediated by SET domain-containing nuclear protein 2 (NSD2) or SET domain-containing nuclear protein 3 (NSD3) in an individual; preferably, the disease, disorder or condition mediated by SET domain-containing nuclear protein 2 (NSD2) is selected from solid tumors, leukemia, myeloma, lymphoma and hypertension; Preferably, the disease, disorder or condition mediated by SET domain-containing nuclear protein 2 (NSD2) is selected from breast cancer, cervical cancer, skin cancer, ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, colon cancer, head and neck cancer, thyroid cancer, peripheral nerve sheath tumors, osteosarcoma, multiple myeloma, neuroblastoma, leukemia, non-Hodgkin's lymphoma and pulmonary hypertension; More preferably, the disease, disorder or condition mediated by SET domain-containing nuclear protein 2 (NSD2) is selected from acute lymphoblastic leukemia, cutaneous squamous cell carcinoma or mantle cell lymphoma; Preferably, the disease, disorder or condition mediated by SET domain-containing nuclear protein 3 (NSD3) is selected from squamous cell lung carcinoma, breast cancer, esophageal cancer, head and neck cancer, bile duct cancer, hepatocellular carcinoma, gastric adenocarcinoma, pancreatic cancer and osteosarcoma.
Citation Information
Cited By
Piperidinyl-methylpurine pyridines and related compounds and their use in treating diseases and conditions
WO2026213567A1
